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Chapter 1
INTRODUCTION
Cancer is a disease that is the leading cause of death in the Netherlands for both men and 
women.[1] Cancer is a disease that involves abnormal and uncontrolled growth of cells that 
have the potential to invade and spread (metastasize) to other parts of the body. When can-
cer is detected early and has not yet metastasized to lymph nodes or other organs, it is 
curable by resection. Unfortunately, cancer is often detected in a stage where it already has 
metastasized. To date, in most cases metastasized cancer is not curable, and treatment of 
metastasized disease aims at preventing disease progression. The “traditional” treatment 
modalities in oncology are in addition to resection or debulking of tumors, radiotherapy and 
chemotherapy. However, one of the new promising therapeutic options that has emerged in 
the last decade is Immunotherapy.[2] Immunotherapy of cancer is a strategy that harnesses 
the body’s immune system to combat tumors.
IMMUNE SYSTEM
The immune system protects us from extraneous agents and pathogens but plays also a role 
in the recognition and eradication of premalignant or malignant cells. The immune system 
can roughly be divided into two subsystems: innate- and adaptive immune system. These two 
subsystems are complementary and strongly interact with each other. 
Innate immune system
The main compartments of the innate immune system are physical and chemical barriers 
(skin, mucous membranes, saliva, etc.), and the complement system. In addition, the innate 
immune system also harbours multiple immune cells like: basophils, dendritic cells, eosino-
phils, mast cells, macrophages, neutrophils, and natural killer cells. All these immune cells 
have their own specific role in the recognition and elimination of pathogens. In addition, 
macrophages and dendritic cells are important not only in immediate recognition of patho-
gens but also in killing, digestion and exposing (“presentation”) of pathogen-derived antigen 
fragments (peptides), called “epitopes”. Therefore, these cells are also known as antigen-pre-
senting cells (APC).[3-5] The presented antigens can subsequently be recognized by T cells 
from the adaptive immune system. Lastly, the initial activation of innate immune cells at the 
site of inflammation can set off production of chemo- and cytokines by innate immune cells 
themselves and/or tumor cells, fibroblasts or endothelial cells. These chemo- and cytokines 
attract other immune cells to the site of inflammation.
Adaptive immune system
The adaptive immune system consists out of highly specialised cells, which are able to recog-
nize unique antigens. The adaptive immune system roughly comprises (antibody producing) 
B cells, CD4+ helper T cells, and CD8+ cytotoxic T cells. After presentation of pathogenic an-
tigens by APCs, B cells can recognize antigens directly via the B cell receptor (BCR), whereas 
T cells recognize antigens as peptides presented by major histocompatibility complex (MHC) 
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molecules via the T Cell Receptor (TCR). These receptors are unique and arise mainly from 
genetic recombination of the DNA encoded segments in individual T and B cells. This enables 
the formation of T and B lymphocytes that are able to distinguish many different antigens, in-
cluding self-antigens that are presented by healthy tissues. It is therefore critical for lympho-
cytes to undergo selection during development from lymphocyte precursor to lymphocyte, in 
which process self-reactive lymphocytes are eliminated. Upon antigen recognition by the BCR 
or TCR, B or T cells become activated, rapidly expand and clear aberrant cells positive for the 
target antigen. After reduction of a certain antigen (for instance a pathogen), immunological 
memory cells are formed, which, upon a second encounter with the same pathogen, enable 
accelerated expansion of antigen-specific lymphocytes leading to fast clearance and protec-
tion against such a pathogen. 
Aside from all the above effector immune cells, there are also suppressive immune cells that 
dampen immune responses. This is important, since keeping immune responses in-check 
prevents overt reactions and autoimmunity. Examples of suppressive immune cells include: 
Myeloid derived suppressor cells (MDSC) [6], M2-macrophages [7], and T regulatory cells 
(Tregs) [8]. The relevance of these cells is illustrated by the notions that mice that are deplet-
ed of Tregs [9], or humans who have immunodysregulation polyendocrinopathy enteropathy 
X-linked (IPEX) syndrome due to mutations in FOXP3 have severely increased autoimmunity.
[10, 11]
ANTI-TUMOR IMMUNE RESPONSES AND ITS HISTORY
Tumors are quite heterogeneous, not only with respect to genetic characteristics of tumor 
cells themselves, but also with respect to presence and activation of stromal cells, such as 
fibroblasts, endothelial cells, and immune cells. Here, I would like to zoom in on the im-
mune constituents of tumors. When present, generally the case in subsets of tumors of any 
histological origin, immune constituents comprise many different types of immune cells, as 
illustrated in Figures 1A-G. Rudolf Virchow, already in the 19th century, has described the 
presence of immune cells in tumors, and being ahead of his time pointed to a link between 
inflammation and cancer. Based on these and other observations hinting at the potential of 
the immune system as a mean to treat cancer, researchers in the 1950s demonstrated that 
it was possible to immunize animals and prevent tumor formation. In these experiments, 
tumors (induced by carcinogens) were excised from an animal and, following a short time cul-
ture, re-transplanted onto animals. Strikingly, animals were able to reject a second injection 
with tumor cells.[12-15] These experiments implied that there must be antigens on tumor 
cells that can be recognized by the immune system. Nowadays we know that CD8 T cells play 
a dominant role in recognizing and killing tumor cells. In fact, it has been shown that numbers 
and spatial distribution of CD8 T cells in cancer can strongly influence disease outcome. For 
example, a high frequency of tumor infiltrating lymphocytes (TILs), and in particular the CD8 
T cells, correlates with an increased survival in melanoma, head and neck, breast, urothelial, 
ovarian, colorectal and lung cancer patients [16, 17]. Importantly, the seminal experiments of 
Virchow also demonstrated that tumors initially evade immune reactions. There are several 
1
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immune evasive mechanisms that delay or put on-hold anti-cancer immunity. One strategy 
that tumors exploit to evade CD8 T cell responses is to diminish or prevent antigen presen-
tation and recognition; other. Other strategies may include: reduction in numbers of effector 
immune cells; enhanced numbers of immune suppressor cells; reduction of antigen expres-
sion and/or enhanced expression of immune and metabolic checkpoints.[18, 19]
CANCER IMMUNOTHERAPY
To treat cancer by using the patients own immune system, several approaches have already 
shown promise in clinical trials. The most effective strategies include: 1) antibodies targeting 
immune checkpoints (checkpoint therapy), 2) adoptive T cell therapy with ex vivo expanded 
TILs, and 3) adoptive T cell therapy with ex vivo genetically modified and expanded T cells. 
Also, several other therapeutic have been tested in clinical trials, like treatment with immune 
modulators (e.g., cytokines, such as Interleukin-2 (IL-2) or Interferon alpha); vaccination with 
tumor cell preparations, incl. tumor derived proteins and antigenic peptides alone or in com-
bination with antigen presenting cells; or treatment with oncolytic viruses. Below, we will 
highlight vaccination therapy since this is one of the subjects in this thesis, and subsequently 
checkpoint therapy and adoptive T cell therapy.
Vaccination
Instead of adoptively transferring effector T cells, or use of checkpoint inhibiting antibody 
therapy to (re)activate T cells, T cells can also be primed and/or boosted in vivo by tumor vac-
cination therapy. This can be done by injecting (tumor-derived) proteins or peptides into the 
patient. These proteins or peptides are absorbed and processed by APCs and presented to 
T cells.[20] Alternatively, APCs can be generated ex vivo from isolated blood monocytes and 
loaded with tumor antigens (proteins or peptides) prior to injection into patients to activate 
patient T cells. The vaccine-activated T cells then specifically recognize and attack the tumor 
cells.[21] 
Checkpoint inhibitors
A major breakthrough in the field of cancer immunotherapy was the discovery of immune 
checkpoints and the development of antibodies that bind to such inhibitory receptors (iRs) 
on T cells. By blocking the iRs (or their corresponding ligands on tumor cells) T cells are re-
leased from their inhibitory state and are enabled (again) to kill tumor cells. The first blocking 
antibodies that were evaluated clinically were ipilimumab, nivolumab and pembrolizumab, 
and targeted ‘Cytotoxic T Lymphocyte Associated protein 4’ (CTLA4) and ‘Programmed cell 
Death-1’ (PD1). Clinical trials using these checkpoint inhibitors have shown promising re-
sults, with durable responses in a significant proportion of patients, in particular in melano-
ma patients [22-24]. Checkpoint inhibitors are part of the standard treatment portfolio and 
now FDA-licensed as new therapeutic agents for the treatment of patients with metastatic 
melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma and bladder 
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Figure 1:  Intra-tumoral immune cells represent a diversity of different cell types. 
1A: Multiplex staining of a lymph node metastasis of bladder cancer with antibodies directed to several 
Cluster of Differentiation (CD) markers that typically distinguish different immune cells.  Four-microm-
eter thick formalin-fixed, paraffin-embedded (FFPE) whole tissue slides were probed using a tyramide 
signal amplification multiplexing technique and were exposed to the following antibodies and fluoro-
phores: CD3 (Clone SP7; Sigma-Aldrich, St. Louis, United States ), Opal 520; CD20 (Clone L26; SanBio, 
Uden, the Netherlands), Opal 620; CD8 (Clone C8/144B; SanBio), Opal 570; CD68 (Clone KP-1; San-
Bio), Opal 540; CD56  (Clone MRQ-42; SanBio), Opal 650; Cytokeratine (Clone AE1/AE3; Thermo Fisher, 
Waltham,  United States), Opal 690; DAPI (PerkinElmer, Waltham,  United States). All opal Dyes were 
also derived from PerkinElmer. Each multiplex stained slide was digitally processed by Vectra 3.0 InForm 
tissue finder software. B-G) bright field images of single markers as displayed in A produced with In-
Form tissue finder software. Figure was generated in laboratory of Tumor Immunology, Department of 
Medical Oncology, Erasmus MC.
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cancer [25], but also for patients with tumor showing microsatellite instability, irrespective 
of tumor type.[26]
Adoptive T-cell therapy
The concept of adoptive T cell therapy is to transfer into patients autologous effector T cells 
that are able to find and destroy tumor cells. There are two major classes of adoptive T cell 
therapy.
Tumor Infiltrating Lymphocytes (TIL)
Rosenberg and colleagues explored the adoptive cell transfer (AT) of autologous T cells (de-
rived from excised tumor tissues and rapidly expanded ex vivo) for the treatment of meta-
static melanoma from 1988 onwards[27, 28], but it was only until 2002, when combining AT 
of TIL with prior lymphodepletion with fludarabine and cyclophosphamide that substantial 
clinical successes were obtained[29-31]. With the optimized protocol up to 60% clinical re-
sponses were obtained [29-31] . Figure 2A displays a graphical representation of AT with TILs. 
After these (single institution) successes with TIL therapy more studies in other centers fol-
lowed, mainly focusing on the treatment of melanoma and with objective responses around 
50% and complete responses around 20%.[32, 33] Also in renal cell carcinoma and ovarium 
cancer there are efforts made to use TIL therapy.[34] Key to the success of TIL therapy is the 
ability to isolate tumor reactive T cells from the tumor biopsy. 
Receptor engineered T cells
As it is not always possible to obtain TILs from tumors, an alternative approach was taken, 
in which T cells from patients’ blood are genetically engineered with immune receptors that 
endow these T cells with tumor specificity. The immune receptors can be antibody based, i.e., 
Chimeric Antigen Receptors (CAR) or T cell receptors (TCR) that specifically target an antigen 
of interest expressed by malignant cells. CARs are generally single-chain variable fragments 
(scFv) derived from monoclonal antibodies that are fused to a transmembrane and a signal-
ing domain.[35] A graphical representation of AT with CAR/TCR engineered T cells is depicted 
in figure 2B. When introduced in T cells binding of the CAR with its antigen leads to T cell ac-
tivation. Trials with first generation CARs showed limited success, but trials with second gen-
eration CARs have shown more promising results. Second generation CARs harbor an extra 
intracellular domain derived from co-stimulatory receptors, such as CD28 or 4-1BB (CD137). 
Specifically, adoptive T cell therapy with genetically modified second generation CD19 CAR T 
cells has shown impressive clinical results in hematological CD19 expressing B cell malignan-
cies [36, 37]. Treatment of acute Lymphoblastic B-cell Leukemia (ALL) with CD19 CAR T cells 
resulted in complete responses between of 70 to 100%.[38] This recently resulted in the FDA 
approval of CD19 CAR T cell products for treatment of acute lymphocytic lymphoma (ALL), 
and certain types of non-Hodgkin lymphoma (NHL).[39]
The advantage of treatment of cancer with adoptive transfer of TCR transduced T cells is that 
15
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not only extracellular proteins, but also intracellular proteins can be targeted since intracel-
lular proteins are also processed and presented as peptides by MHC molecules at the cell 
surface. The treatment with T cells expressing the NY-ESO1 TCR demonstrated clinical ob-
jective responses in 61% of the patients with synovial cell sarcoma and 55% of patients with 
melanoma (55%). This trial showed that T cell therapy with the NY-ESO1 TCR is an effective 
therapy for cancer patients are refractory to other treatments.[40] In solid tumors adoptive 
therapy with CAR- or TCR- engineered T cells in different tumor types do show clinical re-
sponses, but results are not yet as impressive nor long-lasting as with the CD19 CAR T cells.
[32, 41]  Of great importance in CAR and TCR T cell therapy is the choice of antigen that is 
targeted by the receptor. When the targeted antigen is expressed not only by the tumor, but 
also by healthy tissue, this could lead to severe (auto-immune like) toxicities.[32, 42] Also, 
due to the potency of T cells high levels of cytokines can appear in patients resulting in shock. 
This is called a cytokine release syndrome (CRS). Luckily, these cytokine storms are manage-
able and transient.[43]
FOCUS OF THIS THESIS: IMMUNE MONITORING 
Despite the above-mentioned promise of immunotherapeutic approaches, a significant frac-
tion of patients does not yet respond to these therapies. To date there is no tool available to 
select patients for immunotherapies as there is a lack of markers that robustly predict thera-
py outcome or provide sufficient understanding into the underlying mechanisms that define 
unsuccessful treatment or toxicity. It is of pivotal importance to obtain such markers, since 
this will lead to improved stratification of patients for immune therapy. Patient stratification 
can prevent unnecessary treatment and increase cost-effectiveness of these treatments. To 
discover predictive markers, extensive monitoring of immunological as well as clinical param-
eters within clinical trials is mandatory.
This thesis is split into two parts. In the first part, we have focused on immune monitoring 
tools in a CAR T cell phase-I trial to find parameters that correlate with in vivo behavior of 
administered T cells.
In the second part, we have monitored changes in T cells numbers, T cell clonality (number of 
different TCRs) and T cell phenotype in the blood compartment in patients receiving Dendrit-
ic Cell therapy in a phase-I trial. In addition, we have assessed the characteristics of intratu-
moral T cells in several soft tissue sarcoma (STS) subtypes in order to identify new parameters 
for immune monitoring in these tumor types.
PART 1: Immune monitoring in adoptive T cell therapy. 
From 2003 until 2011, the laboratory of Tumor Immunology, Department of Medical Oncolo-
gy, Erasmus Medical center has initiated and conducted a clinical phase I trial with CAR T cells 
targeting Carboxy-anhydrase IX (CAIX) to treat patients with clear cell renal cell carcinoma 
(RCC). Twelve patients with metastatic RCC expressing CAIX were treated with CAR T cells. In 
1
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this trial no clinical responses were observed, and patients experienced transient toxicities 
due to CAIX expression in the bile ducts. This trial, the first of its kind in Europe, demonstrat-
ed that CAR T cells were highly potent in vivo as was reflected by the observed on-target/
off-tumor toxicity. It remains not fully clear why no anti-tumor effects were seen against 
CAIX-expressing tumors. Importantly, in this trial, patients were extensively monitored by col-
lecting and storing blood samples on multiple time points following start of treatment. This 
enabled in-depth of post infusion in vivo CAR T cell behavior and characteristics, which may 
explain the lack of anti-tumor effects. Along these lines, we have correlated gene-modified T 
cell numbers in blood with therapy effectiveness [36, 44-46], and we have looked into T cell 
features that predict peripheral persistence of the infused CAR T cells. In Chapter 2, we have 
studied cytokine profiles during ex vivo CAR T cell preparation, and identified cytokines are 
potential surrogate markers for CAR T-cell persistence in peripheral blood.
Next, we have extensively analysed the cellular composition of the infusion product in Chap-
ter 3, in particular whether certain T cell characteristics, such as T cell maturation status in 
the CAR T cell infusion product relate to in vivo T cell expansion.
Chapter 4 provides an up-to-date and complete overview of patient characteristics, treat-
ment schedules, CAIX CAR T cell characteristics, treatment observations and clinical obser-
vations of this phase I CAIX CAR T cell study. Subsequently, in Chapter 5 we review current 
literature on adoptive T cell trials with a special focus on monitoring of the T cell product and 
patients pre-and post-treatment. Together these chapters give recommendations for design 
and monitoring strategies for future CAR/TCR T cell trials
PART 2: immune monitoring beyond adoptive T cell therapy.
The second part of this thesis also provides in-depth T cell monitoring, but in settings dif-
ferent from the above-mentioned adoptive T cell therapy.Chapter 6 describes an extensive 
analysis of the immunological changes during the treatment of pleural mesothelioma pa-
tients treated with autologous monocyte derived dendritic cells that were loaded with meso-
thelioma tumor cell lysate. This phase-I trial demonstrated an impressive clinical response in 
one patient with almost 70% tumour size reduction, and in an additional 2 out of 9 patients 
stabilization of disease.[47] This chapter zooms in on changes in peripheral blood T cell phe-
notype and T cell clonality.
In Chapter 7, we have assessed T cell signatures of 5 different Soft Tissue Sarcoma (STS) 
subtypes, for which immune landscapes are less well described nor immune therapies are 
standardly considered. The aim of this study is to detect differences between STS subtypes to 
enable more rationalized design for (combinatorial) immunotherapies. Differences between 
STS subtypes in T cell numbers, phenotype, and clonality have been assessed and supple-
mented with assessments of immune gene analyses.
Finally, in Chapter 8, main results of chapters 2, 3, 6 and 7, and anticipated implications for 
T cell monitoring of cancers, and their consequences for future immune therapies are sum-
marized and discussed.
1
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ABSTRACT
Autologous T-cells genetically modified to express a Chimeric Antigen Receptor (CAR) against 
carboxy-anhydrase-IX (CAIX) were administered to twelve patients with CAIX-positive meta-
static renal cell carcinoma. Here, we questioned whether plasma cytokine levels following 
treatment or in vitro cytokine production from the T-cell infusion products could serve as 
predictors for peripheral T-cell persistence or in vivo T-cell activity.  We demonstrated that 
CAR surface as well as gene expression are down-regulated following T-cell infusion, and that 
peripheral numbers of CAR T-cells are best captured by flow cytometry and not by qPCR. 
Numbers of CAR T-cells in blood correlated with plasma levels of IFN-γ and IL-6, but not with 
any of the other cytokines tested. Plasma IFN-γ or IL-6 levels did not correlate with liver en-
zyme values. Thus, out of 27 cytokines tested, IFN-γ and IL-6 levels in plasma are potential 
surrogate markers for CAR T-cell persistence in solid tumors.
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INTRODUCTION
With the use of gene transfer technologies, T-cells can be genetically modified to stably ex-
press antibody molecules on their cell surface. The first generation of Chimeric Antigen Re-
ceptors (CARs) consisted of constructs in which an extracellular antibody-based recognition 
domain was combined with the intracellular signaling domain of the CD3-zeta (CD3ζ) or Fc(ε)
RIγ chains into one single protein.[1] In the so-called second or third generation CARs, one 
or two additional intracellular co-signaling domains that are generally derived from the CD28 
or 4-1BB co-stimulatory molecules, are added.[2, 3] The introduction of such an extra intra-
cellular co-stimulatory domain increases the clinical effectivity of CAR T-cells, and coincided 
with enhanced in vivo persistence, and in vivo expansion of CAR T-cells.[2, 4-6] In recent 
years, CAR T-cell therapy has shown impressive clinical responses in hematological B-cell ma-
lignancies [7]. Also correlations between T-cell persistence and clinical effectivity have been 
described.[2, 4-6] In solid tumors, however, the number of clinical CAR T-cell studies has 
lagged behind with only a few clinical responses reported.[8, 9] 
Obviously, in this emerging field there is a need for markers that provide information about 
early CAR T-cell persistence and in vivo activity.[7] With the increasing number of studies 
valuable data becomes available to perform such analysis.
One of the first CAR T-cell trials, performed at Erasmus MC Rotterdam, used a CAR:Fc(ε)RIγ 
directed to carboxy-anhydrase-IX (CAIX), an antigen that is over-expressed on Renal Cell Car-
cinoma (RCC). T cells were transduced with the CAIX CAR by the SFG γ-retroviral vector. [10] A 
total of twelve RCC patients were treated in this phase-I dose escalating trial with CAR T-cells 
and low dose IL-2 without prior chemotherapy in three separate cohorts (see materials and 
methods). Four out of eight patients in cohorts 1 and 2 experienced severe, but transient liver 
toxicities, which were most likely due to CAIX antigen expression on the surface of epithelial 
cells lining the bile ducts in the liver, and its recognition by the administered CAIX CAR T-cells.
[11, 12] Another four patients in cohort 3 were pre-treated with CAIX monoclonal antibodies 
(mAb) to preferentially block CAIX in the liver but not in RCC lesions, a scheme that success-
fully prevented severe liver toxicity in these patients.[11, 12] Though we could demonstrate 
in vivo activity of CAIX CAR T-cells, as measured by the observed on-target liver toxicities, 
objective clinical responses were not seen.[11, 13] In the study described here, we measured 
the concentration of an extended set of cytokines in blood samples taken at multiple time 
points during treatment, as well as in culture supernatants from T-cell infusion products, and 
assessed whether or not cytokine values correlated with numbers of circulating T-cells that 
express CAR and/or liver toxicity. To the best of our knowledge, such information was not yet 
available for CAR T-cell treatments of a solid tumor. 
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MATERIALS AND METHODS
Patient treatment schedule and evaluation
Patients were diagnosed with clear cell RCC with progressive disease, not suitable for curative 
surgery, for whom no standard treatment existed, and with the primary tumor expressing 
CAIX.[12] Specific patient characteristics are described elsewhere.[11] Patients were treated 
after written informed consent, and treated according to three patient cohorts due to serious 
adverse events observed in the first patients treated.[11] In short, in cohort 1, it was aimed 
to assess toxicity and to establish the maximum tolerated dose (MTD) of CAIX CAR T-cells by 
an in-patient dose escalation scheme. Treatment consisted of intravenous administration of 
2x107 T-cells at day 1; 2x108 T-cells at day 2; and 2x109 T-cells at days 3-5 (treatment cycle 1) 
and days 17-19 (treatment cycle 2). Simultaneously patients received twice daily subcutane-
ous injections of IL-2, 5 x 105 IU/m2 on day 1-10 and day 17-26. Because of liver toxicity, the 
schedule was changed in cohort 2. it was aimed to assess several dose levels starting at 1 x 
108 CAR T-cells per infusion and extending to 2, 4, 8, 16, 20, 25, and 30 × 108 cells in subse-
quent dose levels, and applying a maximum of 10 T-cell infusions at days 1–5 and days 29–33 
combined with IL-2, subcutaneously, 5 × 105 IU/m2 twice daily at days 1–10 and days 29–38.
In cohort 3, patients were treated as in cohort 2, but received an extra intravenous infusion 
of 5 mg of the anti-CAIX mAb G250, 3 days before start of each series of CAR T-cell infusions, 
in order to block CAIX antigen in the liver and leaving accessible CAIX antigen at RCC tumor 
sites.[14-16] Patients from this latter cohort were not included in the analyses of in vivo 
parameters because of additional pre-treatment with anti-CAIX mAb, which has led to differ-
ences in T cell persistence between the first two cohorts versus the third cohorts.[11] For the 
analyses of infusion products, however, all patients and treatment cycles were included, as 
preparations of CAR T-cells were independent of patient cohorts and treatment cycles.
Preparation of CAIX CAR T-cell infusion products and their superna-
tants
Patient peripheral blood mononuclear cells (PBMCs) from leukapheresis were activated in 
a complete Mixed Medium (MixMed) [17] using 10 ng/mL CD3 mAb OKT3 (Janssen-Cilag 
Beerse, Belgium), without addition of exogenous IL-2. At days 2 and 3, T-cells were transduc-
ed with the CAIX CAR vector (batch #M4.50086; BioReliance, Sterling, UK) as described [10] 
in the presence of 100 IU/ml IL-2 (Chiron, Amsterdam, The Netherlands). From day 4 onward, 
T-cells were expanded in complete MixMed supplemented with 360 IU/ml IL-2. Lymphocytes 
were counted every 2–3 days and adjusted to 0.5x106 cells/ml by adding fresh culture me-
dium and IL-2 until day 15. At culture days 2, 3, 4, 7, 9, 11 and 14 aliquots of culture super-
natants were collected, cleared by centrifugation (10 min at 3000g) and stored at -70°C for 
retrospective analysis.
Blood samples
We obtained blood samples at regular intervals before, during, and after treatment for flow 
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cytometric analysis, isolation of PBMCs, genomic DNA, RNA and plasma was as described 
elsewhere. [13, 18] We aliquoted and cryopreserved PBMCs in liquid nitrogen, and stored 
genomic DNA, RNA and serum samples at -70°C.
Enumeration of transduced T-cells in infusion products and blood 
samples
Number of T-cells with membrane expression of CAIX CAR in cultures as well as blood was 
assessed by flow cytometry (FCM) using the anti-CAIX CAR idiotype mAb NUH82 [19] (kindly 
provided by Dr. E. Oosterwijk, Nijmegen, The Netherlands) (Limit of quantification: 0.01% 
CAIX-CAR+ cells within CD3+ cells).[18, 20] Gene expression of CAIX CAR was assessed by 
qRT-PCR. To this end, RNA was isolated from T cell cultures or blood samples using the 
ChargeSwitch Total RNA Cell Kit (Invitrogen, Carlsbad, CA, USA) and QIAamp® RNA Blood 
Minikit (Qiagen, Valencia, CA, USA), respectively, according to the manufacturer’s guidelines. 
Complementary DNA (cDNA) synthesis was done using Reverse Transcriptase Superscript III 
(Invitrogen) under standard conditions. The quantitative real time PCR to detect CAIX CAR 
cDNA copies was performed as described previously.[18] CAIX CAR RNA levels in blood were 
only assessed in cohort 2 and 3. Additionally, genomic DNA was isolated from blood aliquots 
and T cell cultures using the QI Amp DNA mini kit (Qiagen, Hilden, Germany). The quantitative 
real time PCR to detect CAIX CAR DNA copies was again performed as described previously.
[18] 
Assessment of cytokine levels
The concentrations of IL-1β, IL-2ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, 
IL-15, IL-17, Eotaxin, FGF-Basic, G-CSF, GM-CSF, IFN-γ, IP-10 (CXCL10), MCP-1, MIP-1α, MIP-
1β, PDGF-bb, RANTES, TNF-α, and VEGF in plasma samples and culture supernatants were 
determined using a commercially available 27-multiplex bead assay (BioRab Laboratories, 
Inc., Veenendaal, The Netherlands/Minneapolis, MN, USA) according to the manufacturers’ 
instructions. For array specificities and lower limit of quantification levels, see Supplementary 
Table S1.
Statistical analysis
Cytokine levels in culture supernatant were normalized to the levels at day 2 (i.e., 40h after 
anti-CD3 mAb activation of PBMCs) and the cytokine levels in plasma were normalized to 
the baseline plasma levels at day 1. The Spearman correlation coefficient method was used 
to assess linear association between two continuous variables. P-values < 0.05 were con-
sidered significant. Differences between two categories with respect to paired continuous 
parameters were determined using an exact Wilcoxon rank sum test. Statistical analyses were 
performed with SPSS software (version 21) for Windows (IBM Corporation, Illinois, U.S.A.). 
Graphpad Prism v5.0 was used to prepare graphs and calculation of the Area Under the Curve 
(AUC) for cytokines and CAR T-cell numbers was performed using non-normalized data in 
linear X- and Y-axis plots. 
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RESULTS
Patients
In total, twelve RCC patients were treated with CAR T-cells. Specific patient characteristics 
are described elsewhere.[11] Four out of eight patients treated in the first two cohorts devel-
oped grades 3-4 liver toxicities and therefore three of them did not receive a second cycle of 
CAR T-cell infusions. Six out of eight patients developed anti-CAR cellular immune response, 
and 6 out of eight patients developed a humoral immune response. These responses became 
particularly prominent during and after treatment cycle two, compromising CAIX CAR T-cell 
numbers.[20] For this reason, we performed an analysis of circulating CAR T-cell numbers 
and cytokine levels during the first treatment cycle only(cohort 1: day 1 until 17, and cohort 
2: day 1 until 29).
CAIX CAR T-cell numbers in patient blood peak between days 5- 8 af-
ter onset of treatment 
CAIX CAR T-cells and CAIX CAR DNA copies were quantified in patient blood by FCM and qPCR, 
respectively (Fig. 1A,B) and were clearly detectable in all patients during the first cycle of CAR 
T-cell treatment. Since some of the patients received a second cycle of CAR T-cells at day 17, 
we only displayed the CAR T-cell numbers during the first 16 days. Patient 6 demonstrated 
very high levels of CAR DNA copies/μl at days 5, 10 and 16, which was in contrast to mea-
surement by FCM. In addition, qPCR measurements of CAR DNA levels in patient 5 decreased 
between days 5 and 8 while the number of CAR T-cells as measured by FCM increased after 
day 5. Statistical analysis revealed a significant correlation between the number of CAIX CAR 
T-cells and CAIX CAR DNA copies (Spearman correlation; r=0.83; P=0.04) on day 5 only, but 
no significant correlation on any other day during the first treatment cycle.
CAR DNA copy numbers remain constant but do not reflect CAR ex-
pression by T-cells.
Using T-cell cultures, we observed a significant decline in CAIX CAR membrane expression (ex-
pressed as mean fluorescence intensity, MFI) from culture day 14 to 18 (i.e., treatment days 1 
to 5). (Fig. 2A). Also, CAR RNA levels decreased during T cell culture, as presented for  infusion 
products of day 1 versus  5 (Fig. 2B). Expectedly, CAR DNA levels remained constant (Fig. 2C). 
Analysis of patient blood after treatment showed a decline of the CAIX CAR RNA:DNA ratio 
(Fig. 2D), which extends the in vitro observation and suggests the existence of CAR DNA-con-
taining T cells with a down-regulated expression of CAR. Of note, we calculated a relatively 
high RNA:DNA ratio for patient 6 at day 8 (Fig. 2D), because of an (unexpected relatively low 
CAR DNA level at day 8 when compared to day 5 and day 10 (Fig. 1B).
Kinetics of cytokine levels in patient plasma
We have analysed the levels of 27 cytokines in patient plasma at various time points during 
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Figure 1: Kinetics of CAIX CAR T-cell numbers and CAIX CAR DNA copies in blood.
Patients were treated with CAIX CAR T-cells (days 1-3/5) and monitored for blood numbers of CAIX 
CAR T-cells by FCM A) and CAIX CAR DNA copy numbers by Q-PCR B) during and after treatment up 
to day 16 of treatment cycle 1. Results are expressed in numbers per microliter blood. Values for 8 
individual patients treated in cohorts 1 and 2 and the median observation are shown.
  
        









 


 
 


 
 
  
        








 
 
 
 
 
 
 
 

 

 

 



 
 
 
A B
Figure 2: CAIX CAR expression decreases during T cell culture and after T cell infusion in 
patients.
Patient CAIX CAR T cell cultures at treatment days 1 and 5 (i.e., culture days 14 and 18) were ana-
lysed for A) CAIX CAR membrane expression by T cells, expressed as mean fluorescence intensity 
(MFI); B) CAIX CAR RNA levels, and C) CAR DNA levels, both expressed as ng per 106 CAR-express-
ing T cells. A-C: 19 paired samples; D) Patient blood samples after CAIX CAR T cell infusion were 
analysed for CAIX CAR RNA and DNA levels and data is presented as RNA:DNA ratio’s relative to 
treatment day 2, i.e., 1 day after first single CAIX CAR T cell infusion; 5 patients from cohort 2 were 
included ratio of blood levels of CAIX CAR RNA over CAIX CAR DNA.  Results are expressed relative 
to the value at treatment day 1 (day 1 ratio=1). 
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treatment with CAR T-cells, see Supplemental Fig. S1. CAR T-cell therapy induced fluctuations 
in plasma levels of about half of the analysed cytokines. Most of these cytokines peaked at 
day 2 (after the first CAR T-cell infusion), and declined thereafter, whereas other cytokines 
either peaked at later time points (i.e., IL-5, IFN-γ, IP-10) or showed constant elevated levels, 
(i.e., G-CSF, GM-CSF, PDGF-bb). The mean levels of IL-5, IFN-γ, IP-10 and PDGF-bb showed an 
over 5-fold increase from baseline on at least 1 time point, and an over 2-fold increase from 
baseline at 2 or more time points after the first CAR T-cell infusion. The mean levels of the 
following cytokines showed an over 2-fold increase from baseline between days 2 to 16, i.e., 
IL-1ra, IL-2, IL-4, IL-12(p70), IL-17, G-CSF, FGF-Basic, G-CSF. (Fig. 3A-C).
Plasma levels of IFN-γ and IL-6 correlate to numbers of CAIX CAR 
T-cells in blood
In order to assess whether changes in plasma levels of cytokines were related to peripheral 
Figure 3: Kinetics of cytokines levels in patient plasma during CAIX CAR T-cell treatment.
Plasma samples were collected from 8 patients during and after CAIX CAR T-cell treatment up to 
day 16 and analysed for multiple cytokines using the Bio-PlexTM human cytokine 27-plex; for assay 
specificities see Supplemental Table S1. Patients presented with considerable variation in base-
line (pre-treatment) cytokine levels, therefore we normalized cytokine levels relative to baseline 
for subsequent analysis. Cytokine levels relative to day 1 (pre-treatment) are presented in panels 
A, B, C, showing 9 cytokines each. Dashed lines represent cytokines demonstrating a > 5-fold in-
crease on at least 1 time point and a > 2-fold increase at 2 or more time points after the first CAR 
T-cell infusion. Horizontal dotted lines indicate 5-fold increases relative to day 1.
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persistence of CAR T-cells, we analysed the correlation between the absolute CAR T-cell num-
bers in blood and the plasma levels of individual cytokines. Since peak levels of either T-cell 
numbers or cytokines differed per patient between days 5 and 8, we used areas under the 
curve (AUC). AUCs were determined between the last day of T-cell infusion and the day at 
which CAR T cell numbers generally started to decline (day 5 and 8, respectively). Using this 
approach, we found strong correlations between CAIX CAR T-cell numbers as determined by 
FCM and IL-6 (Spearman correlation; r=0.86; P=0.01) as well as IFN-γ (Spearman correlation; 
r=0.73; P=0.04), but not for any of the other cytokines analysed (Fig. 4). No such correlation 
was found for CAIX CAR DNA copy numbers and cytokine levels.
IFN-γ and IL-6 are not constitutively produced by CAIX CAR T-cells 
The different plasma cytokine patterns raised the question whether these might be the con-
sequence of either constitutive or CAR-mediated production by the infused CAR T-cells. We 
previously showed that CAR T-cells upon CAIX specific interaction in vitro produced predom-
inantly IFN-γ, and low levels of IL-5, TNF-α and IL-4.[13] To distinguish between constitutive 
and CAR-mediated cytokine production in this study, we assessed the cytokine production 
during the CAR T-cell culture period prior to T-cell infusion (Supplemental Fig. 2). In these 
cultures PBMCs were stimulated for 2 days with CD3-mAb (without exogenous IL-2), followed 
by CAR transduction and subsequent culture with IL-2 and without CAIX antigen until T-cell 
infusion. The CD3 mAb T-cell activation induced an initial burst in the production of many cy-
tokines (day 2), after which we observed a clear decline in the accumulation of most of them, 
including IL-6 and IFN-γ (Fig. 5A,B; supplemental Fig. 2). These observations suggest that the 
elevated IL-6 and IFN-γ levels measured in plasma during and after therapy, are not constitu-
tively produced by CAR T-cells nor that such production depends on IL-2. The latter observa-
tion is noteworthy since CAR T-cell treatment in patients was administered concomitantly by 
subcutaneous IL-2 injections up to day 10. Aside from IL-6 and IFN-γ, also IP-10 and PDGF-bb 
demonstrate similar patterns of production during CAR T-cell culture and in patient plasma. 
Interestingly, a gradual increase of cytokines the levels during the 14 day culturing period 
was observed for IL-2 (added to the culture), IL-5 and IL-13, and to a lesser extent for IL-4, 
, IL-12(p70), FGF-basic, GM-CSF, MIP-1a, Rantes and VEGF (Fig. 5A). As previously report-
ed[13], IL-5 production by (CAR) T-cells is mediated by IL-2; and indeed both the IL-5 levels in 
culture supernatants and in plasma clearly coincided with the application of exogenous IL-2. 
Accordingly, cessation of the in vivo IL-2 injections at day 10 was followed by a sharp decline 
in plasma IL-5 levels of the patients (day 16). From the cytokines that were constitutively pro-
duced by the cultured CAR T-cells at time of infusion, only IL-4 showed a weak raise in plasma 
levels at treatment day 2 (Fig. 3A). In addition, the day 2 elevated plasma levels of IL-1ra, 
G-CSF, GM-CSF, MIP-1a and TNF-a cannot be related to constitutive production by CAR T-cells. 
Collectively, our data support the notion that constitutively produced cytokines by CAR T-cells 
hardly affect plasma cytokine levels following CAR T-cell infusion.
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Figure 4: Plasma levels of IL-6 and INF-γ correlate with circulating CAIX CAR T-cell numbers
CAIX CAR T-cell numbers in blood, expressed as Area Under the Curve (AUC), between days 5 to 8 
(i.e., during the 3 days following the last CAR T-cell infusion) for each individual patient were cor-
related with the absolute plasma levels of A) IL-6 and B) INF-γ, also expressed as AUC over same 
time period. Statistical significance was assessed by Spearman correlation analysis; p-value < 0.05 
is considered significant. 
Figure 5: Kinetics of cytokine levels in supernatants of CAIX CAR T-cell infusion products
PBMCs were activated by soluble anti-CD3 mAb (days 0+1), transduced with the CAIX CAR (days 
2+3) and subsequently expanded in an IL-2-supported culture up to day 16. Culture supernatants 
were collected every 2-3 days from day 2 onwards to day 16 and analysed for their cytokine levels 
using the cytokine 27-plex; for details see legend in Fig. 3. Kinetics of the absolute values (mean 
+/- standard error; n=5) per cytokine is shown in Supplemental Fig. S2. Cytokine levels in CAR T-cell 
culture supernatants relative to day 2 (post-activation) are presented in panels A, B; panel A) 8 
cytokines with increasing levels. Dashed lines represent cytokines demonstrating an over 5-fold 
increase relative to day 2. Horizontal dotted line indicates a 2-fold increase relative to day 2; panel 
B) 19 cytokines with decreasing levels.
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Plasma cytokine levels do not correlate with CAIX CAR T-cell activity 
in terms of liver toxicity
During treatment, all 8 patients showed slight to dramatic elevations of liver enzyme levels in 
blood,  reaching Common Terminology Criteria for Adverse Events (CTCAE) grade 3-4 in 3 pa-
tients (patients 1, 3 and 8) during treatment cycle 1,  highly likely due to recognition by CAR T 
cells of CAIX expressed on the bile duct epithelium. Blood levels of the liver enzymes bilirubin 
(Bili), alkaline phosphatase (AP), gamma-glutamyl transpeptidase (g-GT), aspartate transam-
inase (ASAT), and alanine transaminase (ALAT) during treatment are represented in Fig. 6A. 
The recognition of CAIX on the bile duct epithelium by the CAR T cells (so-called “on-target” 
toxicity) coincided with an inflammation reaction in the portal triangles around the bile ducts. 
The direct and indirect actions of the CAR T cells upon recognition of CAIX on bile duct epi-
thelium, i.e., T cell effector functions (killing and cytokine release, a.o. IFN-γ) and induction 
of an inflammatory reaction respectively, lead to an increase of all liver enzymes. We used 
these liver enzyme elevations as a surrogate marker for CAR T cell activity (Supplementary 
Fig. 4). Although mean blood levels of AP, g-GT, ASAT, and ALAT displayed a similar kinetics as 
the numbers of CAR T-cells in blood (assessed with either FCM or Q-PCR) (Fig. 6A, and Fig. 
1A-B), neither liver enzymes nor their derivative, the CTCAE toxicity grading, did significantly 
correlate with CAR T-cell numbers. Moreover, we could not demonstrate any correlation be-
tween plasma cytokine levels and liver enzyme levels or toxicity grading (Fig. 6B).
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Figure 6: No significant correlation between plasma levels of cytokines and liver enzymes.
Blood samples from 8 patients during CAIX CAR T-cell treatment were and analysed for levels of 
liver enzymes and cytokines; panel A) presents levels of bilirubin (Bili), alkaline phosphatase (AP), 
gamma-glutamyl transpeptidase (γ-GT), aspartate transaminase (ASAT), and alanine transaminase 
(ALAT) (mean +/- standard error; n=8). Levels of liver enzymes were correlated with plasma cyto-
kine levels; and correlations were found not to be significant; panel B) example of two non-sig-
nificant correlations between the AUC of IL-6 and IFN-γ with the AUC of ALAT between days 5-8.
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DISCUSSION
Here we provide an extensive analysis of cytokine plasma profiles in metastatic RCC patients 
treated with T-cells transduced with CAR:Fc(ε)RIγ specific for CAIX [11, 12], and assessed 
whether cytokine plasma levels relate to in vivo numbers and activity of CAR T-cells in terms 
of on-target liver toxicity.
CAIX CAR T-cells in patient blood were quantified by FCM for CAR protein and qPCR for CAR 
DNA. However, in contrast to a previous report [21], we did not find significant correlations 
between numbers of CAIX CAR T-cells and CAIX CAR DNA copies, except for the last treatment 
day (day 5). In addition to existing variation in CAR DNA copy numbers in T-cell preparations 
between individual patients [11], we would like to argue that CAR DNA levels do not directly 
reflect the level of CAR membrane expression and may in fact overestimate the number of 
T cells that are reactive to CAIX in vivo. Notably, a decrease in CAR surface expression was 
accompanied by a decrease in CAR mRNA expression in T cell infusion products as well in 
blood following T-cell treatment, possibly the consequence of decreased gene transcription 
in non-activated T-cells. In a previous study, using a similar γ-retroviral vector backbone, a 
decreased expression has also been observed for a TCR transgene, which was attributed to 
a waning LTR-driven gene transcription due to metabolic quiescence of gene-transduced 
T-cells.[22] This loss of transgene expression might be vector dependent as so far no such 
event has been described in other studies using different vector backbones. 
Our observation that following T-cell infusion, CAR RNA:DNA ratio in blood decreased sug-
gests that circulating CAR T-cells have not been activated in vivo. Yet, blood cytokine signa-
ture suggests in vivo CAR T cell activation. Therefore we anticipate that CAR T cells that have 
encountered CAIX target antigen (in tumor and liver) and have released cytokines will be 
located in the respective tissues.
Most CAR T-cell trials, especially in solid tumors, have monitored only a limited number of 
blood cytokines aside from IFN-γ and TNF-α. Some CD19 CAR T-cell trials reported data on 
multiple cytokines and showed similar plasma patterns as described in the current study, 
including a prominent increase of IFN-γ and IP-10 levels in the first days after a (single) CAR 
T-cell infusion, and subsequent normalization to baseline.[3, 4, 6, 21, 23] In the current study, 
IFN-γ increased >15 fold , though not as high as in a second generation CD19 CAR T-cell trial 
where a >1000 fold increase of IFN-γ levels was observed.[21] The prominent increase in 
plasma IFN-γ levels in the latter studies may be attributed to the extent of the disease bur-
den in these hematological patients as well as the co-stimulatory format of the CAR used 
yielding higher activity. The increased levels of IP-10 and PDGF-bb may be the consequence 
of increased levels of IFN-γ since the latter cytokine is known to prime IP-10 and PDGF-bb 
production by amongst others, monocytes, endothelial cells and fibroblasts.[24, 25]
In our study, we also observed a clear increase in IL-5 plasma levels in vivo, which, based on 
our in vitro data, we link to IL-2-induced production of this cytokine. Aside from our own ob-
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servations, others also described that IL-2 can induce production of IL-5 and IL-13 by T-cells.
[26] Accordingly, in another CAR T-cell trial targeting Epidermal Growth Factor Receptor 2 
(HER2) positive sarcoma without IL-2 administration, no changes in IL-5 or IL-13 plasma levels 
were observed.[27] In the reported CD19 CAR T-cell trials no IL-2 was co-administered to the 
patients, which may explain that no changes in IL-5 plasma levels were reported.[6] Thus, our 
current observation strongly suggests that the elevation in IL-5 plasma levels is rather an IL-2 
induced effect than a demonstration of CAR T-cell activity upon CAIX-antigen recognition.[13]
In the recently reported CD19 CAR T-cell trials, plasma cytokine levels of GM-CSF, IL-2, IL-10, 
TNF-α, IFN-γ and in particular IL-6 were closely monitored because these cytokines were 
strongly elevated in patients with clinical symptoms of a cytokine storm.[2-4, 6, 21, 23, 28-
32] In CD19 CAR T-cell studies, cytokine storms are a frequent observation and are probably 
mainly due to the extended tumor burden in these patients with a high load of accessible 
targets together with highly active CAR T-cells. In our CAIX CAR T-cell trial only one patient 
showed a high increase of IL-6 plasma levels. Interestingly, this particular patient received the 
highest CAIX CAR T-cell dose, but did not present with clinical symptoms of a cytokine storm. 
All patients demonstrated peak numbers of CAR T-cells as well as peak levels of cytokines be-
tween the last day of infusion (day 5) and day 8, i.e., up to 3 days after the last T-cell infusion. 
A correlation was observed between levels of IL-6 and IFN-γ and number of CAR T-cells, sug-
gesting that these cytokines represent a measure of in vivo CAR T-cell activity. In fact, plasma 
levels for these cytokines may reflect exposure of CAR T-cells to CAIX antigen since days 5-8 
post infusion PBMCs produced significant levels of IFN-γ after ex vivo CAIX recognition.[13] 
From the kinetics of IL-6 and IFN-γ in CAR T-cell culture supernatant it can be concluded that it 
is unlikely that constitutive production or IL-2 is involved in phenomenon. In addition, no cor-
relations were found between the absolute number of B-cells, CD4+, CD8+, or CD15+CD56+ 
cells in patient blood and plasma cytokines. Of note, no correlations were found between 
the CAIX CAR DNA copy numbers and plasma cytokine levels. This contributes to our earlier 
statement that CAR T-cells measured by FCM may give a better representation of the in vivo 
presence of functional CAR T-cells since CAR DNA measured by qPCR also detects CAR T-cells 
with down-modulated CAR expression and thereby not functional CAR expressing cells.
In addition to peripheral T-cell persistence, we attempted to correlate plasma cytokine lev-
els to liver enzyme abnormalities as a measure of on-target effects, and assessed whether 
plasma levels of liver enzymes could serve as correlates for in vivo activity of CAIX CAR T-cells 
towards the CAIX antigen expressed on the bile duct epithelium.[11, 12] Despite apparently 
similar kinetics of some of the liver enzymes, CAR T-cell numbers and some cytokines, no 
statistically significant correlations were found between the levels of liver enzymes and the 
latter two parameters. This is probably due to the fact that T-cell numbers and cytokine levels 
in the periphery do not adequately reflect the presence and activity of CAR T-cells in the liver 
parenchyma and bile ducts. 
In conclusion, in the current study we found a correlation between plasma levels of IL-6 
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and IFN-γ and peripheral numbers of CAIX CAR T-cells but not with liver toxicity. We argue 
that monitoring of CAR T cells in patients should preferably be performed by FCM using an 
anti-CAR antibody to specifically detect those T cells reactive towards target antigen. Even 
though the number of patients in our analysis was limited, and our analyses may be under-
powered to detect differences with respect to other cytokines, we advocate the measure-
ments of plasma levels of IFN-γ and IL-6 during T-cell therapy trials. We argue that these two 
cytokines serve as indicators for T-cell persistence. Further studies are warranted to establish 
whether IFN-γ and IL-6 are associated with anti-tumor activities of gene-modified T-cells.
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Lower limit of detection Range standard curve (pg/mL)
CYTOKINE [PG/ML]* MIN MAX
Hu IL-1b 3,1 3,2 52178
Hu IL-1ra 5,0 5,2 85727
Hu IL-2 1,3 1,3 21614
Hu IL-4 0,4 0,4 6303
Hu IL-5 3,1 3,1 50609
Hu IL-6 2,2 2,3 38185
Hu IL-7 3,1 3,1 50240
Hu IL-8 1,9 1,9 31062
Hu IL-9 2,0 2,1 34790
Hu IL-10 2,2 2,2 36166
Hu IL-12(p70) 3,2 3,3 53588
Hu IL-13 3,6 3,7 60505
Hu IL-15 ) 2,1 2,1 34157
Hu IL-17 2,7 3,1 50051
Hu Eotaxin 2,3 2,3 37440
Hu FGF basic 1,6 1,6 26755
Hu G-CSF 2,4 2,4 40031
Hu GM-CSF 0,9 1,2 19070
Hu IFN-g 5,0 3,2 52719
Hu IP-10 6,8 6,7 109911
Hu MCP-1(MCAF) 1,4 1,4 22566
Hu MIP-1a 1,5 1,4 22566
Hu MIP-1b 2,1 2,0 33283
Hu PDGF-bb 3,3 3,2 51933
Hu RANTES 2,2 2,2 35250
Hu TNF-a 5,6 5,8 95484
Hu VEGF 3,3 3,4 56237
Supplementary Table S1 - Bio-plexTM human cytokine 27-plex bead array specificities 
* L.O.D. is  defined as the value calculate d from the standard curve at the point of 2 standard devi-
ations above the mean background MFI (ten replicates). 
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Supplemental Figure 1: Kinetics of cytokines levels in patient blood during CAIX CAR T-cell 
treatment.
Plasma samples were collected from 8 patients during and after CAIX CAR T-cell treatment up 
to day 16 of treatment cycle 1 and analyzed for multiple cytokines using the Bio-PlexTM human 
cytokine 27-plex; for assay specificities see Supplemental Table S1. Absolute values for individual 
patients and median observations are shown per cytokine and per time point
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Supplemental Figure 2: Kinetics of cytokine levels in CAIX CAR T-cell culture supernatant.
PBMC were activated by soluble anti-CD3 mAb (days 0+1), transduced with the CAIX CAR (days 2+3) 
and subsequently expanded in an IL-2-supported culture up to day 16. Culture supernatants were 
collected every 2-3 days from day 2 onwards to day 16 and analyzed for their cytokine levels using the 
cytokine 27-plex; Absolute values (mean +/- standard error; n=5) are shown. 
Supplemental Figure 3: AUC calculations of cytokine levels
Area under the curves  (AUCs) were determined between the last day of T-cell infusion and the day at 
which CAR T cell numbers generally started to decline (day 5 and 8, respectively). Graphpad Prism v5.0 
was used to prepare graphs and calculation of the Area Under the Curve (AUC) for cytokines and CAR 
T-cell numbers and was performed using non-normalized data in linear X- and Y-axis plots.
  
                 




 



 

 

                 





 
 




 

41
Plasma IFN-γ and IL-6 levels correlate with peripheral CAR T-cell numbers
CAIX CAR 
T cell
IFNy production
Inltration of T cells leads to liver toxicity, inammation and 
release of liverenzymes: ASAT, ALAT, g-GT and AP 
“On-target” toxicity due to CAIX expression on bile duct epithelium 
Hepatocyte
Bile Duct epithelium
CAIX CAR T cell
Bili, ASAT, ALAT, g-GT and AP
Supplemental Figure 4: On target toxicity as a surrogate marker of T cell activity.
On target toxicity due to recognition of CAIX on the bile duct epithelium by the CAIX CAR T cells. 
Upon recognition of CAIX on bile duct epithelium CAR T cells exert direct T cell effector functions, 
such as killing and cytokine release (amongst others,  IFN-γ), and induced an inflammatory reac-
tion. It is assumed that this sequence of actions has led to an increase of all liver enzymes. We 
used these liver enzyme elevations as a surrogate marker for CAR T cell activity.
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T cell maturation stage prior to and during 
GMP processing informs on CAR T cell 
expansion in patients.
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ABSTRACT
Autologous T cells were genetically modified to express a Chimeric Antigen Receptor (CAR) 
directed towards carboxy-anhydrase-IX (CAIX) and used to treat patients with CAIX-positive 
metastatic renal cell carcinoma. In the present study, we questioned whether the T cell mat-
uration stage in the pre-infusion product affected CAIX CAR expression and function in vitro 
as well as in vivo CAR T cell numbers and expansion. During the 14 days expansion of CAR 
T cells prior to administration, we observed shifts from a predominant CD4 to a CD8 T cell 
phenotype, and from a significant fraction of naïve to central effector T cells. Surface expres-
sion of the CAR was equally distributed among different T cell subsets and T cell maturation 
stages. During T cell culture days 14 to 18 (which covered patient treatment days 1 to 5), T 
cells demonstrated a decline in CAR expression level per cell irrespective of T cell matura-
tion stage, although the proportion of CAR positive T cells and CAR-mediated T cell effector 
functions remained similar for both CD4 and CD8 T cell populations. Notably, patients with 
a higher fraction of naïve CD8 T cells at baseline (prior to genetic modification) or central ef-
fector CD8 T cells at 2 weeks of CAR T cell culture demonstrated a higher fold expansion and 
absolute numbers of circulating CAR T cells at 1 month after start of therapy. We conclude 
that the T cell maturation stage prior to and during CAR T cell expansion culture is related to 
in vivo CAR T cell expansion.
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INTRODUCTION
Despite clinical successes in B-cell malignancies, adoptive transfer of T cells genetically mod-
ified with chimeric antigen receptor (CARs) or T cell receptors (TCRs) to treat solid tumors 
is challenged by limited patient responses.[1] The efficacy of adoptive T cell therapy (in he-
matological malignancies) correlates with numbers and persistence of circulating modified T 
cells [2-5]. Building on this notion, several approaches have been explored to improve per-
sistence of genetically modified T cells in vivo. For example, the introduction in receptors of 
intracellular domains from the CD28 and/or CD137 co-stimulatory molecules has led to an 
increased CAR T cell persistence as well as expansion in vivo, and consequently in clinical 
responses.[6, 7] 
Furthermore, preclinical studies in mice and monkeys suggest that improved in vivo per-
sistence and anti-tumor responses are obtained when T cells in early stages of differentiation 
(such as naïve or central memory cells) are used for genetic modification and treatment[8, 
9]. In fact, the differentiation state of CD8+ T cells appeared to be inversely related to their 
capacity to proliferate and persist.[10, 11] We have previously generated CAR T cells directed 
against carboxy-anhydrase-IX (CAIX) and treated patients with CAIX-positive metastatic renal 
cell carcinoma (mRCC).[12] Here, we assessed T cell maturation stage prior to and during 
CAR T cell expansion cultures, analyzed whether the T cell maturation stage affects CAR ex-
pression and function in vitro as well as the in vivo properties of CAR T cells, in particular 
expansion potential and absolute numbers of circulating CAR T cells. 
MATERIALS AND METHODS
Patients and treatment
Patients, diagnosed with CAIX-positive mRCC and for whom no standard treatment was 
available, were included in this phase-I trial. Patients were treated in 3 cohorts, and aimed 
to assess toxicity and to establish the maximum tolerated dose of the number of CAR 
T cells. Treatment schedule was previously presented [13] and was, in brief: in cohort 1, 
treatment consisted of intravenous administration of 2x107 T-cells at day 1, 2x108 T-cells 
at day 2, and 2x109 T-cells at days 3-5 (treatment cycle 1) and days 17-19 (treatment cy-
cle 2). Simultaneously, patients received twice daily subcutaneous  injections of IL-2 at 5 
x 105 IU/m2 on days 1-10 and days 17-26. Because of liver toxicity [13] this schedule was 
changed in cohort 2, to a classic 3x3 dose-escalating phase I schedule starting at 1 x 108 
CAR T-cells per infusion and extending to 2, 4, 8, 16, 20, 25, and 30 × 108 cells at subse-
quent dose levels, and applying a maximum of 10 T-cell infusions at days 1–5 and days 29–33 
combined with sc IL-2 at 5 × 105 IU/m2 twice daily at days 1–10 and days 29–38. In cohort 
3, patients were treated as in cohort 2, but received an extra iv infusion of 5 mg of the 
anti-CAIX mAb G250, 3 days before start of each series of CAR T-cell infusions, in order to 
block CAIX antigen in the liver and leaving accessible CAIX antigen at RCC tumor sites.[14-16] 
For the analyses of CAR T cell persistence, only patients treated in cohort 2 and 3 were as-
3
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sessed until day 29, as from day 29 eight out of nine patients received a second treatment 
cycle of CAR T cells. Since patients in cohort 1 received varying numbers of CAR T cells, and 
1 patient already received a second cycle of CAR T cells on days 17-19, cohort 1 was not as-
sessed in the persistence analyses.
Patients did not receive lympho-depleting pretreatment. The clinical protocol and amend-
ments were approved by governmental regulatory authorities (Central committee on re-
search involving Human Subjects) as well as the Erasmus MC institutional medical ethical 
review board. The clinical protocol (DDHK97-29/P00.0040C) adheres to the declaration of 
Helsinki protocols. Patient characteristics are detailed elsewhere.[13] 
T cell infusion product and post-treatment blood sampling
Patient peripheral blood mononuclear cells (PBMC) from leukapheresis (n=9) were activated 
at day 0 with soluble anti-CD3 mAb OKT3 (10ng/mL) without IL-2. At days 2 and 3 T cells were 
retrovirally transduced with the CAIX CAR in the presence of 100 IU/ml IL-2. From days 4 to 18 
T cells were expanded in medium supplemented with 360 IU/ml IL-2. Patients were treated 
with 5 daily infusions of ‘fresh’ CAIX CAR T cells harvested from culture at days 14 to 18[13, 
17]. We obtained blood samples at regular intervals before, during, and after treatment for 
direct flow cytometric (FCM) analysis and isolation and cryopreservation of PBMC in liquid 
nitrogen[18, 19] 
Flow cytometry 
CAIX CAR-positive T cells in cultures and blood samples were assessed by FCM using the an-
ti-CAIX CAR idiotype mAb NuH82, as described in [18] and supplementary figure S1. The start-
ing T cell product (PBMC from leukapheresis) and T cell cultures were analyzed for various 
lymphocyte subsets, a.o. CD4+ and CD8+ T cells and T cell maturation subsets using following 
markers: CD27, CD28, CD45RA, CD45RO, CD62L and CCR7. The starting T cell product (PBMC 
from leukapheresis) is referred to the “baseline” sample or measurement in the rest of this 
study. In addition, T cell maturation subsets were analyzed for CAR-expression (supplementa-
ry figure S1) and CAR-mediated effector function in response to CAIX+ RCC cell line (SKRC-17 
MW1-clone4) by means of up-regulated expression of CD107. Information on antibodies and 
staining combinations used in multi-color FCM is specified in supplementary Table S1. Sam-
ples were measured on the FACS Canto, and analyzed with FCS express v. 4.07 software (De 
Novo software). Gating strategy to determine the T cell maturation stage is demonstrated in 
Supplementary Fig 1A+B.
Statistical analysis
Statistical analyses were performed with SPSS software (version 21) for Windows (IBM Corpo-
ration, Illinois, U.S.A.). Graphpad Prism v5.0 was used to prepare graphs.
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RESULTS
T cell phenotype
Patient PBMC at baseline (from leukapheresis) were activated, transduced with the CAIX CAR 
and expanded. During the 14 days of expansion, the phenotype of the T cells shifted signifi-
cantly. Although the extent varied per patient, T cell cultures reproducibly demonstrated a 
shift from a CD4+ to a CD8+ predominance compared to baseline (Figure 1A, supplementary 
Figure S2). During the 18 days culture period, individual markers expressed on CD3+ T cells 
demonstrated a clear shift, especially during the first 14 days. (Supplementary Figure S3). 
When assessing CD8 T cell maturation according to the markers CD45RA, CD45RO, CD27 and 
CD28, we observed that during culture the most prevalent subset drastically shifted from 
TES at baseline to TEM at day 14. (Figure 1B; see legend to Figure 1 for the definition of matu-
ration stages: TN (Naïve), TINT (Intermediate between TN and TCM), TCM (Central Memory), TEM 
(Effector Memory), TCE (Central Effector) and TES (End Stage) T cells). Following T cell culture, 
there was also a decrease in the fraction of TN and an increase in the fraction of TCE, yet the 
overall change was in favor of younger T cells (TCM + TEM) at the expense of further maturated 
T cells (TCE+TES). CD4
+ T cells showed also a culture-dependent decrease in the fraction of TN 
and an increase in the fraction of TEM, yet the most prevalent subset at baseline, i.e., TCM, 
remained unchanged (Figure 1C). Interestingly, in contrast with CD8+ T cells cultured CD4+ T 
cells harbored almost no TCE cells. Additional analysis with different T cell maturation markers 
(CD45RA, CCR7 (CD197) and CD62L) showed high concordance with the maturation stages 
and kinetics as described above (Supplementary Figure S4).
Figure 1: T cell phenotype and maturation during clinical T cell expansion cultures.
A) Proportions of CD4 and CD8 T cells at baseline (leukapheresis, day 0) and culture day 14. Data of 
individual patients are presented in supplementary Figure S1. Maturation stages of CD8+ B) and CD4+ 
C) T cells at baseline and culture day 14 and at day 18 defined according to the expression of CD45RA, 
CD45RO and CD27/CD28 as indicated in insert: Naïve, TN: CD45RA+, CD45RO-, CD27/CD28+; Central 
Memory, TCM: CD45RA-, CD45RO+, CD27/28+; Effector Memory, TEM: CD45RA-, CD45RO+ or CD27/CD28-
; Central Effector, TCE : CD45RA+, CD45RO+, CD27/CD28-) and End Stage TES: CD45RA+, CD45RO-, CD27/
CD28- T cells. A small fraction was CD45RA+, CD45RO+ and CD27/CD28+ and this population was de-
fined as interphase (Int1) T cells. Data are presented as stacked bars of means of 9 patients.
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Figure 2: CAIX CAR expression of T cells in infusion products according to T cell maturation.
Proportions of CAIX CAR-positive CD8+ (A) and CD4+ (B) T cells and CAIX CAR expression levels 
(expressed as mean fluorescence intensity, MFI) on CD8+ (C) and CD4+ (D) T cells at culture days 14 
and 18 according to T cell maturation. Differences between culture days 14 and 18 with respect to 
paired continuous parameters were determined using an exact Wilcoxon rank sum test. * p < 0.05; 
** p < 0.01; ns: not significant. Bars represent mean + SEM from 16 independent clinical CAIX CAR 
T cell cultures for the treatment of 9 patients, of which 7 received infusions in two treatment cycles. 
See also legend to Figure 1.
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Figure 3: CAIX CAR-mediated function by T cell maturation subsets.
CAIX CAR T cell cultures at days 14 and 18 were assayed for CAIX CAR-mediated cytolytic (degran-
ulation) potential. CAIX CAR T cells were co-cultured (2 hours) with the CAIX-positive RCC cell line 
(SKRC-17 MW1-clone4) or the CAIX-negative cell line K562 and subsequently analyzed by flow 
cytometry. Results are presented as proportions of CD107 positivity within differently matured 
CD8+ A) and CD4+ B) T cells. Dotted line represents the average proportion of CD107 positivity of 
CD8+ T cells after co-culture with the CAIX positive RCC cell line. T cell maturations subsets were 
defined by the markers CD45RA and CCR7 as follows: TN: CD45RA+,CCR7+; TCM: CD45RA-,CCR7+; 
TEM: CD45RA-,CCR7-; TEF: CD45RA+,CCR7-. Bars represent mean + SEM (n=3).
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CAIX CAR expression in T cell maturation subsets
At culture day 14, the proportion of CAIX CAR-expressing cells was about equal for various T 
cell subpopulations, such as CD3 positive T cells in combination with CD4, CD8, CD56, CD57, 
TCRγδ, CD45RA, CD45RO, CD62L or CCR7 (supplementary Figure S5). The proportion of CAIX 
CAR-expressing cells within CD8+ and CD4+ T cells was stable during patient treatment (cul-
ture days 14-18), and appeared highest in the TINT 
+ TCM and lowest in the TES maturation 
stages (Figure 2A+B). When considering the CAR expression level per cell (MFI), we observed 
a significant decrease of CAR expression between days 14 to 18 for almost all maturation 
stages with exception of CD8+ TN, CD8
+ TES cells, and CD4
+ TES cells (Figure 2C+D). This obser-
vation is in extension to a previous report on a general loss of CAR expression during the last 
5 days of the T cell culture.[20] Data at MFI level also reinforced the above observation that 
CAR expression was highest in the TINT + TCM and lowest in the TES maturation stages (Figure 
2C+D). Further, we analyzed the CAIX CAR-mediated function (degranulation) and found no 
significant differences in CD107-upregulation between the different maturation stages or T 
cell culture times following co-culture of CAR T cells with a CAIX-positive RCC cell line or 
CAIX-negative K562 cells. Thus, the relatively small decrease in CAR expression did not result 
in a measurable decrease in CAR-mediated function (Figure 3A+B).
T cell maturation correlates with in vivo CAR T cell expansion.
We analyzed whether phenotype of T cells at baseline and after culture correlated with num-
bers of CAR T cells in patient blood and expansion (fold increase) of these CAR T cells during 
5 days after the last infusion. Kinetics of circulating CAR T cell numbers irrespective of mat-
uration stage in patients have been reported elsewhere.[20] Here, we reveal a significant 
correlation between the fold increase in CAR T cell numbers in patients and the proportions 
of CD8+ TN cells at baseline (Figure 4A) and CD8
+ TCE in the infusion product at culture day 14 
(Figure 4B) and on day 18 (r=0.683, p=0.042 (data not shown). Patients with higher propor-
tions of CD8+ TN cells in the baseline PBMC and CD8
+ TCE in the infusion product, in general, 
had higher absolute numbers of circulating CAR T cells up to 29 days after the first infusion 
(Figure 4C+D). Our in vitro analyses considered both CD8+ and CD4+ T cells (Figures 1-3). 
Correlations between the relative occurrence of T cell maturation stages (prior to and during 
T cell processing) and numbers of T cells in post-treatment patient blood samples were as-
sessed for both CD8+ and CD4+ T cells. Significant correlations, however, were only found 
for CD8+ T cells but not CD4+ T cells (data not shown). We found no correlations between 
proportion of CAR-positive T cells or CAR expression (MFI) in the infusion product and CAR T 
cell numbers or expansion in patients (data not shown).
DISCUSSION
Here we document T cell phenotypic changes during IL-2-supported CAIX CAR T cell cultures 
in preparation of a clinical trial to treat RCC patients. During the 2-week expansion period, 
T cells skewed from a CD4 to CD8 phenotype and the proportion of naïve CAR T cells (TN: 
3
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CD45RA+,CD45RO-,CD27/CD28+) strongly declined, while the proportions of TEM (CD45RA
-, 
CD45RO+, CD27/CD28-) and TCE (CD45RA
+, CD45RO+, CD27/CD28-) cells significantly increased. 
We noted a shift from TN cells to more maturated stages as was described before for other 
transduced T cell products cultured with IL-2.[21] Interestingly, also the frequency of TES de-
clined during the CAR T cell culture. We anticipate that the less maturated cells like TCM and 
TEM have proliferated faster, and thereby have overgrown the TES cells. We demonstrated a 
small decline in CAR expression level per cell during the 5-day CAR T cell culture covering 
the days of T cell administration (day 14-18) that was independent of T cell maturation stage 
and did not affect CAR-mediated function. We conclude that the 5 sequential and ‘freshly’ 
prepared clinical preparations of CAIX CAR T cells had about equal phenotypic and functional 
properties.
Figure 4: Correlations between T cell maturation (pre-infusion) and increase of CAR T cell 
numbers in patients.
Correlation plots of proportions of TN, TCM, TEM, TCE, and TES cells at baseline A) and culture day 14 B) 
versus increase of CAR T cell numbers in vivo during the first 5 days after the last T cell infusion of 
treatment cycle 1 (see refs [13, 20]). Dotted lines represent the 95% confidence bands of the best 
fitted line. The Spearman correlation coefficient method was used to assess linear association. 
P-values less than 0.05 were considered significant. Patients were divided into above or below 
median values (high and low, respectively) of TN at baseline (day 0) C) or TCE cells at culture day 
14 D) and plotted for absolute numbers of circulating CAR T cells during treatment cycle 1 (days 
1-29). See also legend to Figure 1 for further details.
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In adoptive CAR T cell treatment, circulating numbers, persistence and in vivo expansion po-
tential of infused CAR T cells are currently the only parameters revealed to be associated 
with improved clinical outcome.[22] Most CAR T cell trials targeting CD19 in hematological 
malignancies show strong T cell expansion, mainly due to a high load and accessibility of tar-
get antigen, the nature of tumor cells (B cells being able to provide co-stimulation) and highly 
active (second generation) CAR T cells. Along these lines we sought to define pre-infusion 
characteristics that may predict the in vivo behavior of infused CAR T cells. Here, we showed 
that patients with more CD8+ TN cells in baseline PBMC (from leukapheresis) or more CD8
+ TCE 
in the infusion product at culture day 14, showed a higher fold increase in numbers of CAR 
T cells in vivo, resulting in higher blood levels of CAR T cells in these patients for at least 4 
weeks. In fact, a correlation exists between characteristics of both baseline PBMC (propor-
tion CD8+ TN) and infusion product (proportion CD8
+ TCE) and numbers of circulation CAR T 
cells after treatment. Such findings bear clinical relevance, as younger T cells were shown to 
positively correlate with clinical effectiveness in adoptive T cell trials.[1, 23, 24] To our knowl-
edge, our study is the first CAR T cell trials targeting a solid tumor, in which a correlation is 
demonstrated between pre-infusion and pre-expansion T cell characteristics and in vivo CAR 
T cell expansion potential. In only one other non-CD19 CAR trial, targeting neuroblastoma 
with GD2 CAR T cells, a correlation was described between in vivo CAR T cell persistence and 
the proportion of CD4+ or TCM cells in the infusion product.[24] Our observation is in line with 
the report that effector T cells derived from naive rather than memory T cell subsets possess 
superior features for adoptive immunotherapy, though no correlations were made with in 
vivo parameters.[25]
The observation that the proportion CD8+ TN in baseline PBMC determines the in vivo behav-
ior of CAR T cells is intriguing and provides a means to manipulate leukapheresis products 
for a better clinical outcome, especially for patients with low proportions of TN cells in PBMC. 
This could include enrichment for TN cells before transduction or changing the culturing con-
ditions by addition of cytokines such as IL-15 and IL-21 during expansion[21, 26]. These data 
may provide clues to adapt the in vitro T cell processing towards optimal T cell fitness and 
may enable to develop an improved protocol for adoptive T cell therapy.
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Supplementary figure S1: Gating strategy of T cell cultures for CAR expression and T cell 
maturation 
Gating strategy for the CD45RA/CD45RO/CD27/CD28 maturation panel, and (B) the gating strategy 
for the CD45RA/CD62L/CCR7 maturation panel. Both panels also determined the CAIX CAR expression 
(upper right panels). The NuH82-biotin (b) + Streptavidin (SA) gate was set based on an “unstained” 
tube,  in which the NuH82-biotin mAb was left out in the first staining step. A Boolean gating approach, 
was used to automatically generate the combinations of the maturation stage and CAIX CAR expres-
sion. Plots show  a representative T cell culture at day 14 of the culture. 
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Supplementary figure S2: Kinetics of major lymphocyte subsets during CAIX CAR T-cell 
expansion cultures. 
Patient PBMC from 9 patients were activated, transduced and cultured two-times as detailed in 
Materials and Methods section to generate therapeutic doses of CAIX CAR T-cells for treatment 
cycle 1 and treatment cycle 2; for both clinical cultures, non-transduced T-cells were cultured in 
parallel, resulting in 4 independent T-cell cultures per patient. FCM analysis of lymphocyte sub-
sets revealed that phenotypic shifts were independent of transduction and reproducible for each 
patient, therefore mean values of the 4 individual cultures are presented (one dot per patient per 
time point). Day 14 and day 18, represent the infusion product on the first and last of the 5 daily 
infusions of CAIX CAR T-cells.  Presented lymphocyte subsets: CD3+; CD3-CD56+ (NK); CD3+CD4+; 
CD3+CD8+; CD3+TCRgd+; CD3+CD57+; CD3+CD56+, and % CD56+ of CD3+CD4+, and % CD56+ of 
CDC3+CD8+. Horizontal lines represent the median values.
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Supplementary figure S3: Kinetics of T-cell maturation markers expressed by different 
T-cell subsets during CAIX CAR T-cell expansion cultures. 
Patient PBMC from 9 patients were propagated as detailed in the legend to Figure S2. FCM anal-
ysis of maturation markers CD45RA, CD45RA, CD27/CD28, CD62L and CCR7 on CD3+ T-cells and 
CD3+CD4+ and CD3+CD8+ T-cells was performed at baseline and culture days 14 and 18. The 
mean values of the 2 clinical CAIX CAR T-cell cultures are presented (one dot per patient /time 
point). Horizontal lines represent the median values.
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Supplementary figure S4: T-cell maturation during clinical T-cell expansion cultures using 
CD45RA, CD62L and CCR7. 
CAIX CAR T-cell cultures were generated as described. Proportions of T-cell maturation sub-
sets within CD8+ (A) and CD4+ (B) T-cells were assessed at baseline (PBMC from leukaphere-
sis, day 0), culture day 14, and culture day 18 according to the expression of CD45RA, CD62L 
and CCR7 as indicated the in insert: Naïve, TN: CD45RA+, CD62L+, CCR7+; Central Memory, TCM: 
CD45RA-, CD62L+, CCR7+/-; Effector Memory, TEM: CD45RA-, CD62L-, CCR7-; Central Effector, 
TCE: CD45RA+, CD62L+, CCR7-; and End Stage TES: CD45RA+, CD62L-, CCR7-; T-cells. Data are 
presented as stacked bars of means of 9 patients.
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Supplementary figure S5: CAIX CAR is expressed homogenously among different T-cell 
subsets. 
CAIX CAR T-cell cultures were generated as described. At culture day 14 proportions of CAIX CAR+ 
cells were assessed per lymphocyte subset by FCM. The mean values of CAIX CAR expression of 
the 2 individual CAIX CAR T-cell cultures are presented (one dot per patient). Lymphocyte subsets 
inlcuded: CD3+; CD3+CD4+; CD3+CD8+; CD3+CD56+; CD3+CD57+; CD3+TCRgd+; CD3+CD45RA+; 
CD3+CD45RO+; CD3+CD27/28+; CD3+CD62L+; CD3+CCR7+, and CD3-CD56+ (NK) cells. Graphs 
represent individual (dot) and median values (horizontal line). Differences from expression in 
CD3+ were tested using the paired Student t-test, * p < 0.05.
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ABSTRACT
We studied safety and proof of concept of a phase I/II trial with Chimeric Antigen Receptor 
(CAR) T-cells in patients with metastatic renal cell carcinoma (mRCC). The CAR was based on 
the G250 mAb that recognized an epitope of carboxy-anhydrase-IX (CAIX). Twelve patients 
with CAIX+ mRCC were treated in three cohorts with a maximum of 10 daily infusions of 
2x107 to 2x109 CAR T-cells. Circulating CAR T-cells were transiently detectable in all patients 
and maintained antigen-specific immune functions following their isolation post-treatment. 
Blood cytokine profiles mirrored CAR T-cell presence and in vivo activity. Unfortunately, pa-
tients developed anti-CAR T-cell antibodies and cellular immune responses. Moreover, CAR 
T-cell infusions induced liver enzyme disturbances reaching CTC grades 2 to 4, which necessi-
tated cessation of treatment in 4 out of 8 patients (cohort 1+2). Examination of liver biopsies 
revealed T-cell infiltration around bile ducts and CAIX expression on bile duct epithelium, 
adding to the notion of on-target toxicity. No such toxicities were observed in four patients 
that were pretreated with G250 mAb (cohort 3). The study was stopped due to the advent of 
competing treatments before reaching therapeutic or maximum tolerated dose in cohort 3. 
No clinical responses have been recorded. Despite that, from this trial numerous recommen-
dations for future trials and their immune monitoring could be formulated, such as choice 
of the target antigen, format and immunogenicity of receptor and how the latter relates to 
peripheral T cell persistence.
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INTRODUCTION
Adoptive transfer of antigen-specific T-cells has shown therapeutic successes in the treat-
ment of viral infections and tumors.[1-5] Treatment of patients with gene-engineered T-cells 
equipped with either chimeric antigen receptors (CARs) or T-cell receptors (TCRs) provides 
an attractive strategy to provide therapeutic immunity against malignancies. Despite some 
marked successes in hematological malignancies[6, 7], so far, gene-engineered T-cells failed 
to yield anti-tumor responses in a substantial number of patients in solid tumors.[8-12] 
Improved insight into several aspects is urgently needed in order to fully explore the po-
tential of gene-engineered T-cells as a treatment option for solid tumors. One of the main 
challenges in the field of T-cell engineering is, for example, receptor specificity. Engineered 
T-cells endowed with high-affinity receptors proved significantly toxic when tumor-associated 
antigens were targeted that were also expressed, even at low level, on normal tissue,[8, 11-
15]so-called ‘on-target’ toxicity. Other important aspects include choice of receptor format, 
strategies to prolong T-cell persistence and to reduce immunogenicity and sensitization of 
the suppressive tumor micro milieu.[16]
We have designed a first generation CAR directed against carboxy-anhydrase-IX (CAIX) and 
treated patients with CAIX-expressing metastatic renal cell carcinoma (mRCC)[17]. In this pa-
per we present a study overview and will summarize the clinical observations and immune 
monitoring performed on this clinical study including published and non-published data.
CAIX CAR T-CELLS
The first generation CAR was constructed from the single chain variable domain (scFv) of the 
murine monoclonal antibody (mAb) G250 and the intracellular part of the γ-chain from the 
Fc(ε)RI receptor present on mast cells.[18, 19] The G250 mAb recognizes an epitope on CAIX, 
which is frequently overexpressed on clear cell RCC.[20] Following retroviral introduction of 
the CAIX CAR into primary human T-cells, the CAR  became surface expressed, which enabled 
T cells to recognize CAIX and to exert antigen-specific effector functions, such as cytokine 
production and killing of RCC cell lines.[21] Next, we established and validated a Good Man-
ufacturing Procedure (GMP)-compliant protocol, based on  T-cell activation with sCD3 mAb, 
retronectin-based transduction and IL-2 supported T-cell expansion to generate CAR T-cells in 
a closed culture system for patient treatment.[21-23]
PRE-TREATMENT OBSERVATIONS: ANALYSES OF INFUSION 
PRODUCTS
The transduction protocol highly efficiently transduced all lymphocyte subsets, including 
CD4+, CD8+, CD57+ and TCRγδ+ T-cells.[24] Detailed phenotypic analysis showed that the 
CAR T-cell cultures were skewed towards differentiated CD8+ T-cells (as defined by markers 
CD45RA, CD45RO, CD62L, CCR7 and CD28). Of note, during culture all differentiation markers 
shifted along the anticipated T-cell differentiation lines.[25] At culture day 14 the majority of 
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the T-cells were central memory (TCM) and effector memory (TEM) T-cells and the CAR expres-
sion was slightly higher on TCM and TEM when compared to the naive (TN) and end stage (TES) 
T-cells.[24] Remarkably, all T-cell differentiation stages within both CD4+ and CD8+ T-cell sub-
sets exerted similar levels of CAR specific CD107a mobilization, suggesting the CAR expres-
sion levels in all of these subsets was above a functional expression level and that in addition 
to CD8 CAR T cells also CD4 CAR T cells may exert effector T cell functions.[24]
Patients were treated with multiple T-cells infusions (see below) that were freshly prepared 
on culture days 14 to 18 in two treatment cycles. The CAR T-cell infusions of treatment day 1 
(culture day 14) versus day 5 (culture day 18) had similar T-cell phenotypes and proportions 
of CAR expressing T-cells, yet the expression level (mean fluorescence intensity, MFI) of the 
CAR was lower at day 5. The latter observation was confirmed by decreased CAR mRNA levels 
at treatment day 5 versus day 1 while the CAR DNA levels were equal.[26],[27] Our obser-
vations are in line with those of Burns et al.[28], who further showed that the loss of trans-
gene expression in human lymphocytes transduced with a similar (MFG) retroviral vector was 
LTR-driven, and subject to global cellular mechanisms.[28]
Further characteristics of the pre-infusion CAIX CAR T-cells are summarized elsewhere.[29] 
In short, T cell infusion products showed a median of 61% were CD8+ (range, 18–83%) and 
53% (range, 24–65%) expressed the CAIX CAR. The CAR T-cells had incorporated a median 
of 2.6 copies of the CAR transgene in their DNA (range, 1.2–12.9). We reported a median 
CAIX-specific cytolytic activity of 107 LU20/10
6 CAR T-cells (range, 18–372) and  interferon-γ 
(IFN-γ) production of 29 ng/24 hours/106 CAR T-cells (range, 1–47). Specific IFN-γ production 
by T-cell from the therapeutic infusions was at least 20-fold higher than production of inter-
leukin-5 (IL-5), tumor necrosis factor (TNF-)α, and IL-4.[29]
PATIENT TREATMENTS
Between March 2003 and December 2010, we treated 12 patients with CAIX-expressing met-
astatic RCC, not amendable for curative surgery, and for whom no standard treatment exist-
ed.[8] Specific patient characteristics are described elsewhere.[29]
Patients were not subjected to lymphodepleting preconditioning and were treated with two 
cycles of multiple intravenous (i.v.) infusions of CAR T-cells accompanied with subcutaneous 
(s.c.) IL-2 injections (2x/d IL-2, 5x105 IU/m2) during 10 days from the start of a treatment cy-
cle. Patients were treated in three cohorts, e.a. featuring a treatment scheme that included 
adaptations in response to serious adverse events, see Figure 1.[29]
Cohort 1, the study was designed as a phase I/II study comprising of an in-patient dose esca-
lation (i.e., day 1, 2x107 T-cells; day 2, 2x108 T-cells; day 3, 2x109 T-cells), followed by a con-
solidation dose of 2x109 T-cells at days 4-5 (treatment cycle 1) and 2x109 T-cells at days 17-19 
(treatment cycle 2) (Figure 1 – scheme 1). In this scheme, three patients were treated, two 
of which developed dose-limiting toxicities in terms of liver enzyme disturbances, hence the 
treatment protocol was amended.
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The amended protocol was a conventional 3×3 phase I study, applying a maximum of up to 10 
CAR T cell infusions at days 1–5 (treatment cycle 1) and days 29–33 (treatment cycle 2), at a 
start dose of 1×108 CAR T-cells per infusion and projected escalations to 2-, 4-, 8, 16-, 20, 25- 
and 30x108 CAR T cells per infusion. The study comprised 2 steps, the first without ‘protective 
measures’ in order to assess the net maximum tolerable dose (MTD) of the CAIX CAR T cells 
with IL-2 support, and a second step including ‘protective measures’ being i.v. infusions of 5 
mg of the anti-CAIX mAb G250 3 days before start of each treatment cycle.  The pretreatment 
with G250 mAb was intended to block CAIX in liver and prevent elevation in liver enzyme 
values, while not blocking CAIX in RCC metastasis.[30-32] In step 2, we  aimed at increasing 
the MTD of the CAIX CAR T cells and accomplish a clinical effective dose. In case dose limiting 
toxicities were recorded in 2 patients at a particular dose level in step 1, subsequent patients 
would be treated at the same dose level in step 2. 
In cohort 2, 5 patients were treated according to step 1 of the conventional 3×3 phase I 
approach (Figure 1 – scheme 2). At the starting dose of 1×108 CAR T-cells per infusion (max-
imum cumulative dose of 1×109), again a dose-limiting toxicity (DLT) was observed with re-
spect to liver enzyme values in the third patient after 10 infusions (cumulative dose 1×109 
CAR T cells) and in the fifth patient after 3 infusions (cumulative dose 0.3×109 CAR T cells). 
Therefore, cohort 2 was closed without a proper assessment of a MTD of CAIX CAR T-cells. 
In cohort 3, 4 patients were treated as in cohort 2, but with pre-treatment of an i.v. infusion 
of 5 mg of the anti-CAIX mAb G250 3 days before start of each T cell treatment cycle (Figure 
1 – scheme 3). Three patients were treated at the starting (cumulative) dose of 1×109 CAR 
T-cells without toxicity and the CAR T-cell dose was increased to 2×109 CAR T-cells (cumula-
tive) for the next 3 patients. Due to limited patient accrual because of competing treatments 
given the introduction of VEGFR-TKIs with proven activity in mRCC patients, the study was 
terminated after one patient in the second dose level of cohort 3.
CLINICAL OBSERVATIONS
No clinical responses were noted and the median overall survival was 9.5 months (range: 
3–33 months) for patients treated in cohorts 1+2 (n = 8 patients), and 12.5 months (6–24 
months) for cohort 3 (n = 4 patients).
Toxicities were restricted to elevations in blood levels of  liver enzymes in 4 out of 8 patients 
treated in cohort 1 and 2, as described above. Liver biopsies taken from 3 of these patients 
revealed CAIX expression on bile duct epithelium, discrete cholangitis with inflamed portal 
triangles and infiltration of T-cells, including CAIX CAR T-cells.[8, 29] We concluded that the 
liver toxicity was probably due to the specific interaction of the CAR T-cells with CAIX ex-
pressed on the bile duct epithelium. Indeed, blocking of CAIX in the liver by G250 mAb infu-
sion allowed treatment of the next 4 patients (cohort 3) at a (cumulative) dose of 1-2x109 CAR 
T-cells without any toxicity. From one patient a peripheral metastasis was excised however no 
significant T-cell infiltrate was observed by immunohistochemistry.
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Figure 1: Treatment schemes 
Treatment schemes, adapted from: Lamers, C.H., et al. Immune responses to transgene and ret-
roviral vector in patients treated with ex vivo-engineered T cells. Blood 117, 72-82 (2011), ©the 
American Society of Hematology. In cohort 1 (scheme1), we treated patients with CAIX CAR T-cells 
in an in-patient dose escalation (i.e., day 1, 2x107 T-cells; day 2, 2x108 T-cells; day 3, 2x109 T-cells), 
followed by a consolidation dose of 2x109 T-cells at days 4-5 (treatment cycle 1) and 2x109 T-cells 
at days 17-19 (treatment cycle 2), in combination with sub cutanous (s.c.) injections of 5x105 IU/
m2 human recombinant interleukin-2 (IL-2, Chiron, Amsterdam), twice daily administered at days 
1-10 and days 17-26. For each treatment cycle a new T cell culture was initiated from which fresh 
T cell infusions were prepared. Patients 1 and 3 developed liver enzyme disturbances reaching 
CTC grades 3-4 following 4 T-cell infusions, which necessitated cessation of treatment in patients 
1 and 3, corticosteroid treatment in patient 1 and reduction of the maximal T-cell dose to 2 x 108 
T-cells in patients 2 and 3ref [8]; In cohort 2 (scheme 2), we treated patients with CAR T-cells in a 
conventional phase I strategy with a maximum of 10 CAR T-cell infusions at days 1-5 and days 29-
33 and staring at a CAR T cells dose of 1x108 per infusion and projected dose escalations to 2-, 4-, 
8, 16-, 20, 25- and 30x108 CAR T cells per infusion. CAR T cell infusions were in combination with 
IL-2, s.c., 5x105 IU/m2 twice daily administered at days 1-10 and days 29-38. In cohort 3 (scheme 
3), we treated patients as in cohort 2, but applied a strategy to block CAIX CAR recognition of cog-
nate antigen on normal liver tissue. To that end we included an extra i.v. infusion of 5 mg cG250 
mAb (kindly provided by L. Old, LIRC New York), three days prior to start of each series of CAR 
T-cell infusions, which blocks CAIX in the liver and leaving accessible CAIX at RCC tumor sites[31, 
32]. Of note, in this clinical trial patients were not subjected to pre-treatment lymphodepletion 
conditioning
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PATIENT MONITORING
CAR T-cells were quantified in blood by FCM using the anti-idiotype mAb NuH82. In ad-
dition, CAR DNA copies and CAR mRNA levels were quantified by qPCR and RT-qPCR, re-
spectively. CAR T-cell, DNA and mRNA levels showed peak levels between treatment days 
4 to 8 (for both cycles); peak levels were: CAR T-cells, median 2.7 cells/ul (range 0.8 – 
10.0); CAR DNA levels; 0.070 fg/ul (0.018 – 0,566) which was equal to 10 transgene cop-
ies/ul (3 – 81); and CAR mRNA levels, 0.139 fg/ul (0.024 – 0.905). CAR T cells, DNA and 
mRNA levels gradually decreased between both treatment cycles, but levelled off more 
rapidly after the second treatment cycle, see Figure 2A-C. This observation may have 
been caused by an anti-CAIX CAR immune response (see below), which became prom-
inent after the second treatment cycle.[33] This notion is supported by the observa-
tion that patients treated in cohort 3, receiving the protective G250 mAb infusions, had 
detectable G250 mAb blood levels up to treatment day 10, but developed less anti-CAIX 
CAR immunity[33], and showed longer persistence of the CAIX CAR T-cells (Figure 3A,B). 
Here we add additional data to our previous observation on the loss of CAR membrane ex-
pression following T cell administration to patients.[27] The ratio of the CAIX CAR mRNA : 
DNA levels in blood gradually declined after treatment cycle 1 and showed a steep decrease 
after treatment cycle 2 (Figure 1D). Decreased CAR gene and surface expression are indica-
tive for limited in vivo lymphocyte activation.[28] In vivo expansion of the infused T-cells were 
only seen in treatment cycle 1 in just 3 out of 8 patients (cohort 2+3; Figure 2A).
Our observations on limited persistence of CAR T-cells concur with other reports on first 
generation CARs.[9, 34, 35] However, in case virus specific T-cells were gene-modified with a 
first generation CAR, these CAR T-cells persisted for months to years, likely due to repetitive 
viral re-stimulation.[36] Second generation CARs harbour intracellular co-signalling domains 
derived from molecules such as CD28 or 4-1BB. T-cells with second generation CARs showed 
improved in vivo expansion and prolonged persistence irrespective of lymphodepleting pre-
conditioning.[37-40] These results have boosted the number of trials using second genera-
tion CD19 CAR T-cells to treat B-cell malignancies, which so far have shown impressive clinical 
results.[41, 42] 
Blood cytokine levels were assessed using multiplex bead technologies, and revealed cyto-
kine peak levels at day 5 (median; range, 5-8) in cycle 1 and at day 3 (range, 1-5) in cycle 2. 
Most prominent were elevations of IL-2, IL-5 and IFN-γ, potentially driven by IL-2 administra-
tion and in vivo activation of CAR T-cells.[29] Significant fluctuations were also recorded for: 
IL-1ra, IL-4, IL-12(p70), FGF-basic, G-CSF, GM-CSF, IP-10 and PDGF-bb. Analysis of cytokine 
levels after the last T-cell infusion revealed that IFN-γ and IL-6 levels correlated with numbers 
of peripheral CAR T-cells but not with liver enzyme toxicity scores.[26] 
Post-treatment PBMC displayed CAIX-specific T-cell functions, both cytolysis and IFN-γ pro-
duction.[29, 43] The CAIX-specific IFN-γ production peaked simultaneously (days 5-8) with 
the numbers of CAR T-cells in the circulation. Moreover, we showed that IFN-γ production by 
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Figure 2: In vivo loss of CAIX CAR transgene expression 
Patients were treated with CAIX CAR T-cells (days 1-5) and monitored for blood numbers of CAR 
T-cells by FCM A) and blood levels of CAR DNA B) and RNA C) by PCR and RT-PCR, respectively. 
Results are expressed relative to the value at treatment day 5 (day 5 ratio=1). D) relative CAR RNA 
over CAR DNA ratio. Values for 9 individual patients treated in cohorts 2 (filled symbols) and 3 
(open symbols) and the median observation are shown.
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post-infusion PBMC correlated with pre-infusion CAIX CAR T-cell IFN-γ production potency.
[29] Thus, CAR T-cells maintain their transgene-specific immune functions in vivo.
IMMUNOGENICITY
The CAIX CAR is constructed from the variable parts (Fv) of the murine mAb G250. The hu-
manized G250 mAb has been applied for treatment of mRCC in monotherapy or in combi-
nation with IL-2 or IFN-γ. In such therapies, patients received bi-weekly doses of 50mg G250 
mAb with a human Fc portion for 12 weeks, without noticeable induction of anti-G250 mAb 
immune responses.[44] 
However, patients treated with CAR T-cells developed distinct anti-CAIX CAR humoral immune 
responses in 7 out of 12 patients (not in 3 out of 4 patients treated in cohort 3) and cellular 
immune responses in 9 out of 10 evaluable patients.[33] Human anti-CAIX CAR antibodies 
were  directed against the G250 mAb’s idiotype and were able to neutralize CAR-mediated 
T-cell functions. Mapping of the anti-CAR cellular immune responses revealed reactivities 
against CDR2/3 and Vk FR3/4 domains. Remarkably, patients showed unique and single epi-
topes and none of the epitopes covered ‘fusion’ proteins that are part of the CAR. Of note, in 
this analysis we also detected immunity towards vector-encoded epitopes expressed by the 
CAR T-cells.[33] Thus, murine Fv domains in the context of a CAR and presented on T-cells 
can serve as strong immunogens[33, 45] when compared to the soluble mAb.[44] Only a few 
studies report on immunogenicity of CAR or TCR modified T-cells[34, 46], probably due to the 
commonly applied non-myoablative patient pretreatment.
SUMMARY
Infusion product observations
First-generation CAR genes showed homogeneous transduction efficiency and, once ex-
pressed, good antigen-specific function within different T-cell subsets/differentiation stag-
es;[23, 24]
Infused patient CAR T-cells displayed predominantly a central memory (Tcm) and effector 
memory (Tem) phenotype;[24]
Clinical observations
	 CAR T-cells did not significantly expand in vivo, nor persist > 4 weeks post infusion 
and showed gradually decreasing CAR gene and surface expression;[26, 27, 33]
	 Blood cytokine profiles, in particular IFN-γ and IL-6,  mirrored CAR T-cell presence 
and in vivo T-cell activity;[26, 29]
	 CAR T-cells displayed antigen-specific functions;[43]
	 Patients presented with dose limiting elevations of liver enzymes in blood highly 
likely as a consequence of specific recognition of CAIX on lining cells of the bile ducts 
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A
B
Figure 3
Figure 3: Patient pre-treatment with cG250 mAb infusions prolonged CAR T-cell persistence.
Patients in cohort 3 received i.v. 5mg of cG250 mAb, 3 days prior to T-cell infusion in both treat-
ment cycles 1 and 2. Blood levels of cG250 mAb were assayed by sandwich ELISA using the anti-Id 
G250 mAb NuH82. A) Kinetics of cG250 blood levels during and after treatment cycle 1 and 2 for 
individual patients 9 to 12 (blood cG250 t1/2 values were pt 9: Cycle (C) 1, could not be deter-
mined; C2 (mean values) 2.3 days; pt 10, C1 2.9; C2 2.7 days; pt11 C1 1.7; C2 1.7 days; pt 12 C1 
1.3, C2 1.5 days); B) CAR T-cell persistence is defined as last day of detectable FCM values relative 
to the start of treatment cycle 2 in patients receiving a cumulative dose of 1x109 CAIX CAR T-cells 
(cohort 2: pt 4-7; cohort 3: pt 9-11; t-test, p value = 0.053). Of note, pt 12 received cumulative 
dose of 2x109 CAIX CAR T-cells and developed anti-CAR antibodies from day 6 of treatment cycle II 
onwards[29], which interfered with the cG250 mAb detection assay. 
69
CAIX CAR T cell trial - a completed study overview
by CAR T-cells;[8, 29]
	 Blocking CAR by parental mAb (G250) infusion decreased liver enzyme values in 
blood;[29]
	 CAR T-cells induced both humoral and cellular immune responses in patients direct-
ed against murine Fv domains, and which preceded loss of CAR T-cells;[33]
GENERAL REMARKS
	 CAR T-cell treatment schedule, including 2 treatment cycles with repeated doses 
of freshly generated cells was logistically not convenient, and resulted in a reduced 
CAR expression in the latest T-cell infusions[26] and induction of anti-CAR immune 
responses;[33]
	 Study was stopped due to competing therapies with TKIs prior to establishing a ther-
apeutic dose. No clinical responses were recorded.
	 CAIX CAR T-cells displayed strong on-target effects, however the presence of CAIX on 
liver tissue rendered this treatment not feasible to explore further.
RECOMMENDATIONS
We recognized as major limitations in presented first-generation CAIX CAR T-cells clinical 
study, i) the on target/off organ toxicity; ii) immunogenicity of the CAIX CAR receptor (sup-
ported by treatment scheme); and iii) lack of T-cell persistence and therapy efficiency.
In order to improve safety of receptor-engineered T-cell therapy, target antigens should be 
selected that are uniquely expressed by tumor cells and not on normal somatic tissues. For 
CARs it is quite a challenge to find such tumor specific targets, whereas for TCRs promising 
candidates have been identified within the groups of both Cancer Testis (CT) antigens and 
neo-antigens[47, 48], e.g. MAGE-C2[49, 50] and NY-ESO[51]. In case a self-antigen is target-
ed, the biological effect should also be taken into account and, where possible, preserved, 
e.g., the effect of B-cell aplasia following CD19 CAR T-cells treatment can be overcome by im-
munoglobulin infusions.[52] Targeting CT antigens might reveal unanticipated toxicities when 
applying affinity enhanced TCRs[12, 53, 54], emphasizing the need for thorough preclinical 
screening.[55]
In the vast majority of clinical studies, immunogenicity of the receptor has not been recog-
nized as a possible limitation, most likely due to the applied non-myoablative preconditioning 
of patients in most studies, single T-cell infusions and a recent dominance of CD19 CAR T 
cell studies.[41, 42] Yet, our study clearly demonstrated the immunogenicity of xenogeneic 
protein sequences presented by T-cells.[45] Therefore, for construction of CARs and TCRs we 
advocate the use of human CDRs.
To date, it has been shown that T-cell persistence and therapy efficiency improves from mod-
ification of the receptor design, in particular, by including a co-stimulatory domain in the 
receptor.[41, 42] In addition, T-cells armoured with features that can adapt the  immune-sup-
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pressive tumor microenvironment, e.g., by receptor-mediated local production of cytokines, 
chemokines or scFvs also bear therapeutic potential.[16, 56-58] 
T-cells with a ‘young’ phenotype demonstrate improved persistence and therapy outcome.
[59, 60] Strategies to generate T-cells with a ‘young’ phenotype in vitro include, i) T-cell acti-
vation using CD3 and CD28 co-activation[61-63], ii) T cell culture with common-γ cytokine (IL-
7, IL-15, IL-21) support in culture[62-65] and iii) (pre-)selection of T-cells subsets (e.g., CD62L 
selections).[66] These strategies are included in an upcoming TCR T cell adoptive therapy 
clinical trial at Erasmus MC to treat patients with MAGE-C2 positive tumors with co-stimula-
tory TCR T cells.[50, 63, 67]
There still remains a need for markers in adoptive T-cell therapy, whether related to pre-treat-
ment infusion product or post-treatment blood measurements, that correlate with therapy 
effectiveness.[41] Extensive monitoring of these experimental studies is a prerequisite for 
obtaining a better understanding of the biology and mechanisms and will reveal tools and 
recommendations to improve the adoptive receptor-engineered T-cell approach. 
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ABSTRACT
Cancer immune therapy, in particular the use of checkpoint inhibitors and adoptive trans-
fer of T cells has recently demonstrated significant clinical responses against several tumor 
types. Unfortunately, these therapies are frequently accompanied by severe toxicities, un-
derscoring the need for markers that provide information on therapy response. Monitoring 
immune responses in the tumor micro-environment and peripheral blood prior to and during 
these therapies will provide better insight into the mechanisms underlying clinical activities, 
and will potentially enable the identification of such markers. In this review, we present an 
overview of adoptive T cell trials conducted with a special focus on immune monitoring, and 
argue that accurate monitoring of T cells is pivotal to further development of immune ther-
apies to treat cancer.
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INTRODUCTION
Immunotherapy is becoming part of the systemic treatment options for cancer patients. In 
particular immunomodulating agents, like the checkpoint blocking antibodies that block the 
negative regulators of T cell immunity. Recently, ipilimumab, that blocks CTLA-4 and nivolum-
ab and lambrolizumab, that block PD-1, have drawn a lot of attention.[1-8] These agents 
applied as monotherapy have shown promising clinical results, in particular in patients with 
metastatic melanoma. The combination of ipilimumab and nivolumab resulted even in a 
higher objective response rate up to 53%, whereas adverse effects were comparable to those 
experienced with monotherapy.[9] Investigations in clinical application of these agents for 
other cancer types is rapidly expanding. 
In addition to immunomodulating drugs, another promising immunotherapeutic approach 
is adoptive T cell therapy, an immunotherapeutic treatment that is based on the principle 
of transferring autologous and ex vivo expanded tumor-specific T cells to patients. In recent 
years, T cell therapy has yielded impressive clinical results in patients who had previously 
failed to standard treatments. Adoptively transferred T cells have the capacity to kill anti-
gen-expressing tumor cells and thereby provide a direct cytolytic effector function. Therapy 
with tumor infiltrating lymphocytes (TILs) has shown initial objective responses in about 50% 
of the metastatic melanoma patients, and complete responses that ranged between 10 and 
20%, including durable complete responses beyond 3 years. [10-13] Although these results 
are promising, the majority of patients are not eligible for TIL therapy, as not all patients 
have pre-existing tumor reactive T cells and in many cancers it is still difficult to identify and 
obtain tumor reactive lymphocytes. To overcome this limitation, the genetic introduction 
of chimeric antigen receptors (CARs) and T cell receptors (TCRs) into autologous T cells is 
considered an alternative, rendering T cell therapy available for a larger group of patients. 
CARs are single-chain variable fragments (scFv) derived from monoclonal antibodies that are 
fused to a transmembrane and a signaling domain. When introduced in T cells binding of 
the CAR with its antigen leads to T cell activation. Trials with first generation CARs showed 
limited success, but trials with second generation CARs have shown more promising results. 
Second generation CARs harbor an extra intracellular cosignaling domain derived from CD28 
or 4-1BB (CD137). Recently in two clinical trials with second-generation CAR T cells, patients 
with B-cell acute lymphocytic leukemia (B-ALL) were treated with a CAR targeting CD19, and 
remarkable high complete response percentages of 90% were reported.[14-16] Also, several 
TCR gene-modified T cell trials have shown successes, although with variable response rates. 
T cells endowed with a TCR against NY-ESO1/HLA-A2 showed an objective response in about 
50% of patients with metastatic melanoma, and in about 70% of patients with metastatic sy-
novial cell sarcoma with no detectable toxicities.[17] Other TCR trials have shown anti-tumor 
responses that in some cases were accompanied by toxicities affecting tissues that expressed 
the same or a highly similar antigen as the one targeted by the introduced TCR transgene. 
See for a recent review.[18]
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Trials with immunotherapeutic agents, like checkpoint inhibiting antibodies, have shown 
response patterns distinct from those of the traditional cytostatic/-lytic chemotherapeutic 
agents. These immunomodulating agents can show late responses with unconventional ki-
netics, immune related adverse events, and unusual late patterns of toxicity, but also have 
the ability to re-respond to therapy after progression.[19] In contrast, adoptively transferred 
T cells have the capacity to directly kill tumor cells, enabling fast tumor reduction, but also 
can initiate late adaptive responses by other compartments of the immune system. Yet, 
adoptive T-cell therapies also have shown unique clinical toxicities, either caused by overt 
reactivity of transferred T cells toward easily accessible and high numbers of (mostly hema-
tological) tumor cells causing cytokine release syndrome (CRS), or by reactivity of transferred 
T cells toward healthy tissues expressing low levels of the target antigen or antigen that is 
highly similar to target antigen.[18, 20] 
Although promising clinical results are seen in the T cell therapy trials described above, it is 
still hard to predict the efficacy and safety of treatment with T cells. The development of tools 
to identify patients who are likely to benefit from adoptive T cell therapy is needed. Immune 
markers that are related to the tumor microenvironment or peripheral blood could possibly 
give more detailed, and specific information about the patient’s eligibility and, combined with 
the characteristics of the transferred T cells, might be predictive for effects of T cell therapy. 
In 2011, the joint International Society for Biological Therapy of Cancer-Society for Immuno-
therapy of Cancer (iSBTc-SITC), US FDA and NCI Taskforce for the development of biomark-
ers in immune therapy trials stated: “good biomarkers offer prospect for focusing expensive 
and invasive therapies on the right populations, monitoring disease progression, therapeu-
tic benefits as well as facilitate drug development” and formulated recommendations and 
guidelines in an attempt to standardize and harmonize immune monitoring assays.[21] We 
endorse these efforts, and emphasize that accurate immune monitoring is pivotal to our 
understanding and further development of T cell therapies, and other immunotherapeutic 
agents to treat cancer.
In this review, we provide an overview of TIL, CAR- and TCR T cell clinical trials with a focus 
on immune monitoring. Next, we list the different methodological efforts to monitor immune 
markers to better select eligible patients, and predict antitumor and adverse effects. Finally, 
we discuss the value of immune parameters and the feasibility of assessing such parameters 
in future cancer immune therapy trials. Donor lymphocyte infusion (DLI) following allogeneic 
stem cell transplantation or the use of intentionally mismatched killer cells without stem cell 
transplantation have shown clear clinical effectiveness, but are not part of the current review.
[22-24]
CURRENT IMMUNE MONITORING IN ADOPTIVE T CELL THER-
APY TRIALS
In most clinical studies, in addition to exploring the antitumor effects and toxicity of adop-
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tively transferred T cells, attempts were made to identify markers associated with treatment 
outcome. These efforts particularly focused on peripheral persistence of postinfusion T cells 
as well as phenotype and function of preinfusion T cells.
TIL trials
The first TIL trial with impressive cancer regression and treatment response was described 
by Dudley et al. reporting a partial response in six of 13 melanoma patients that received 
nonmyeloablative lymphodepletion (NMA) before autologous TIL infusion.[25] Subsequently, 
they confirmed these results for a total of 35 patients, attempted to identify characteristics of 
the administered T cell treatment that could predict patient response, and reported that the 
infused T cell clones were no longer detectable in blood 2 weeks after infusion.[26] Robbins 
et al. showed that in these patients [25, 26] there was a significant correlation between tu-
mor regression and the degree of the peripheral persistence of the transferred T cell clones.
[27] In addition, a case study has been reported showing a very long persisting T cell clone 
in blood that expressed relatively high levels of the CD28 and CD27 co-stimulatory markers, 
indicating a beneficial feature of a putative slow differentiation towards an end stage effector 
T cells.[28] 
Besser et al. studied the effect of shortly cultured TILs, designated “young TILs” (Y-TIL). 
Despite the small number of patients, the results of this study were promising, especially 
since preparation of Y-TILs was much less labor intensive.[29] In a Phase II trial, Besser et 
al. demonstrated a significant difference between the days of TIL culture prior to infusion of 
responding (about 13 days) and nonresponding (about 19 days) patients. There was no dif-
ference in CD28 or CD27 expression on TILs between the responding and nonresponding pa-
tients in this study, though the total number of infused CD8+ T cells was significantly higher in 
the responding group.[10] Dudley et al. used Y-TIL and additionally enriched the transferred 
cells for CD8+ T cells. The latter study demonstrated that the in vivo persistence of CD8+ T 
cells at 1 month after Y-TIL infusion highly correlated with response, and again demonstrat-
ed that a longer culture time of TIL was significantly more prevalent in the non-responder 
group.[30] Radvanyi et al. have looked at the expression of several co-inhibitory molecules 
before infusion on the administered TILs. They examined the expression of PD-1 (CD279), 
BTLA (CD272), LAG3 (CD223), and Tim-3 (CD366) on TILs in the infusion product. Notably, 
responding patients displayed significantly higher percentages of CD8+, BTLA+ T cells as well 
as more differentiated T-effector cells.[31]
In search for a discriminating marker for TIL functionality, most of the TIL-trials assessed IFN-γ 
production of the cultured T cells after stimulation with autologous tumor cells, allogeneic 
matched melanoma cell lines or tumor epitope peptides. Initially IFN-γ production was used 
as a selection criterion for the clinical use of the TIL since IFN-γ production may correlate 
with a higher response rate.[32] However, other studies could not find an association be-
tween a positive in vitro antitumor reactivity of the cultured T cells and clinical response.
[29, 31] Ellebaek et al monitored the T cell functionality with intracellular staining of IFN-γ 
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and TNF-α in CD3+, CD8+ PBMCs after stimulation with autologous melanoma tumor cells, 
and demonstrated elevated percentages of cytokine-positive peripheral CD8+ T cells in one 
patient with a complete response.[12] Even though this patient was previously vaccinated 
with autologous DCs and the TIL product contained a high percentage of ‘vaccine specif-
ic’ T cells, the above results are indicative of increased numbers of tumor-specific CD8+ T 
cells following TIL treatment. Verdegaal et al, treated patients with peripheral blood-derived 
polyclonal tumor-specific T cells in combination with low-dose IFN-α , and analyzed cytokine 
profiles of infused T cells, and found predominantly Th-1 cytokine production (IFN-γ, IL-2, 
TNF-α) in responding patients, and predominantly Th-2 cytokine production (IL-4, IL-5, IL-10) 
in nonresponding patients. These data suggest that a predominant Th-1 cytokine profile is 
beneficial for clinical outcome although results were not statistically significant due to low 
patient number.[33]
CAR T cell trials
One of the first CAR T cell trials has been performed by our own group, in which a CAR was 
used against CAIX antigen that is overexpressed on renal cell carcinoma (RCC). Eight patients 
were treated with 1x109 CAR T cells and low dose IL-2 without prior chemotherapy. Four of 
them presented with severe, but transient liver toxicities, which were most likely due to CAIX 
antigen expression on the surface of epithelial cells lining the bile ducts in the liver (albeit 
at a low level).[34] Another four patients received a preinfusion of 5 mg of the humanized 
anti-CAIX mAb to block CAIX antigen expressed on normal tissues while leaving CAIX antigen 
on RCC tissue available for T cell treatment. Subsequently, these four patients were treated 
with 1x109 (n=3) or 2x109 (n=1) CAR T cells and low dose IL-2 without the occurrence of any 
toxicity.[34, 35] Transgene-specific immune functions of CAIX CAR T cells prior to infusions 
were maintained in vivo and ex vivo production of IFN-γ by post treatment PBMC correlated 
with IFN-γ production of pretreatment CAR T cells. The used T cell doses were low and did 
not yield clinical responses. CAR T cells did not persist in the circulation for more than 30 days 
following infusion due to an immune response directed against the CAR construct.[35-37] 
Also another CAR T cell trial in ovarian cancer patients showed a very short in vivo CAR T cell 
persistence, and in addition this study revealed a lack of localization of 111In-labeled CAR T 
cells to the tumor sites, except in one patient.[38] In contrast to the above two studies, Bren-
ner et al. showed prolonged in vivo persistence of a CAR that was introduced in Epstein-Barr 
virus (EBV)-specific T cells and emphasized the importance of costimulatory molecules which 
were more present on these EBV specific T cells. They demonstrated that persistence of even 
low levels of CAR T cells at or beyond 6 weeks was associated with a significantly longer time 
to disease progression. Interestingly, they observed that CAR T cell in vivo expansion and 
persistence were highly concordant with the proportion of CD4+ T cells and central memory 
CD8+ T cells (CD45RO+ CD62L+) in the infused T cell product.[39, 40] Notably, Gattinoni et al 
have identified a human stem cell-like memory T cell, and likewise, Xu et al. demonstrated in 
a clinical setting that a subset of CD8 T cells that phenotypically resembled these “T-memory 
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stem cells” within the pool of CAR T cells correlated with in vivo T cell expansion.[41, 42] 
The introduction of so-called second generation CARs, harboring an extra intracellular cosig-
naling domain derived from CD28 or 4-1BB, seems to increase clinical activity of transferred T 
cells as well as their in vivo expansion and persistence. The group of June used a CAR specific 
for CD19 with addition of a 4-1BB costimulatory domain coupled to CD3ζ, to treat three B-CLL 
patients and demonstrated an over 1000-fold in vivo expansion of the CAR T cells. These CAR 
T cells were able to traffic to bone marrow (BM) and continued to express functional CARs 
at high levels for at least 6 months post-treatment. All three patients in this study obtained 
an objective response, of which two were complete responders.[43] Prolonged T cell per-
sistence and in vivo expansion were also reported for second generation CARs including a 
CD28 co-stimulatory domain.[44-47] Collectively, these results have boosted the number of 
trials using CD19 CAR T cells to treat B-cell malignancies, which so far have shown impressive 
clinical results.[48] The in vivo persistence and expansion of CAR T cells appear to be markers 
of therapy effectiveness. In addition, trafficking to and infiltration of sites of solid tumors 
by CAR T-cells is of importance, though so far such monitoring was only performed in a few 
trials. In addition to the suggested T cell differentiation[39, 41], one may anticipate a role for 
costimulatory or inhibitory T cell molecules with respect to T cell persistence and expansion. 
Although studies are limited, some trials have looked at PD-1 expression, but no clear correla-
tions with outcome or CAR T cell persistence have been found.[15, 16, 43, 49, 50]
TCR T cell trials
Morgan et al. performed the first clinical TCR T cell trial and treated 17 melanoma patients 
with MART-1/HLA-A2-specifc T cells and obtained an objective response in two (12%) of 
them.[51] The ex vivo cultured TCR T cells displayed specific IFN-γ release prior to infusion, 
and TCR T cells persisted in the circulation for at least 2 months and maximally up to a year 
in the two responding patients. In a subsequent study, Johnson et al. used a higher affinity 
MART-1 TCR, and a TCR specific for the gp100/HLA-A2 in melanoma patients resulting in an 
increased (30%) objective response.[52] In the latter study, TCR T cells persisted at high levels 
in the blood of all patients 1 month after treatment and shifted toward a less differentiated 
T cell phenotype. PBMC obtained from responding patients showed a higher ex vivo antitu-
mor reactivity than PBMC obtained from nonresponders. The fact that some nonresponding 
patients also had very high levels of circulating TCR T cells suggest that also using this ap-
proach, T cell persistence may be an important, yet not exclusive criterion related to tumor 
regression.
Choice of target antigen is critical to the success of T cell therapy trials, which has been re-
viewed elsewhere.[18] In a clinical trial in melanoma and synovial sarcoma patients, Robbins 
et al. used a TCR that targeted the cancer testis antigen NY-ESO-1/HLA-A2 and obtained sig-
nificant objective responses in 55 and 61% of melanoma and synovial sarcoma respectively.
[17, 53] In this study, tumor regression could not be correlated with specific function of pe-
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ripheral TCR T cells as measured by NY-ESO-1 tetramer staining and IFN-γ Elispot; however, 
they found that responders had a significant higher total number of infused T cells.
METHODOLOGY OF IMMUNE MONITORING IN ADOPTIVE T 
CELL THERAPY TRIALS
To support comparison across studies and acquisition of reliable data, robust, standardized, 
and validated methods are highly needed. Here, an overview is provided of the most com-
monly used techniques for immune monitoring. 
T cell persistence
In early studies using TIL clones or highly selected tumor-reactive T cells populations, TCR-Vb 
analysis provided insight in the in vivo fate of transferred T cells, see Table 1.[25, 54]. The 
polyclonal origin of therapeutic TILs may make this approach less applicable to monitor per-
sistence of administered TILs. Recently, tools have become available to screen TIL cultures for 
their specificity toward a variety of tumor-associated or specific antigens. T cell specificities 
toward known epitopes of differentiation antigens, overexpressed antigens and Cancer Tes-
tis (CT) antigens can be screened by flow cytometry (FCM) and using peptide-MHC (pMHC) 
multimers, even for multiple epitopes in small volumes of the same sample [55, 56]. More 
recently also methods have been developed to identify epitopes of antigens that arise as a 
consequence of mutations in the cancer cell DNA, and T cells recognizing these so-called 
neo-epitopes (see below: Immune markers in tumor environment). Both neo-epitope-spe-
cific CD8+ T cells [57-59] and CD4+ T cells [60, 61] have been identified in TIL cultures from 
melanoma, cholangiocarcinoma, and ovarian cancer patients. Once single or multiple T cell 
specificities have been identified, one is able to in vivo track these T cells by means of FCM 
pMHC multimers or TCR-Vb analysis.[60, 62]
In clinical studies using gene (both CAR and TCR)-engineered T cells both quantitative poly-
merase chain reaction (qPCR) and FCM are applied to detect and quantify transferred T cells 
in blood. These two techniques, although routine methods in multiple laboratories, have to 
be set up and validated to specifically monitor the T cell population of interest. Quantitative 
PCR is based on primers and probes targeting and amplifying CAR or TCR-encoding DNA (ei-
ther genomic DNA or copied DNA from RNA) and needs positive control DNA in order to ob-
tain quantifiable results.[50, 63] Most CAR T cell studies listed in Table 2 apply qPCR for in vivo 
tracking of CAR T cells in blood and other compartments like bone marrow and tumor sites. 
FCM can be as sensitive in detecting CAR T cells in blood as qPCR [37, 63], provided specific 
mAbs are available, e.g., anti-idiotype (Id) mAbs that specifically bind the CAR variable bind-
ing region. [63, 64] Such anti-Id mAbs can be applied both on freshly drawn whole blood sam-
ples as well as cryopreserved PBMC. Using FCM to detect CAIX CAR T cells in patient blood, 
we were able to set a limit of quantification of 0.01% CAIX-CAR+ cells within the CD3+ T cells 
[37]. Advantage of FCM is the ability for simultaneous detection of multiple parameters on 
a single cell, which would allow to detect CARs (or TCRs) in combination with markers linked 
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to T cell differentiation, activation and exhaustion on these cells. [43, 65] So far, the number 
of adoptive TCR T cells studies is limited (Table 3), but to date both qPCR and FCM have also 
been applied for in vivo tracking of TCR T cells. In case of FCM, investigators have monitored 
T cells both with TCR-Vb mAbs specific for the introduced TCRb-chain and pMHC multimers, 
often combined with staining for T cell differentiation markers.[52, 66] In fact, peptide-MHC 
multimers have become one of the most widely used tools to measure Ag-specific T cells in 
humans and is based on commonly studied HLA alleles. However, van Buuren et al. showed 
that detection of Ag-specific T cells for a given peptide is affected by micropolymorphic differ-
ences between HLA subtypes and advise to consider this issue in pMHC-based personalized 
immunomonitoring.[67]
T cell effector function
T cell effector functions often monitored include cytolytic potential, cytokine release and pro-
liferation upon antigen-specific encounter (see Tables 1-3). Such assays revealed that upon 
adoptive transfer, gene-modified T cells maintain their transgene-specific immune functions 
in vivo.[35, 36] Assays used for patient monitoring of these receptor-specific functions, gen-
erally are co-cultures of post-treatment PBMC with tumor target cells or peptide loaded 
antigen presenting and assessment of antigen-specific T cell functions, such as cytolysis by 
51Cr release [35, 36, 40], CD107 degranulation [43, 68, 69] and more commonly by cytokine 
production. With respect to cytokines, IFN-γ and to a lesser extent TNF-α production have 
been analyzed in individual cells using Elispot [17, 52], intracellularly using FCM staining [12, 
68, 69] or in culture supernatant using ELISA.[35] Assessment of cytokine concentrations 
in PBMC culture supernatant reflects the specific reactivity of immune cells within this cell 
population. Elispot allows quantifying the number of specific cytokine producing cells in the 
PBMC, whereas IC-FCM enables direct enumeration of cytokine producing cells within lym-
phocyte subsets in combination with other T cell markers.
Measurements in serum/plasma
Elevated cytokine blood levels, in particular of the most prominent Th-1 effector cytokine 
IFN-γ, are considered a measure of in vivo activity of transferred T cells.[36]. Cytokine blood 
levels are commonly assessed by ELISA or bead-based multiplex assays, with the last method-
ology allowing simultaneous detection of multiple soluble factors in a small test sample[43, 
70]. Cytokine blood levels are also prominent markers for (severe) adverse events such as 
tumor lysis syndrome (TLS) and CRS including inflammatory markers such as Fractalkine, 
GMCSF, IL-6, TNF-α, IFN-γ, IL-2Ra, CRP and Ferritin.[14-16] 
IMMUNE MARKERS & THEIR VALUE IN T CELL THERAPY TRI-
ALS
As described above, monitoring efforts of most of the T-cell therapy trials focus on the char-
acteristics of the transferred T cells and the in vivo T cell persistence, phenotype and func-
tion. In tumor immunology field there is a strong belief that monitoring of immune markers 
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in tumor environment and in peripheral blood are required for further fine-tuning of T cell 
approaches. In recent years, several studies performed in a wide spectrum of tumor types 
and treatments other than T cell therapy, have revealed several interesting immune markers 
in the tumor environment and peripheral blood that are potentially suitable as prognostic 
and or predictive markers in adoptive T-cell therapy.
Immune markers in tumor micro-environment
There is mounting evidence that in melanoma, colon-, ovarian-, and lung cancer, the pres-
ence of immune cells in the tumor, in particular CD8+ T cells, strongly correlates with clinical 
outcome.[71-74] Notably, Zhang et al. showed that in ovarian cancer patients, a survival ad-
vantage following chemotherapy was only observed in patients with TILs and not in patients 
without TILs.[74] Galon et al. reported that high numbers of CD45RO+, CD8+ T cell popu-
lations, both in the center and in the invasive margin of colo-rectal tumors, have a more 
favorable prognostic value when compared to conventional clinicopathological (TNM) criteria 
that are based on tumor burden (T), presence of cancer cells in regional lymph nodes (N) and 
presence of metastases (M).[75-78] Based on these results, authors advocate routine patient 
evaluation of presence and characteristics of TILs, among others numbers and ratio of CD4 
and CD8 T cells, defined in a so-called “Immunoscore”.[79] In addition, the T-helper cell (Th) 
signature of the intra and peri-tumoral T cells mirrors their anti-tumor (often a Th-1 profile: 
IFN-γ, IL-12, TNF-α) or pro-tumor (often a Th-2 profile: like IL-4, IL-10 and TGF-β) feature, 
which might serve as a possible marker.[80]
In addition to immune markers related to cellular immunity also markers related to humor-
al immunity have been considered. In head and neck squamous cell carcinoma, not only 
CD8+ TILs in metastatic tumors but also peri-tumoral CD20+ B-cell infiltration[81] and high 
numbers of B-cells in lymph node metastases were associated with favorable outcome.[82] 
Moreover, in ovarian cancer the presence of both CD20+ B-lymphocytes and CD8+ T-lym-
phocytes correlated with favorable prognosis, compared with the presence of CD8+ T-lym-
phocytes alone.[83, 84] Schmidt et al. described the predictive value of immunoglobin G 
kappa chain (IGKC) gene expression toward response to anthracycline-based neoadjuvant 
chemotherapy in breast cancer. IGKC, primarily derived from tumor infiltrating plasma cells, 
was consistently associated with metastasis-free survival across different molecular subtypes 
in lymph node-negative breast cancer. In addition to breast carcinoma, IGKC gene expression 
was prognostic for overall survival in patients with non-small-cell-lung cancer (NSCLC) and 
colorectal cancer.[85]
When looking at immune suppressive immune cells, it has generally been considered that 
increased frequencies of CD4+, CD25Hi, FOXP3+ regulatory T cells (Tregs ) in various types 
of tumors are correlated to poor patient prognosis.[86-88] Unexpectedly, however, some 
studies showed a better control of loco regional tumors in case of higher numbers of Tregs.
[89, 90] So far, data on Tregs appear inconclusive, possibly due to Tregs being a cell type defi-
nition that has not been uniformly defined to serve as a proper immune marker in cancer to 
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date. The same holds for tumor associated myeloid derived suppressor cells (MDSC), which 
are also considered to have a negative prognostic value for survival in patients with cancer. 
In example, in patients with head and neck cancer, early myeloid lineage (CD34+) cells were 
found in tumor infiltrates, and their levels were associated with the suppression of T cells.
[91] Only a few studies have focused on the characterization of human MDSC infiltrating tu-
mor sites. Such efforts are generally hampered by the cellular heterogeneity in the myeloid 
compartment, the plasticity of MDSCs in response to the complex environment of tumors, as 
well as technical difficulties such as loss of CD15+ and CD30+ cellular subsets after processing 
of tumor samples for flow-cytometry or after cryopreservation.[92, 93]
In almost all adoptive T cell therapy trials, patients are pretreated with nonmyeloablative lym-
phodepletion (NMA) before administration of the T cells, which, at least in part, overcomes 
suppression by endogenous immune cells. Some trials intensified the chemotherapeutic pre-
treatment with total body irradiation. Although no significant differences were seen in overall 
response rate among the patient cohorts, there was an increased rate of complete responses 
associated with increasing dose of total body irradiation.[11, 13] This is suggestive for the fact 
that there are still immune inhibiting cells present after chemotherapeutic NMA that may 
limit the therapeutic efficacy of transferred T cells. 
Aside from presence and diversity of immune cells in the tumor, also the prevalence and 
abundance of tumor specific antigens, in particular selected MAGE antigens or neo-antigens 
are thought to be important for the ability to induce an antitumor T cell response.[94, 95] 
Of note, melanoma the cancer type most prominently treated in TIL and TCR T cell thera-
py studies has the highest median prevalence of such somatic mutations. Identification of 
neoantigen epitopes recognized by CD8 T cells was realized by a combination of next gener-
ation sequencing techniques and algorithms that identify epitopes that are processed and 
presented by tumor cell MHC class I. Such neo-epitope specific CD8 T cells can be isolated 
using pMHC-sorting, and subsequently can be used to isolate the neo-epitope specific TCR.
[57-59] Recently, MHC class II neo-epitopes were identified by using peptides that covered 
individual mutation derived neo-epitopes and that were loaded on B-cells to screen for CD4+ 
TILs. IFN-g producing cells were enriched and exposed to techniques to capture TCR genes. 
[61] Recently, Snyder et al. demonstrated a neo-antigen landscape that is specifically present 
in tumors that show a strong response to CTLA-4 blockade. This neo-antigen signature po-
tentially enables the determination on forehand whether patients would benefit from CTLA-
4 therapy or not, and thereby reduce unnecessary side-effects and costs of treatment.[96] 
Along these lines, the presence of T cells that recognize these neo-antigens could serve to 
predict therapy outcome in cancer (immune)therapy, especially in cancer treatment with 
checkpoint inhibitors or TILs.
Immune markers in peripheral blood
Blood levels of CD8+, CD28- effector T cells have shown to be significantly increased in both 
melanoma and hemato-oncological patients. [97-99] These early observations were con-
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firmed by Tsukishiro et al. who demonstrated that in head and neck cancer patients frequen-
cies of CD8+, CD45RO-, CD28+ T cells were low, whereas frequencies of memory CD45RO+, 
CD28+ T cells and effector CD8+, CD28- T cells were high when compared with normal 
healthy and age-matched controls.[100] Notably, after surgical resection, the frequency of 
CD8+, CD28- T cells normalized in head and neck cancer patients indicating that the presence 
of tumor influenced the numbers of these T cells in the blood. In addition, Czystowska et al. 
showed in patients with this type of tumor that the frequency of less differentiated CD8+, 
CCR7+ T cells in blood was much lower when compared to normal controls, and demonstrat-
ed that disease-free survival was significantly shorter in patients with less than 28% of circu-
lating CD8+, CCR7+ T cells.[101] Interestingly, Almand et al. found in breast cancer patients 
a population of CD34+, CD33+, CD15- cells in blood, consisting for one third of immature 
macrophages and dendritic cells and two thirds of immature myeloid cells, and were able to 
reduce ex vivo T cell proliferation and T cell effector functions.[102] 
Since NMA greatly depletes cells in the peripheral blood, the cell composition of this com-
partment prior to therapy has probably less influence on the efficacy of T cell therapy efficacy. 
However, progress in receptor design, such as co-stimulatory receptors [103] in combination 
with T cell preparation towards optimally fit T cells [104], may eliminate the need for NMA 
and IL-2 and may make treatments more simplified and less of a burden to patients. Such 
developments would also allow monitoring of immune cells in the peripheral blood prior to 
and during T cell treatment in search for parameters that are related to therapy outcome.
Immune markers to monitor safety of T cell therapy trials
Monitoring of immune markers can also possibly lead to the detection of parameters that are 
able to predict adverse effects of T-cell therapy. Tables 1-3 depict the immune related adverse 
effects of TIL, CAR and TCR T cell therapy trials. The adverse effects and toxicities related to 
NMA are not depicted in Tables 1-3, though in most trials NMA led to grade 3-4 hematolog-
ical toxicities like neutropenia, thrombocytopenia, and lymphocytopenia. In some patients 
this could lead to opportunistic infections.[105] Also, the IL-2 which was administered in the 
majority of trials to support persistence and function of transferred T cells, led to transient 
adverse effects like chills, low grade fever, nausea and fatigue. 
In the TIL trials in melanoma, mainly melanocyte destruction, or in some cases vitiligo and 
uveitis, was observed. In the clinical CAR and TCR T cell trials more severe adverse effects of 
T cell infusion have been demonstrated, generally because of “on-target” toxicity, where the 
infused T cells attack healthy tissues expressing low levels of the target antigen or a highly 
similar antigen.[34, 36, 52, 69, 70, 106] These toxicities most likely relate to the specificity 
and affinity of the receptor under study, and are expected to be addressed or even resolved 
by choosing receptors with tumor-specific specificities, such as selected MAGEs and neo-epi-
topes.
In addition to on-target toxicities, several CD19 CAR T cell trials also reported the so-called 
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“cytokine release syndrome” (CRS), which is characterized by a systemic inflammatory re-
sponse, highly elevated cytokine levels and massive T cell activation and proliferation. Severe 
CRS can lead to life threatening conditions with vascular leakage, hypotension, respiratory 
and renal insufficiency, cytopenias, and coagulopathy.[15] It was shown that the plasma cy-
tokine (IFN-γ) levels in CAR T cell-infused patients correlate with tumor burden of the pa-
tient[16] and that the blood levels of C-reactive protein (CRP) can serve as a reliable indicator 
for the severity of CRS.[15] Maude et al. showed that CAR T cell-infused patients who had 
severe CRS had significantly higher peak levels of IL-6, CRP, ferritin and soluble interleukin-2 
receptor than patients with milder CRS. It is noteworthy that severe CRS symptoms can effec-
tively be treated with the anti-IL-6 receptor antibody Tocilizumab.[14]
CONCLUSIONS AND FUTURE DIRECTIONS
In adoptive T cell therapy, the pre- and postinfusion characteristics of transferred T cells as 
well as other immune markers will provide valuable information toward the mechanisms that 
underlie clinical responses, and potentially enables the identification of prognostic and/or 
predictive markers.
So far, parameters that have been recognized to be relevant for effective and save T cell ther-
apy are primarily related to the T cell product: 
- For TILs, parameters that have shown significant differences between responding and 
nonresponding patients primarily include shorter culture times, higher absolute CD8+ T 
cell numbers and expression of CD8+ T cell memory markers (e.g., CD28, CD27), CD8 T 
cell co-inhibitory molecules (e.g., BTLA) and CD8 T cell Th1 cytokine production (IFN-γ, 
IL-2, TNF-α). In general, these parameters were also linked to longer in vivo persistence 
of postinfusion TILs. 
- For CAR T cells, receptors including a costimulatory module (2nd generation receptor), a 
high proportion of CD4+ T cells and a high proportion of naive (CD45RA+, CCR7+) or cen-
tral memory (CD45RO+, CD62L+) CD8+ T cells correlated with in vivo persistence and ex-
pansion of CAR T cells, which in turn seems to be indispensable for effective CAR therapy. 
- In the relatively limited number of TCR T cell studies, no clear predictors of the T cell prod-
uct have been assigned yet. Again, T cell persistence is considered an important although 
most likely not exclusive criterion related to tumor regression. 
The increasing number of patients that are being treated in dozens of currently running 
adoptive T cell trials (see at: www.clinicaltrials.gov), extend the available data on the charac-
teristics of pre- and post-infusion T cells, with special attention to T cell differentiation and 
costimulatory/inhibitory molecules and T cell functions. These extended data sets will better 
allow the finding of correlates between the properties of the T cells and therapy outcome.
In future immune monitoring of T cell therapy trials, we think pretreatment analysis of im-
mune markers might be of great additional value. Various tumor-related and systemic im-
5
90
Chapter 5
mune parameters have already been investigated for their prognostic and predictive value in 
cancer patients treated with conventional therapies. From such studies, the most significant 
tumor-related marker with prognostic value is the number of intra- and peritumoral CD8+ 
T cells, in addition peritumoral CD20+ B-cell and immunoglobin G kappa chain (IGKC) gene 
expression have been associated with favorable therapy outcome. More recently the assess-
ment of the “neoantigen landscape” allowed response prediction to treatment with anti-CT-
LA-4 checkpoint inhibitors. These tumor-related markers bear great promise for identifying 
also those patients that are likely to benefit from adoptive T cell therapy. A first step could be 
implementation of the so-called “Immunoscore”, which characterizes the immune cell infil-
tration in tumors, and may provide a novel manner to classify cancer. However, quantitative 
immunostainings, necessary to score immune cell infiltration, is complex and there are con-
siderable protocol variations across laboratories, which underline an urgent requirement for 
assay harmonization. The worldwide Taskforce “Immunoscore” is trying to achieve this assay 
harmonization and implementation.[79] 
So far, systemic immune parameters with prognostic value are scarce, for example, dis-
ease-free survival was significantly shorter in patients with less differentiated CD8+, CCR7+ T 
cells in head and neck cancer patients. Pretreatment analysis of local and systemic immune 
parameters has not yet been considered in adoptive T cell therapies. In addition, such anal-
yses may be troubled by the fact that patients generally receive NMA prior to cell infusion. 
However, pretreatment immune status may correlate with the extent and quality of immuno-
logical reconstitution following NMA, and as such could be informative towards persistence 
and function of adoptively transferred T cells. Also, considering the impressive results in trials 
with checkpoint inhibitors, determination of coinhibitory and costimulatory molecule expres-
sion on (infused) T cells or peritumoral (immune) cells may provide a valuable addition to 
immune monitoring panels. Future developments to improve T cell therapy trials, such as 
newer costimulatory CARs or TCRs and optimized T cell preparation regimens, may eliminate 
the need for NMA and IL-2 and are expected to enlarge the window to monitor immune cells 
in peripheral blood prior to and during T-cell treatment.
Importantly, confirmation of proposed and identification of new immune markers relies on 
accurate banking of sufficient biosamples from preinfusion T cells as well as cells, serum/plas-
ma, DNA and RNA samples from blood taken prior to and at regular intervals postinfusion. 
Such bio-banks will facilitate controlled and systematic analyses and allow multicenter (inter)
national initiatives to obtain better powered studies. Sample preparation, storage and docu-
mentation should be performed according to international standards. Finally, immune mon-
itoring assays require harmonization and standardization in order to improve comparison 
of different trials. To this end, we endorse the recommendations by the iSBTc-SITC/FDA/NCI 
Workshop on Immunotherapy Biomarkers, MIATA (Minimum Information About T cell Assays) 
guidelines, and other initiatives, which collectively highlighted the importance of standard-
ization and harmonization of these monitoring protocols. [21, 107-113]
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In conclusion, adoptive T cell therapy trials are extending rapidly. Analysis of local and periph-
eral immune markers, prior to and post-therapy, has only scarcely been part of the monitor-
ing of these therapies. Integrated analysis of the therapeutic T cell product as well as local 
and systemic immune parameters should be part of contemporary immune monitoring and 
should guide development of future adoptive T cell therapies.
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ABSTRACT 
Introduction: Malignant pleural mesothelioma (MPM) is a malignancy with a very poor prog-
nosis for which new treatment options are urgently needed. We have previously shown that 
dendritic cell (DC) immunotherapy provides a clinically feasible treatment option. In the cur-
rent study, we set out to assess the immunological changes induced by DC immunotherapy 
in peripheral blood of MPM patients.
Methods: Peripheral blood was collected from nine patients enrolled in a phase I dose esca-
lation study, before and after treatment with DCs that were pulsed with an allogeneic tumor 
lysate preparation consisting of a mixture of five cultured mesothelioma cell lines. We used 
immune profiling by multiplex flow cytometry to characterize different populations of im-
mune cells. In particular, we determined frequencies of T cell subsets that showed single and 
combinatorial expression of multiple markers that signify T cell activation, maturation and 
inhibition. Therapy-induced T cell reactivity was assessed in peptide/MHC multimer stain-
ings using mesothelin as a prototypic target antigen with confirmed expression in the clinical 
tumor lysate preparation. T cell receptor (TCR) diversity was evaluated by TCRB geneβ PCR 
assays.
Results: We observed an increase in the numbers of B cells, CD4 and CD8 T cells, but not NK 
cells at 6 weeks post treatment. The increases in B and T lymphocytes were not accompanied 
by major changes in T cell reactivity towards mesothelin nor in TCRB diversity. Notably, we did 
observe enhanced proportions of CD4 T cells expressing HLA-DR, PD-1 (at 2 weeks after onset 
of treatment) and ICOS (6 weeks) and a CD8 T cell population expressing LAG3 (2 weeks). 
Discussion: DC immunotherapy using allogeneic tumor lysate resulted in enhanced frequen-
cies of B cells and T cells in blood. We did not detect a skewed antigen-reactivity of periph-
eral CD8 T cells. Interestingly, frequencies of CD4 T cells expressing activation markers and 
PD-1 were increased. These findings indicate a systemic activation of the adaptive immune 
response and may guide future immune monitoring studies of DC therapies.
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INTRODUCTION
Malignant pleural mesothelioma (MPM) is a solid tumor of the pleural lining that is strongly 
related to the exposure to asbestos (1). Overall survival is poor with a median survival of less 
than a year, and conventional therapies like chemotherapy and radiotherapy being able to 
improve survival only by a few months (2). Immunotherapy has evolved as an important new 
treatment modality in various kinds of cancer, with checkpoint inhibitors currently being FDA 
approved as first line therapy for several cancer types.  Initial results of clinical studies for 
MPM with checkpoint inhibitors as second line treatment showed response rates of 9-25% 
(3). 
MPM is characterized by a strong immunosuppressive component, with relatively low num-
bers of T cells infiltrating the tumor (1, 4). These low numbers of tumor-infiltrating T cells 
have prognostic value in MPM (5) and might explain the relatively low response rates to 
checkpoint inhibitors (1).
Furthermore, in MPM patients dendritic cells (DCs) have been shown to be reduced in num-
bers and in antigen-processing function compared to healthy controls, which negatively af-
fected survival outcomes (6). The reduced functionality of DCs is thought to relate to low 
intra-tumoral T cell numbers. Along these lines, DC vaccination represents a promising ther-
apeutic strategy. 
Previously, we have developed a cellular therapy for MPM, consisting of autologous DCs 
pulsed with autologous tumor lysate with the intention to cover a broad range of tumor anti-
gens (7). This vaccination strategy was shown to be safe with promising clinical outcomes (7, 
8). However, the availability and quality of tumor material that could be obtained, limited the 
feasibility of the treatment with DCs loaded with autologous tumor lysate. To overcome this 
limitation, DC vaccination using allogeneic tumor lysate was developed and tested for safety 
and feasibility in a phase I clinical trial (9). Allogeneic tumor lysate derived from five in vitro 
cultured clinical-grade human mesothelioma cell lines was used to pulse autologous DCs and 
the resulting DC vaccine was administered to patients i.d. and i.v. once every two weeks for 
three cycles, with a booster vaccination at three and six months after the start of treatment. 
The study was set up as a dose escalation study with three cohorts of three patients, and 
each cohort received 10 million, 25 million or 50 million DCs per vaccination, respectively. By 
circumventing the immunosuppressive tumor immune environment and providing enhanced 
tumor antigen presentation with DC vaccination, impressive objective responses could be 
obtained, as exemplified by a tumor reduction of ~70% at 6 weeks post-treatment in one of 
the patients in this phase-I trial (9).
In the current study we aimed to characterize the immunological changes induced by DC 
immunotherapy in these nine MPM patients. For a better understanding of the immunolog-
ical changes induced by DC immunotherapy we monitored peripheral blood, which is the 
preferred compartment for sequential sampling. We used extensive multiplex flow cytometry 
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with a focus on T cell activation and inhibitory markers and characterized T cell specificity 
using peptide-MHC multimers to obtain a detailed immune profile and immune dynamics 
following DC immunotherapy.   
METHODS
Patients
The nine patients in this study participated in a first-in-human clinical trial as described by 
Aerts et al (9). In short, all patients had pathologically-proven MPM and were included in 
the study at least 6 weeks after their last chemotherapy treatment, or were treatment-naive 
if they had refused chemotherapy treatment. After inclusion in the study, patients received 
leukapheresis, which was used as a source of autologous DCs.
The DCs were prepared as described (9) and pulsed with a lysate, consisting of a mixture of 
five in vitro cultured mesothelioma cell lines. Patients received a total of 3 vaccinations every 
two weeks and blood samples were obtained at baseline and at week 2, 4, 6 and 8 following 
initial vaccination. Booster vaccinations were administered at 3 and 6 months (9). One third 
of the dose was administered intradermally (i.d.), and two thirds of the dose intravenously 
(i.v.). As this was a dose escalation study, patients 1-3 received 10 million DCs per vaccination, 
patients 4-6 received 25 million DCs per vaccination and patients 7-9 received 50 million DCs 
per vaccination. Patients 7 and 9 did not receive their second booster vaccination due to 
shortage of patient material. All other patients completed the full treatment scheme (Table 
S1 in Supplementary Material). For flow cytometry (FCM) analysis, cohort 1 was not included 
since the collected peripheral blood samples of patients in cohort 1 were immediately pro-
cessed and stored. For cohort 2 and 3 the protocol was amended to enable absolute immune 
cell quantification.
Collection and processing of peripheral blood samples
Ethylene diamine tetra acetic acid (EDTA) anticoagulated peripheral blood was drawn from 
patients at baseline prior to the first vaccination (week 0), at 2 weeks after the first vaccina-
tion, i.e., prior to the second vaccination (week 2) and 2 weeks after the third vaccination at 
week 6 and analyzed within 6 hours by multiplex FCM. One ml of whole blood was used for 
multiplex FCM and from the remaining blood, peripheral blood mononuclear cells (PBMCs) 
were isolated by standard Ficoll density gradient centrifugation, and were stored at -80 °C for 
further analyses. 
Multiplex flow cytometric assessment of numbers and phenotype of 
immune cells
To enumerate immune cell populations, whole blood (100μl) was stained with the ‘absolute 
numbers’ panel (Table S2 in Supplementary Material) and incubated for 15 min at room tem-
perature. Subsequently, 2 ml of lysis buffer (NH4Cl: 8,26 mg/ml, KHCO3: 1 mg/ml and EDTA: 
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37μg/ml) was added to the blood and incubated for 15 min at room temperature. Subse-
quently 100μl of Flow-Count Fluorospheres (Beckman Coulter Inc) was added and samples 
were measured on a BD LSRFortessa™ flow cytometer. A minimum of 10,000 CD45+ cells 
were measured to enable clear distinction of defined immune cell populations. Subsequently, 
data was analyzed with FlowJo version X (FlowJo, LCC) using the gating strategy as exempli-
fied in Figure S1 in Supplementary Material. Values were expressed as cells per microliter. 
To determine the phenotype of T cells, the T cell maturation, activation, co-inhibitory and 
co-stimulatory receptors were analyzed on whole blood with different FCM panels (Table S2 
in Supplementary Material). 100μl of whole blood was stained with each of the panels and 
incubated for 15 minutes at room temperature. Subsequently, 2 ml of lysis buffer was added 
to the blood and after an incubation of 15 minutes at room temperature, the cell suspensions 
were centrifuged at 450g for 5 minutes, washed and resuspended in buffered 0.1% parafor-
maldehyde (PFA). A minimum of 30.000 CD3+ cells were measured on the LSRFortessa™ flow 
cytometer to obtain clearly detectable immune populations. The FCM data were analyzed 
with FlowJo version X. 
Determination of mesothelin-specific T cells
PBMCs were thawed and subsequently T cells were rapidly expanded with a feeder system as 
described elsewhere (10). After this rapid expansion protocol, T cells were co-cultured with 
artificial antigen presenting cells (aAPC) (11) loaded with mesothelin peptide A: SLLFLLFSL 
(mesothelin20-28), or mesothelin peptide B: VLPLTVAEV (mesothelin531-539)(Immudex, Copen-
hagen, Denmark). The aAPC cell line is based on K562 cells, retrovirally transduced with 
CD80, CD83, and HLA-A2 for optimal antigen presentation and co-stimulation, and enables 
enrichment of antigen-reactive T cells with protocols optimized in our laboratory (12). 2.5 x 
106 aAPC cells/ml were incubated at room temperature for five hours with 10μg/ml peptide 
and subsequently irradiated (120 Gy). Subsequently, these peptide-loaded aAPC cells were 
co-cultured with T cells (ratio 1:20) in T cell medium (RPMI Hepes [Lonza] supplemented with 
10% human serum [Sanquin, Amsterdam, The Netherlands], 1% L-glutamine and 1% peni-
cilline/streptomycine), 180 IU IL-2 per ml (Chiron, Amsterdam, The Netherlands), and 5 ng 
IL-15 per ml (Le-Perray-en-Yvelines, France). Mesothelin-driven T cell expansion was contin-
ued for 4 cycles, after which T cells were examined for their binding ability to corresponding 
mesothelin peptide-HLA-A2 complex multimers. In this study, we performed a maximum of 4 
peptide-specific expansion cycles. 
Dextramer A: PE-conjugated HLA-A2 dextramer with peptide SLLFLLFSL (mesothelin20-28) and 
dextramer B: APC-conjugated HLA-A2 dextramer with peptide VLPLTVAEV (mesothelin531-539) 
were both ordered from Immudex (Copenhagen, Denmark). Dextramer staining was per-
formed according to manufacturer’s protocol. Anti-CD3-BV711 (clone UCHT1) and anti-CD8-
FITC (clone SK1) mAbs (both from BD Biosciences) were used together with dextramers for 
extracellular staining. 4’,6-diamidino-2-phenylindole (DAPI) was used as viability dye. Sam-
ples were measured on an LSR-II flow cytometer (BD). Fluorescence-minus-one (FMO) con-
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trols were used to enable gating and determine dextramer-positive populations.
GeneScan T cell clonality analysis
Cell pellets from PBMC samples were frozen and stored until further use. Genomic DNA was 
isolated using the AllPrep DNA / RNA Mini kit (QIAGEN, Hilden, Germany) according to manu-
facturer’s instructions. T-cell receptor (TCR) β gene repertoire was measured using commer-
cially available multiplex TCR Vβ-Jβ PCR assays (Invivoscribe, San Diego, CA, USA) as devel-
oped and approved by the BIOMED-2 / EuroClonality consortium (13). GeneScan fragment 
analysis was done on an ABI 3130 xl instrument (ThermoFisher Scientific) and data were 
analyzed using PeakScanner software. Data interpretation was based on GeneScan patterns 
of duplicate PCR results, largely following the EuroClonality guideline (14).
Statistical analyses
Statistical analyses and graphs were made with Graphpad Prism v5.0. For comparison of 
changes from baseline measurements, Wilcoxon signed-ranks test was used to test for sig-
nificance between baseline measurements and other time points. The heatmap was made 
in R for windows version 3.4.1 using the package in “gplots” (https://cran.r-project.org/web/
packages/gplots/). Clustering was performed with a complete agglomeration method, and 
distance matrix of all variables was computed with euclidean distance.
RESULTS
Numbers of B, CD4 and CD8 T lymphocytes in peripheral blood in-
crease upon vaccination with DCs
We first assessed the absolute numbers of specific lymphocyte subsets (CD3+CD4+, 
CD3+CD8+, CD3-CD19+ and CD3-CD56+) from the six patients treated in the second and third 
cohort (dosage 25 million and 50 million DC per vaccination), using the gating strategy as 
shown in Figure S1 in Supplementary Material. Patients showed a significant increase at week 
6 (after 3 vaccinations) compared to baseline in (median) numbers of CD4+ T cells (increase 
from 522 to 634 cells/μl), CD8+ T cells (from 256 to 304 cells/μl) and B cells (from 162 to 199 
cells/μl), but not Natural Killer (NK) cells (Figure 1). Together, these results are indicative for a 
potentiation of adaptive immunity in peripheral blood after DC immunotherapy.
Mesothelin-specific T cells are detectable in peripheral blood of meso-
thelioma patients
Next, we investigated whether the increased numbers of T cells due to DC vaccination har-
bored vaccine-specific CD8 T cells. To identify vaccine-specific CD8 T cells, we selected meso-
thelin as a prototypic antigen based on the following lines of evidence. Firstly, RNA sequenc-
ing and western blot data obtained from the mesothelioma cell lines used to generate the 
lysate preparation validated mesothelin mRNA and protein expression. Secondly, immune 
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Figure 1: Absolute number of lymphocyte subsets in peripheral blood of patients before 
and after DC immunotherapy.
Quantification of absolute numbers of CD4 T cells (CD45+/CD3+/CD4+), CD8 T cells (CD45+/CD3+/
CD8+), B cells (CD45+/CD3-/CD19+), and NK cells (CD45+/CD3-/CD56+) in peripheral blood of pa-
tients in cohort 2 and 3 on baseline prior to the first vaccination (week 0), 2 weeks after the first 
vaccination, i.e., prior to the second vaccination (week 2) and 2 weeks after the third vaccination 
(week 6). Differences between week 0 and week 6 with respect to paired continuous parameters 
were determined using the exact Wilcoxon signed rank test. * p < 0.05; ns: not significant.
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histochemistry confirmed the expression of mesothelin in eight out of eight available patient 
biopsies. Lastly, mesothelin peptide/HLA-A2 complexes with reported immune reactivity (15, 
16), (peptide A: SLLFLLFSL and peptide B: VLPLTVAEV) were bound by CD8 T cells derived 
from patient skin biopsies after challenge with DC vaccine (9), as summarized in Table S2 in 
Supplementary Material. To determine whether DC therapy would induce changes in the 
frequency of mesothelin-specific CD8 T cells, we measured the binding of two mesothe-
lin-peptide/HLA-A2 multimers by CD8 T cells in pre- versus post-vaccination peripheral blood 
samples. To this end, T cell fractions were first propagated using four T cell culture cycles in 
the presence of mesothelin peptides (A and B). Figures 2A and 2B show flow cytometry plots 
for one of the two mesothelin epitopes (peptide B) in propagated CD8 T cell fractions from 
HLA-A2-positive patients (8 out of 9 patients). These analyses show that the frequency of 
mesothelin-specific CD8 T cells is variable among patients, and already pre-exists in 5 out of 8 
HLA-A2 positive patients and does not change significantly upon treatment. Similar data were 
obtained for a second mesothelin epitope (peptide A; Figure S2 in Supplementary Material) 
and no correlation was observed between the frequencies of CD8 T cells specific for the two 
epitopes analyzed (data not shown).
In addition, we studied TCRB diversity of total T cells as a global measure of T cell reactivity via 
GeneScan TCRB PCR (Figure 2C). While some patients showed dominant peaks (e.g. patient 
9), the GeneScan patterns were generally similar in pre-treatment and post-treatment PBMC 
fractions from the MPM patients, indicating that DC therapy did not induce clonal T cell ex-
pansion or selection. Collectively, these findings show that DC vaccination-specific T cells are 
detectable, but that this is not accompanied by an overall enhancement of frequencies in 
peripheral blood, nor obvious shifts in T cell TCRB repertoire.
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Figure 2: Mesothelin-specific CD8 T cells in HLA-A2 positive patients are measurable in 
pre- and post-vaccination samples. 
A) Peripheral blood samples were collected at baseline (week 0) and 2 weeks after the third vac-
cination (week 6). CD8 T cells were propagated in four culture cycles with mesothelin-peptide-B 
loaded aAPC, after which mesothelin-peptide B/HLA-A2 dextramers were used to detect meso-
thelin-specific CD8 T cells. Gating was based on the negative controls, FMO staining and the non-
CD8 T cell population. All HLA-A2 positive patients are shown; patient 5 was excluded (haplotype 
HLA-A3/HLA-A68). B) Values of gated dextramer-binding CD8 T cells - as shown in panel A - pre-
sented as proportions of total CD8 T cells. C) Relative frequencies of complementarity determining 
region-3 (CDR3) lengths in pre- and post-therapy total T cells from PBMC samples of all patients. 
The Y-axis represents relative frequency as assessed by fluorescence intensity, with the various 
CDR3 lengths on the X-axis. A polyclonal repertoire would follow a normal distribution. 
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Figure 3: Heatmap of percentages of several different lymphocyte subsets and T cell 
surface markers in peripheral blood from patients in cohort 2 and 3 (MCV004 – MCV009). 
Columns represent different patient samples at week 0, week 2 and week 6 after start of treat-
ment. Rows represent the proportions of CD4 T cell, CD8 T cell and CD45 lymphocyte populations 
that express defined markers. Percentages were normalized according to mean values of all mea-
surements and were clustered by non-hierarchical clustering.
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Increased frequencies of PD-1, HLA-DR and ICOS positive CD4+ T 
cells after DC vaccination.
We then evaluated changes in frequencies of CD4 or CD8 T cells expressing surface activa-
tion, maturation or co-signaling markers and compiled a heatmap of all variables measured 
by FCM at pre- and post-therapy time points (Figure 3). Hierarchical clustering of samples 
showed clustering of the different time points per patient for the measured variables. This 
demonstrates that intra-individual differences over time are relatively small, compared to 
inter-individual differences in the immunological variables that were measured.
To further explore immunological parameters that were modulated by DC immunotherapy, 
we assessed the expression of the various surface markers at multiple time points. Figure 
4A-D display the expression of T cell activation, co-inhibitory and co-stimulatory markers that 
were significantly altered either early after the start of treatment (2 weeks after the first vac-
cination) or later during treatment (2 weeks after the third vaccination). In particular, CD4+ T 
cells in peripheral blood showed a significant gain of HLA-DR+ and PD-1+ T cells (Figure 4A, B) 
after the first vaccination. After 3 vaccinations, we detected a significant increase of CD278 
(inducible T-cell co-stimulator; ICOS) positive CD4+ T cells compared to baseline (Figure 4D). 
CD8 T cells did not show any significant increase of these markers, although CD8+ T cells 
demonstrated a significant enrichment of CD223+ (Lymphocyte activation gene-3; LAG-3) T 
cells (Figure 4C). No significant changes were observed in the following markers on both CD4+ 
and CD8+ T cells: CD25, CD69, CD272 (BTLA), CD137 (4-1BB), CD154 (CD40L), CD134 (OX40); 
(Figure S3 in Supplementary Material).
In summary, these findings show that following autologous DC therapy in mesothelioma pa-
tients the frequencies of circulating CD4 T cells expressing HLA-DR, PD-1 or ICOS, as well as 
CD8 T cells expressing the co-inhibitory receptor LAG3 are significantly increased.  
DISCUSSION
Here we document on the effects of treatment of MPM patients with DC immunotherapy – 
autologous dendritic cells loaded with an allogeneic tumor lysate prepared from five human 
MPM cell lines – on blood immune composition. We observed an increase in absolute num-
bers of B cells, and CD4+ and CD8+ T cells in peripheral blood, suggesting induction of both a 
cellular and humoral immune response. Additionally, we found a significant increase of HLA-
DR, PD-1, and ICOS-positive CD4+ T cells, and an increase of LAG3-positive CD8+ T cells after 
treatment with DC vaccination therapy.
The DC immunotherapy was designed to induce a broad immune response towards mul-
tiple tumor antigens present in the tumor lysates (9). To detect whether the increase in T 
cell numbers was accompanied by a gain of vaccine-specific T cells, we chose to monitor 
mesothelin-specific T cells in peripheral blood during treatment. Since mesothelin was deter-
mined to be present in the tumor lysate, and expressed on the tumor cells of the patients, it 
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Figure 4: T cell activation and co-stimulatory molecule expression changes induced by DC 
immunotherapy. 
Representative histograms of flow cytometry data (left) and quantification for patients 4 to 9 at 
week 0, week 2 and week 6 after start of treatment (right). A) Proportions of HLA-DR-positive CD4 
and CD8 T cells. B) Proportions of PD-1-positive CD4 and CD8 T cells. C) Proportions of LAG3-pos-
itive CD4 and CD8 T cells and D) Proportions of ICOS-positive CD4 and CD8 T cells. * p<0.05 - Wil-
coxon paired signed-rank test, n.s. = not significant.
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was regarded to be a relevant antigen in this setting. Interestingly, after mesothelin-derived 
peptide-driven in vitro T cell propagation, CD8+ T cells that bind mesothelin peptide/HLA-A2 
complexes could already be detected in baseline blood samples of the majority of patients, 
suggesting that a mesothelin-specific immune response was already present in these pa-
tients prior to therapy. However, DC vaccination did not induce changes in frequencies of the 
mesothelin-specific T cells in peripheral blood. Additionally, as a measure of T cell clonality, 
we analyzed the TCRB repertoire in pre- and post-treatment blood samples and confirmed 
that no major repertoire shifts occurred. Our combined findings of an increase in CD4+ and 
CD8+ T cells and non-skewed TCRB repertoire suggest that DC vaccination induces polyclonal 
T cell responses that still might be enriched in tumor-specific T cells. As we only have moni-
tored specificity against one major model antigen (mesothelin) in this study, we might have 
missed an increase of tumor antigen-specific T cells with other specificities. Furthermore, our 
study did not address whether changes occurred in T cell reactivity in the local compartment. 
However, removal of tumor can be harmful in MPM due to a substantial risk of local tumor 
outgrowth at the intervention site (17), which precludes analysis of local tumor material for 
monitoring purposes. 
Some other studies employing DC immunotherapy in different types of cancer have reported 
an increase in the frequency of tumor-specific T cells in peripheral blood after treatment, as 
determined by IFN-γ ELISPOT (18) or HLA-A2 MHC multimers (19). However, in these studies 
specific peptides were used to pulse DCs, which therefore have likely led to a more easily 
detectable clonal expansion of T cells. Palucka and colleagues found increased frequencies 
of MART-1-specific CD8+ T cells after DC vaccination using allogeneic tumor lysate in 3 out 
of 21 patients, with detectable numbers of these T cells already present at baseline in 2 
out of these 3 patients (20). In previous studies with DC vaccination in mesothelioma using 
autologous tumor material, we found significantly increased cytotoxicity against the tumor 
after treatment, showing induction of a tumor-specific response by DC immunotherapy (7). 
In the current study, no tumor material was collected for ethical reasons, but we anticipate a 
comparable induction of a tumor-specific immune response based on the clinical outcomes 
in our patient cohort (9). As shown here and by others, monitoring of specific T cells in pe-
ripheral blood upon immunotherapy with a broad antigen repertoire, is challenging due to 
the unknown antigen composition and low frequency of individual T cell clones, and requires 
either very immunogenic antigens like NY-ESO-1 or MART-1 (21, 22) or in vitro enrichment 
steps, which makes it less attractive for future use in clinical practice. 
Next to T cell specificity, we investigated T cell phenotype, using extended multiplex flow 
cytometry. We demonstrated that treatment-related differences were most notable for CD4+ 
T cells, with an increase in surface expression of ICOS, PD-1 and HLA-DR after treatment. This 
signifies T cell activation, because T cells upregulate HLA-DR (23), ICOS (24) and PD-1 (25) 
after (TCR) stimulation. 
Interestingly, both HLA-DR+ CD4 T cells and ICOS+ CD4 T cells have been described to in-
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crease after treatment with ipilimumab (anti-CTLA-4 monoclonal antibody) (26). Moreover, 
an increase of ICOS+ CD4 T cells is suggested as a possible pharmacodynamic biomarker for 
response to this checkpoint inhibitor (27-29). Notably, the best responding patient (#5) in 
our study showed the highest numbers of HLA-DR+ CD4+ and ICOS+ CD4+ T cells. Our flow 
cytometry panels did not allow analysis of co-expression of ICOS and HLA-DR. Others have 
demonstrated that ICOS+ T cells also expressed CD45RO (24), indicating that T cells bearing 
high levels of ICOS may be in an advanced maturation phase. This would be in concordance 
with the low proportions of CCR7 and CD27-positive T cells in our patient (#5), which are 
markers of less maturated T cells. In the current study patient numbers are too low to cor-
relate the immune monitoring data with clinical outcome. Yet, our findings suggest that the 
ICOS+ CD4+ T cell subset may have value in the immune monitoring of future trials with DC 
immunotherapy. Furthermore, Fan and colleagues have described a functional role for ICOS 
in the anti-tumor immune response (30), providing a rationale for the combination of DC 
immunotherapy and engagement of ICOS-signaling in future treatments. 
In conclusion, vaccination with a broad spectrum of antigens (as is the case with the alloge-
neic lysate used in the current study) in MPM patients, induced an increase in T cell and B 
cell numbers in peripheral blood. No evidence was found for a mono- or oligo-clonal T cell 
expansion, thus suggesting broad activation of the T lymphocytes after therapy. Additionally, 
changes in the frequencies of defined immune cell markers, in particular the increase of T 
cell activation markers in CD4+ T cells, demonstrated treatment-associated changes that we 
would propose as parameters to be included in the monitoring of DC vaccination treatments. 
Future studies with larger patient groups should evaluate their relation with treatment effi-
cacy.
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+
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+
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SD
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2/A
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+
+
+
-
+
+
* Patient characteristics are further detailed A
erts et al (2017) 
A
bbreviations: D
CK, D
C
’s pulsed w
ith lysate and KLH
; D
C, D
C
’s pulsed w
ith lysate only; lys, tum
or lysate; M
sln, m
esothelin; N
D
, not determ
ined; SD
, 
stable disease; PR, partial response. 
# ++ = >75%
 positive tum
or cells; + = 25-75%
 positive tum
or cells;  
† positive (+) if induration > 2 m
m
 48 hours aft
er injection. 
‡ positive (+) w
hen dextram
er-binding CD
8 T cell frequency ≥2x negative controls
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Table S2: List of antibodies used for multiplex flow cytometry 
MaRkeR label supplieR Cat.no Clone panel*
CD3 FITC BD Biosciences 345764 SK7 1
CD3 Pacific Blue BD Biosciences 558117 UCHT1 2,3,4,5
CD4 PE-Cy7 BD Biosciences 348809 SK3 1
CD4 BV510 BD Biosciences 560769 RPA-T4 2,3,4,5
CCR7 PE R&D FAB197P 150503 2
CD8 APC-Cy7 BD Biosciences 348813 SK1 1
CD8 PerCP BD Biosciences 345774 SK1 2,3,4,5
CD19 APC eBioscience 17-0199-42 HIB19 1
CD25 APC BD Biosciences 340907 2A3 3
CD27 APC-Cy7 BD Biosciences 560222 M-T271 2
CD28 APC BD Biosciences 559770 CD28.2 2
CD45 PerCP BD Biosciences 345809 2D1 1
CD45RA PE-Cy7 BD Biosciences 337186 L48 2
CD56 PE Dako R7251 C5,9 1
CD57 FITC BD Biosciences 333169 HNK-1 2
CD69 PE-Cy7 BD Biosciences 335792 L78 3
CD127 PE BD Biosciences 557938 hIL-7R-M21 3
CD134 FITC eBioscience 11-1347-42 ACT35 (ACT-35) 5
CD137 PE eBioscience 12-1379-42 4B4 (4B4-1) 5
CD154 APC-Cy7 Biolegend 310822 24-31 5
CD223 PE-Cy7 eBioscience 25-2239-42 3DS223H 4
CD272 PE Biolegend 344506 MIH26 4
CD279 APC-Cy7 Biolegend 329922 EH12.2H7 4
CD278 PE-Cy7 eBioscience 25-9948-42 ISA-3 5
HLA-DR APC-Cy7 BD Biosciences 335831 L243 3
TCRgd FITC BD Biosciences 347903 11F2 1
*Panel 1: Absolute numbers, Panel 2: Maturation, Panel 3: Activation/Tregs, Panel 4: 
Co-inhibitory markers, Panel 5: Co-stimulatory markers
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1. Ungated 2. CD45+ 3. CD45+/CD3+ 4. CD45+/CD3+/CD8- 5. CD45+
Supplementary figure S1: Example of gating strategy preceding the enumeration of 
immune cell populations. 
Lymphocytes were defined as CD45+, SSC-Alow (plot1); from CD45+, SSC-Alow lymphocytes, T cells 
(CD3+CD19-) and B cells (CD19+CD3-) were defined (plot 2). T cells were further subdivided in 
CD8+ T cells, and CD4+ T cells (plot3 and 4). Within the CD45+, SSC-Alow lymphocytes, NK cells were 
defined as CD56+CD3- (plot 5). 
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Supplementary figure S2: Activation of post-therapy T cells after co-culture with 
lysate-pulsed DCs. 
Lysate-pulsed DCs were co-cultured for 24h with autologous PBMC obtained at week 0, 2 or 7. A) 
Proportions of CD4 and CD8 T cells expressing CD69, as determined by flow cytometry. B) Propor-
tions of CD4 and CD8 T cells expressing CD137, as determined by flow cytometry. C) Concentration 
of IFNγ in the culture supernatant after 24h, as determined by ELISA.
123
Autologous dendritic cell therapy in mesothelioma 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 6 Patient 7 Patient 8 Patient 9
CD
3
A
Mesothelin HLA-A2 binding
%
 M
es
ot
he
lin
 H
LA
-A
2
bi
nd
in
g 
C
D
8 
T 
ce
lls
B Patient 1
0 6
0.0
0.1
0.2
0.3
0.073
5.55E-3
0.093
4.94E-3
0.087
0
0.093
0
0.27
2.29E-3
0.13
1.45E-3
0.16
2.80E-3
0.16
1.10E-3
0.017
7.45E-4
0.017
6.06E-4
0.039
7.76E-4
0.030
0
0.034
0
0.055
3.74E-3
0.038
0
0.043
0
W
ee
k 
0
W
ee
k 
6
Patient 2
0.0
0.1
0.2
0.3
0 6
Patient 3
0.0
0.1
0.2
0.3
0 6
Patient 4
0.0
0.1
0.2
0.3
0 6
Patient 6
0.0
0.1
0.2
0.3
0 6
Patient 7
0.0
0.1
0.2
0.3
0 6
Patient 8
0.0
0.1
0.2
0.3
0 6
Patient 9
0.0
0.1
0.2
0.3
0 6
CD8+
CD8+
CD8-
CD8-
Supplementary figure S3: Mesothelin peptide A-specific CD8 T cells in HLA-A2 positive 
patients. 
A) Peripheral blood samples were collected at base line (week 0) and 2 weeks after the third 
vaccination (week 6).  CD8 T cells were propagated in four culture cycles with mesothelin-peptide 
loaded aAPC after which mesothelin-peptide/HLA-A2 dextramers were used to detect mesothelin 
specific CD8 T cells. B) Values of gated tetramer positive CD8 T cells - as shown in panel A - pre-
sented as proportions of mesothelin-B HLA-A2-binding cells of total CD8 T cells. Gating was based 
on the negative controls: FMO staining and the non-CD8 T cell population. All HLA-A2 positive 
patients are shown; patient 5 was excluded (haplotype HLA-A3/HLA-A68).
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Supplementary figure S4: Additional frequencies of T cell populations or ratios, as well as 
expression of cell surface markers, showing no change between week 0, 2 and 6. 
A) CD4/CD8 T cell ratio, γδT cells and regulatory T cells (Treg) percentages (upper panels) and rep-
resentative flow cytometry plots (lower panels; γδT cell and Treg). B) CD4 T cells positive for CD25, 
CD69, CD272 (BTLA), CD137 (4-1BB), CD154 (CD40L) and CD134 (OX40). C) CD8 T cells positive for 
CD25, CD69, CD272 (BTLA), CD137 (4-1BB), CD154 (CD40L) and CD134 (OX40)
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ABSTRACT
Introduction: Soft tissue sarcomas (STS) are a heterogeneous group of malignant tumors 
with over 50 subtypes, differing in tumor biology and clinical outcome. Local T cell immunity 
is often associated with tumor evolution and therapy response. Here, quantities and qualities 
of tumor-infiltrating lymphocytes (TIL), and T cell evasive mechanisms that occur in STS sub-
types are investigated. 
Methods: Liposarcoma (LPS), gastro-intestinal stromal tumors (GIST), leiomyosarcoma (LMS), 
myxofibrosarcoma (MFS) and pleomorphic sarcoma (PMS) were freshly obtained after sur-
gery and dissociated into single cell suspensions. lipoma and melanoma were taken along 
as tumors representing a benign soft tissue tumor and immunogenic tumor, respectively. T 
cells were counted per mg tumor tissue, and phenotypically analyzed by flow cytometry, with 
emphasis on CD8 T cell maturation (assessed via CD45RA and CCR7) and T cell co-inhibition 
(PD1, LAG3, TIM3). Also, T cell numbers and localization were determined by quantitative in 
situ stainings. Next Generation Sequencing data from bulk tumor tissues were analyzed for 
TCR diversity, mutational load, relative frequencies of immune cell populations, and expres-
sion of immune-related genes. 
Results: GIST, MFS and PMS were observed to have relatively high numbers of CD8+ TILs 
with highest fractions of differentiated CD8+ T cells in GIST and LPS. These CD8+ TILs gener-
ally expressed the checkpoints PD-1, LAG3 and TIM3, with highest co-expression in MFS and 
PMS but nearly absent co-expression in GIST. Interrogation of NGS data revealed that frac-
tions of dominant T cell clones according to TCR-Vβ sequence were lowest in GIST and LPS, 
whereas mutational load was relatively low for all STS subtypes. Interestingly, in silico analy-
ses revealed that in GIST, myeloid-derived cells are underrepresented, and the expression of 
co-stimulatory ligands, such as B7-2, ICOSL and 4-1BBL, is substantially lowered compared to 
other STS subtypes.
Conclusion: STS subtypes differ in quantity and quality of CD8+ TILs, making these subtypes 
amenable to different forms or combinations of immune therapy. In particular GIST seems to 
lack immunogenicity and may require additional T cell co-stimulation to enhance responsive-
ness to checkpoint inhibition.
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INTRODUCTION
Soft Tissue Sarcomas (STS) are a group of heterogeneous tumors of mesenchymal origin with 
over 50 different subtypes that can originate from fat, muscle, nerves, fibrous, endothelial, 
or deep skin tissues. For most patients with non-metastatic STS standard care of treatment 
includes surgical resection with or without peri-operative (neo)adjuvant chemo- or radio-
therapy. Dependent upon the disease stage and histological subtype, on average 25-50% of 
these patients develop recurrent and/or metastatic disease, and the median overall survival 
of metastasized STS after treatment by chemotherapy is only 10-15 months.[1, 2] Therefore 
there is an urgent need for novel and effective therapies for the treatment of advanced STS.
[3] GIST is different from most STS subtypes, since 85-90% of tumors harbor a KIT tyrosine 
kinase, or platelet derived growth factor receptor α (PDGFRA) mutation resulting in great 
clinical responses to targeted (neo)adjuvant therapy with Imatinib.[4]
Immune therapies have clearly demonstrated therapeutic value in various tumor types. In 
STS, the clinical exploration of immunotherapeutic strategies has been limited. For exam-
ple, interferons (α/β)[5, 6], interleukin-2 [7], and cancer vaccines have been tested and in-
duced limited anti-tumor activity in a small fraction of STS patients showing stable disease 
but no radiological responses .[8] In another example, adoptive transfer of NY-ESO-1 TCR 
gene-modified T cells showed objective responses in 11 out of 18 (61%) patients and with 
3- and 5-year survival rates of 38% and 14%, respectively. [9, 10] In addition, and despite 
pronounced clinical responses in several other tumor types, immune checkpoint inhibiting 
antibodies show inconclusive results in STS.[11-15] In fact, first studies revealed that some 
STS subtypes respond to treatment with anti-PD1 therapy[16], though others report no ef-
fect of anti-PD-1 therapy.[17] A recent phase 2 study treating 85 metastatic STS patients with 
nivolumab (anti-PD1, n=43) or nivolumab plus ipilimumab (anti-CTLA4, n=42) concluded that 
nivolumab monotherapy does not warrant further study in an unselected STS population 
given the limited efficacy. Yet, the nivolumab plus ipilimumab combination treatment arm 
showed promising efficacy in certain STS subtypes like undifferentiated pleomorphic sarcoma 
and leiomyosarcoma.[18]
It has become evident that the numbers and activation state of immune cells in tumors, in 
particular CD8-positive tumor-infiltrating lymphocytes (TIL), have predictive value with re-
spect to the responsiveness to immune therapies.[19, 20] Local CD8 T cell immunity var-
ies significantly between STS subtypes, which may explain the variable clinical effects of 
immunotherapies when treating these tumor types.[21, 22] Interestingly, local CD8 T cell 
immunity is strictly controlled [23], and can be captured by multiple parameters, such as 
the presence of CD8 cells, Major histocompatibility complex (MHC) molecules, suppressor 
cells, as well as immune and metabolic checkpoints.[24, 25] Present study, demonstrates 
a multi-parameter inventory of the immune microenvironment in general, and local CD8 T 
cell profile in particular of different STS subtypes with the intent to get more insight into the 
potential immunogenicity of the most common STS types. To this end, gastro-intestinal stro-
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mal tumors (GIST), leiomyosarcoma (LMS), liposarcoma (LPS), myxofibrosarcoma (MFS) and 
pleomorphic sarcoma (PMS) are prospectively assessed for quantities and qualities of TILs, 
and T cell evasive mechanisms by the use in situ stainings and single cell flowcytometry, as 
well as in silico analyses of NGS data to assess mutational load, TCR diversity, frequencies of 
immune cells, and expression of immune-related genes.
MATERIALS AND METHODS:
Patients and samples
Patients with non-metastatic STS eligible for surgery at the Erasmus MC were included and 
covered the following subtypes: gastro-intestinal stromal tumor (GIST) untreated and Ima-
tinib treated, leiomyosarcoma, liposarcoma, myxofibrosarcoma and pleomorphic sarcoma. 
Benign lipoma and melanoma were included as controls. Part of tumor resection specimen 
was formalin fixed and paraffin embedded (FFPE) for routine pathology to confirm STS sub-
type; and retrieved from the department of Pathology, Erasmus MC, for in situ stainings. The 
remainder of the tissue was processed into a single cell suspension to analyze numbers and 
phenotypes of intra-tumoral T cells. Patient characteristics are shown in Table 1. The study 
protocol has been approved by the institutional medical ethical review board (MEC-2012-
436). 
Tumor-derived single cell suspensions
Freshly obtained tumor material was dissociated on the day of acquisition or was stored over-
night in complete medium (RPMI-1640 w/ Hepes [Lonza, Verviers, Belgium], supplement-
ed with 6% human serum [Sanquin, Amsterdam, The Netherlands], 1% L-glutamine [Lonza) 
and 1% penicilline/streptomycine [Lonza]) at 4°C prior to dissociation. The tumor tissue was 
weighted, cut in small fragments of approximately 1 mm3, placed in RPMI-1640 w/ Hepes 
supplemented with 1% penicilline/streptomycine with 0.1 mg/ml collagenase (Type A, Sig-
ma-Aldrich, St. Louis, MO, USA) and 10 µg/ml DNAse (Roche), and mechanically dissociated 
using the gentleMACS™ Dissociator (program C and program h_tumor_01) (Milteyi, Bergisch 
Gladbach, Germany). Subsequently, tumor pieces were incubated for 60 min at 37°C and 5% 
CO2 under continuous rotation, after which cells were passed through a 70µm strainer (Grein-
er bio-one, Kremsmünster, Austria) and washed once with complete medium.
Flow cytometry
Flow cytometry (FCM) panels were used to assess frequencies of T cell subsets according to 
expression of T cell maturation markers and T cell co-inhibitory receptors. For these panels, 
the following mAb-conjugates were used: CD3-Pacific Blue (clone UCHT1, BD Biosciences, San 
Jose, CA, US), CD4-BV785 (clone RPA-T4, Sony Biotechnology, San Jose, CA, US), CD8-BV605 
(clone SK1, BD Biosciences), CD14-PerCP (clone MφP9, BD Biosciences), CD272-APC (BTLA, 
clone MIH26, Sony Biotechnology), CD223-PE-Cy7 (LAG3, clone 3DS223H, eBioscience, San 
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Diego, CA, US), CD279-APC-Cy7 (PD1, clone EH122H7, Biolegend, San Diego, CA, US), CD366-
FITC (TIM3, clone F38-2E2, eBioscience), CCR7-PE (clone 150503, R&D Systems, Germany) 
and CD45RA-BV510 (clone HI100, BD Biosciences). All antibodies fluorochrome combinations 
were selected and titrated to prevent spillover in the different fluorescence channels (data 
not shown). For stainings, 100 µl of single cell suspension was incubated with antibodies for 
15 minutes at room temperature, washed with phosphate-buffered saline (PBS, Lonza), and 
re-suspended in 1% buffered Paraformaldehyde (PBS/PFA). FCM data acquisition was per-
formed on a Celesta flow cytometer (BD Biosciences) equipped with FACSDiVa 8.xsoftware 
(BD Biosciences) following gating on single live cells (7-AAD negative; 7-AAD from BD Biosci-
ences). Analysis was performed using FlowJo software (Ashland, Oregon, USA). Unstained 
controls were taken along for every sample and used to set thresholds for markers. T cell 
number per gram of tumor was calculated by measuring CD3+ T cell counts in 100 µl suspen-
sion (10% of total volume) divided by tumor weight.
Immunohistochemistry
FFPE tissues were cut into 4-μm sections and stained with anti-CD8 (clone: SP57, Ventana, 
Basel, Switserland) and anti-PD1 antibodies (clone: NATIOS, Cell Marque, St. Louis, MO, US). 
Stained slides were developed with DAB chromogen, counterstained with hematoxylin and 
mounted in Optisure Ventana coverslips. Whole tissue slides were scanned (magnification: 
10x) using Vectra 3.0 (Perkin Elmer, Waltham, Massachusetts, USA). Regions of interest (12 
in total: 6 at the tumor margin, and 6 at the tumor center; all evenly distributed) were se-
lected for multispectral imaging (20x). To capture morphological heterogeneity, various sub-
type-specific tissue finding algorithms were generated using InForm tissue finder software 
(Perkin Elmer; Version 2.3) that enabled calculation of the number of CD8+ cells per mm2 
tumor tissue. Spatial distribution of CD8+ T cells was categorized according to: (1) ignorant 
tumors (with <10% of all nucleated cells being CD8+ T cells); (2) inflamed tumors (low, me-
dium and high with 10-29, 30-60, >60% of cells being CD8+ T cells, respectively); and (3) 
excluded tumors (with >10% of cells being CD8+ T cells, and >90% of these CD8+ T cells at 
tumor border (see Figure 1C for representative IHC sections that reflect the different spatial 
distribution patterns and scores).[26] Spatial distribution of both CD8+ as well as PD1+ T cells 
was assessed by two authors (YK and RW) with high concordance (86,5%); and all non-con-
cordant slides were discussed, and when not resolved, a 3rd author re-evaluated and catego-
rized the slide. 
In silico analyses 
Relative frequencies of immune cell populations
Affymetrix U133A data were collected from the Gene Expression Omnibus (GEO) (http://
www.ncbi.nlm.nih.gov/geo/) entries GSE17743 and GSE71121. Number of patient tumor 
samples per STS subtype are displayed in Supplementary table 1. Raw .cel files were pro-
cessed using RMA normalization (per entry), and subsequently uploaded and analyzed with 
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the CIBERSORT algorithm with permutations set at 100 (https://cibersort.stanford.edu/).[27] 
From the CIBERSORT output, only samples with a significant threshold (p<0.05) for deconvo-
lution of the immune cell populations were selected.
Differential gene expression
RNAseq data were gathered from the Gene Expression Omnibus (GEO) (http://www.ncbi.
nlm.nih.gov/geo/) entry GSE71121. Number of patient tumor samples per STS subtype are 
displayed in Supplementary table 1. Raw FASTQ files were aligned with STAR [28] using ref-
erence genome GRCh38, and gene expression read counts were processed in R. Genes with 
read counts lower than 0.5 counts per million in at least 15 patient samples were excluded 
from analysis. The Limma package [29, 30] with Voom transformation (with trend) was used 
to estimate the mean-variance relationship of log-counts, and the Limma empirical Bayes 
analysis pipeline was used to compute differential expression of selected sets of immune-re-
lated genes among STS subtypes.
Mutational load
Whole Exome Sequencing (WES) data were obtained from The Cancer Genome Atlas (TCGA) 
and downloaded from the GDAC Firebrowse website as “level 4” data. Mutational load was 
determined by the sum of synonymous and non-synonymous mutations per Megabase DNA. 
Since GIST samples are not present in TCGA, publicly available raw WES data from the Se-
quence Research Archive (SRA, https://www.ncbi.nlm.nih.gov/sra), entry SRP042250 (FASTQ 
files, paired Tumor and Blood samples), were downloaded and subsequently analyzed by the 
TCGA DNAseq Variant calling pipeline to determine the mutational load (as described above). 
(https://docs.gdc.cancer.gov/Data/Bioinformatics_Pipelines/DNA_Seq_Variant_Calling_
Pipeline/).
TCR clonality
MiXCR software (https://mixcr.readthedocs.io/en/latest/quickstart.html) was used to ana-
lyze T Cell Receptor (TCR)-Vβ diversity.[31] RNAseq FASTQ files (GSE71121) were used to 
determine number of different TCR-Vβ sequences.
Statistical analysis
Statistical tests were performed in R. Significant differences between continuous variables 
of two groups were tested with the Mann-Whitney-U test. Significant differences between 
continuous variables of 3 or more groups were tested with the Kruskall-Wallis test. Results 
were considered as significant when p<0.05.
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RESULTS
GIST, myxofibrosarcoma and pleomorphic sarcoma demonstrate high 
number and inflamed distribution of CD8+ T cells
Tumor specimen from STS subtypes were analyzed by flow cytometry (FCM) as well as in situ 
staining to assess quantity of intra-tumoral T cells. FCM analyses revealed considerable vari-
ation in numbers of CD8+ T cells per gram of tissue across STS subtypes, but these quantities 
were nonetheless significantly enhanced in GIST and myxofibrosarcoma when compared to 
liposarcoma, but not when compared to leiomyosarcoma and pleomorphic Sarcoma (Fig-
ure 1A). T cell enumeration in lipoma, considered benign and relatively non-immunogenic, 
and Melanoma, considered immunogenic, demonstrated very low (almost absent) and high 
numbers of T cells per gram of tissue, respectively, the latter comparable to T cell numbers 
observed in GIST and myxofibrosarcoma. 
In situ quantification demonstrated similar heterogeneity in numbers per mm2 of tissue 
Table 1: Patient characteristics.
Age (years) median  range
61,5 (25 - 86)
Primary tumor size (cm) median  range
9 (1,4 - 55)
Gender n=  
Male 41 73,2%
Female 15 26,8%
Histology n= distribution (%) 
Lipoma 6 10,2%
Melanoma 4 6,8%
GIST 9 15,3%
Leiomyosarcoma 7 11,9%
Liposarcoma* 15 25,4%
Myxofibrosarcoma† 8 13,6%
Pleomorphic sarcoma‡ 10 16,9%
*Well-differentiated n=8; Dedifferentiated n=3; Myxoid n=7; † 4 of 8 and ‡ 5 of 10 patients were 
pre-treated with radiotherapy
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across STS subtypes, and again higher number of CD8+ T cells were observed in GIST and 
myxofibrosarcoma when compared to liposarcoma (Figure 1B).
Next, spatial distribution of CD8+ T cells within STS was assessed, which was categorized 
according to T cell ignorance; exclusion and different extents of inflammation (see for details, 
Materials and Methods). Representative in situ stainings of these different CD8 T cell distribu-
tion patterns are shown in Figure 1C; and frequencies of these patterns per STS subtypes are 
summarized in Figure 1C. About one-third of leiomyosarcoma and liposarcoma demonstrat-
ed the ignored phenotype (27 and 35%, respectively), whereas only about one-tenth of GIST, 
myxofibrosarcoma and pleomorphic sarcoma demonstrated lack of T cells (7, 7 and 13%, 
respectively). myxofibrosarcoma, pleomorphic sarcoma and GIST showed high percentages 
of inflamed tumors, where myxofibrosarcoma and pleomorphic sarcoma had more highly 
inflamed tumors compared to GIST (29, 20 and 7%, respectively). GIST had highest fraction 
of tumors (57 %) with medium inflamed spatial distribution of T cells. Melanoma tumors 
showed highest fraction (50%) of the CD8 T cell excluded pattern compared to all other STS 
subtypes, and lipoma only displayed an ignorant phenotype.
GIST and liposarcoma show no signs of T cell activation
The activation status of CD8+ TILs was measured via FCM analysis of the expression of T 
cell differentiation markers as well as co-inhibitory receptors. When assessing T cell differen-
tiation, leiomyosarcoma, myxofibrosarcoma and pleomorphic sarcoma showed the highest 
fractions of T effector memory (TEM) and T CD45RA+ effector memory (TEMRA) cells (Figure 2A). 
In contrast, GIST showed the lowest fraction of TEM cells within CD8+ TILs, being significantly 
different from myxofibrosarcoma and pleomorphic sarcoma (Figure 2B). Fractions of TEMRA 
within CD8+ TILs were more or less reciprocally related to those of TEM. 
When assessing CD8+ TILs for the expression of inhibitory receptors, PD1 was abundantly ex-
pressed (Figure 3A). Interestingly, myxofibrosarcoma and pleomorphic sarcoma showed the 
highest fractions of PD1+ T cells, whereas GIST displayed the lowest fractions of PD1 positive 
T cells. Also, fractions of TIM3+ T cells, but not LAG3+ T cells, were higher in myxofibrosarco-
ma and pleomorphic sarcoma compared to GIST and liposarcoma. When looking into co-ex-
pression of PD1, LAG3 and TIM3, only a relatively small fraction of CD8+ TILs displayed all 
three inhibitory receptors (Figure 3B). We observed that TIM3 was mostly co-expressed with 
PD1, or with PD1 and LAG3, whereas LAG3 was mostly co-expressed with PD1. In fact, TIM3 
or LAG3 were hardly co-expressed by PD1-negative CD8 TIL. Although patterns in IR (co-) ex-
pression were not specific for particular STS subtypes, it was notable that GIST demonstrated 
the lowest fraction of PD1+ LAG3+ TIM3+ CD8+ TILs. pleomorphic sarcoma had the highest 
fraction of PD1+ LAG3+ TIM3+ CD8+ TILs, being comparable to melanoma. 
GIST and liposarcoma lack dominant T cell clones.
To assess whether numbers of intra-tumoral CD8 T cells and level of T cell activation in STS 
subtypes correspond to a changed TCR repertoire diversity and antigen load, publicly avail-
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Figure 1: GIST and myxofibrosarcoma sarcoma have highest number and predominantly 
inflamed distribution of CD8+ T cells. 
A) Absolute numbers of CD3+ T cells per gram of tumor tissue assessed by FCM after tissue dis-
sociation of surgical specimen of GIST (n=9), leiomyosarcoma (n=7), liposarcoma (n=12), myxo-
fibrosarcoma (n=8), pleomorphic sarcoma (n=9), lipoma (n=5) and Melanoma (n=4). Individual 
(symbols) and median (horizontal lines) observations are shown, Kruskal-Wallis test: p = 0,049. 
B) In situ quantification of CD8+ T cells per mm2 in FFPE tissue sections of different STS subtypes 
(n= 15 specimen per STS subtype), Kruskal-Wallis test: p = 0,038. C) In situ stainings showing 
representative examples of different categories of spatial distribution of CD8+ T cells (bright field 
whole slide images, see materials and methods for details); lower panel: pie charts displaying the 
frequencies of the different categories of spatial T cell distributions for STS subtypes. *represents 
p-value <0.05 according to Mann-Whitney U test.
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Figure 2: GIST shows low fraction of effector memory CD8+ T cells.
A) FCM analysis of maturation stages of CD8+ T cells in different STS subtypes based on expression 
of CD45RA and CCR7 using the following definitions: Naïve (CCR7+/CD45RA+, TN), Central Memory 
(CCR7+/CD45RA-, TCM), Effector Memory (CCR7-/CD45RA-, TEM), and Effector Memory expressing 
CD45RA T cells (CCR7-/CD45RA+, TEMRA). B) TEM cells as percentage of CD8+ T cells. Included in 
analysis of (A) and (B): GIST (n=8), leiomyosarcoma (n=6), liposarcoma (n=10), myxofibrosarcoma 
(n=8), pleomorphic sarcoma (n=9), lipoma (n=3) and Melanoma (n=4); *represents p-value <0.05 
according to Mann-Whitney U test.
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able NGS data was  interrogated. First, using the MiXCR tool [31], number of different TCR-Vβ 
sequences (a measure of different T cell clones) was determined, and showed a high level of 
variability across STS subtypes (Figure 4A), with some subtypes having <10 and others having 
>1000 different T cell clones. GIST showed a trend towards a higher number of T cell clones 
when compared to other STS subtypes, but when analyzing the frequency of the ten most 
dominant T cell clones, GIST and liposarcoma had the lowest fractions when compared to 
leiomyosarcoma, myxofibrosarcoma and pleomorphic sarcoma. Moreover, the most domi-
nant T cell clone in GIST was present at a much lower frequency compared to the most dom-
inant T cell clone in all other STS subtypes (Figure 4B). 
Collectively, investigations of intra-tumoral CD8+ T cells in STS subtypes demonstrated that 
GIST, myxofibrosarcoma and pleomorphic sarcoma have relatively high numbers of such T 
cells. GIST and liposarcoma harbor low fractions of CD8+ TEM cells, and low fractions of CD8+ 
T cells expressing PD1 or co-expressing PD1 and TIM3 when compared to myxofibrosarcoma 
and pleomorphic sarcoma. This low level of T cell activation in GIST and liposarcoma was 
accompanied by significant lower abundance of dominant T cell clones. These findings are 
schematically represented in Figure 8A.
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GIST shows a non-differential mutational load nor antigen presenta-
tion
In addition to the analyses focusing on intra-tumoral CD8+ T cells, the immune micro-envi-
ronment of STS subtypes was investigated. To this end, tumor mutational burden and expres-
sion of genes involved in antigen processing and presentation was analyzed with NGS data. 
Analysis of mutational load, as a surrogate marker for neo-antigens, demonstrated substan-
tial differences among STS subtypes (Figure 5A). In general, the mutational load is low in STS, 
yet myxofibrosarcoma and pleomorphic sarcoma had the highest mutational load, which was 
significantly higher than that of leiomyosarcoma and liposarcoma. GIST did not significantly 
Figure 3: GIST and liposarcoma show decreased fractions of immune checkpoint-positive 
CD8 T cells.
A) FCM analysis of fractions of PD1, LAG3, and TIM3-expressing CD8+ T cells in different STS sub-
types represented by box-and whisker plots. B) FCM analysis of fractions of CD8+ T cells co-ex-
pressing PD1, LAG3 and/or TIM3 in different STS subtypes. FCM analysis was only performed on 
samples with at least 200 CD8+ T cells in the staining tube and included: GIST (n=8), leiomyosarco-
ma (n=6), liposarcoma (n=10), myxofibrosarcoma (n=8), pleomorphic sarcoma (n=9), lipoma (n=3) 
and Melanoma (n=4); *represents p-value <0.05 according to Mann-Whitney U test.
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differ in mutational load when compared to other STS subtypes, arguing that the lower dom-
inance of T cell clones and lack of T cell activation in this STS subtype is not related to a lower 
level of neo-antigens. 
Next, the expression of genes involved in antigen processing and presentation via MHC class 
I was analyzed (Figure 5B) and did not find significant differences between STS subtypes 
with respect to β2-microglobulin (B2M), HLA-A, HLA-B, HLA-C, and Transporter associated 
with antigen Processing 1 and 2 (TAP1 and 2). Also, the expression of genes involved in MHC 
class II (HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DQB1, and HLA−DRB1) did not differ among 
STS subtypes (Figure 5C). Although the expression of some single genes did differ between 
STS subtypes, the difference in expression was lower than 2-fold. 
GIST shows differential presence of immune suppressor cells, and 
decreased expression of T cell co-stimulatory ligands.
Besides measures of immunogenicity (as described above), parameters of local T cell sup-
pression, such as the presence of immune suppressor cells or T cell co-stimulatory or inhib-
itory ligands were examined. To determine the relative frequencies of various immune cell 
Figure 4: GIST and liposarcoma show no enrichment of TCR-Vb sequences.
A) Number of different TCR-Vβ sequences in STS subtypes determined by MiXCR RNAseq analysis 
of publicly available data (see materials and methods for details), and displayed as box and whis-
ker plots. B) Mean fraction of the 10 most dominant T cell clones of all T cell clones with circles 
representing these T cell clones. Dots align the T cell clones according to dominance among the 
different STS subtypes.*represents p-value <0.05 according to Wilcoxon test.
Kruskal−Wallis, p = 0.53
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Figure 5: STS subtypes show differential mutational load but non-differential expression 
of genes involved in antigen presentation.
A) Mutational load in different STS subtypes defined as mutations per Mb according to publicly 
available NGS data, and displayed as box and whisker plots. B) Expression level of genes involved 
in MHC-class I antigen processing and presentation. C) Expression level of genes involved in MHC-
class II antigen presentation *represents p-value <0.05 according to Mann-Whitney U test
types, gene expression data of 257 different STS tissues was analyzed with the CIBERSORT 
algorithm [27] (Figure 6). With respect to regulatory T cells (Tregs), pleomorphic sarcoma 
showed a significantly lower fraction of these suppressor T cells compared to GIST and leio-
myosarcoma. The fraction of undifferentiated macrophages (M0), which may represent my-
eloid-derived suppressor cells (MDSC), was observed to be significantly lower (almost absent) 
in GIST compared to all other subtypes, and in leiomyosarcoma compared to liposarcoma 
and myxofibrosarcoma. The fraction of immune-suppressive M2 macrophages was observed 
to be higher in myxofibrosarcoma and pleomorphic sarcoma compared to all other STS sub-
types, and GIST showed the lowest fraction of M2 macrophages among all STS subtypes.
Finally, differential gene expression of co-stimulatory and inhibitory ligands was assessed. We 
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observed that GIST shows a lowered expression of PDL2, but not PDL1 (Figure 7A). Ligands 
for LAG3, MHC class II molecules, were already assessed and these do not differ among STS 
subtypes (Figure 5B). The ligand for TIM3, Galectin-9, shows a lowered expression in leio-
myosarcoma when compared to liposarcoma, myxofibrosarcoma and pleomorphic sarcoma. 
Notably, when analyzing T cell co-stimulatory ligands, CD86, but not CD80, shows a lowered 
expression in GIST when compared to all other STS subtypes, and in leiomyosarcoma com-
pared to pleomorphic sarcoma and myxofibrosarcoma (Figure 7B). Also, the ICOS ligand and 
the 4-1BB ligand showed lowered expression in GIST, whereas the OX40 ligand did not differ 
significantly among STS subtypes.
Collectively, the in-silico analyses of the immune micro-environment of STS subtypes re-
vealed that myxofibrosarcoma and pleomorphic sarcoma have a higher mutational burden 
compared to leiomyosarcoma and liposarcoma, but not GIST, and that genes involved in an-
tigen processing and presentation were similarly expressed in all STS subtypes. Fractions of 
Tregs were higher and fractions of myeloid cells were lower in GIST compared to other STS 
subtypes. Expression level of the co-inhibitory ligand PDL2 was low in GIST and expression 
level of Galectin-9 was lowest in leiomyosarcoma and highest in myxofibrosarcoma and pleo-
morphic sarcoma. Expression levels of co-stimulatory ligands CD86, ICOSL, and 4-1BB ligand 
were all low in GIST compared to other STS subtypes.  These findings are schematically rep-
resented in Figure 8B.
DISCUSSION
In the current study, we have analyzed the STS subtypes GIST, myxofibrosarcoma, liposarco-
ma, pleomorphic sarcoma and leiomyosarcoma for quantity and quality of CD8+ T cells as 
well as immune parameters of the tumor micro-environment using a combination of FCM, 
microscopy and in silico tools. A high concordance between FCM and in situ analysis for T cell 
quantity per STS subtype was seen, and it was shown that GIST, myxofibrosarcoma and pleo-
morphic sarcoma harbored the highest number of intra-tumoral T cells. Numbers of CD8+ T 
cells were comparable to those as seen in an immunogenic tumor type like melanoma. For 
pleomorphic sarcoma our data concerning T cell enumeration is supported by a recent study 
from Pollack and colleagues [32], but this study lacked GIST and myxofibrosarcoma. Also, 
quantity of TILS was assessed via CD3D gene expression. In another study, T cell quantity in 
GIST was compared to those of other STS subtypes, however, in this study T cell quantity was 
expressed as frequency of total CD45+ cells, not enumerated by absolute numbers, and spa-
tial distribution was not assessed.[33] When addressing T cell localization within STS tumors, 
our microscopic analyses revealed that GIST, myxofibrosarcoma and pleomorphic sarcoma 
mostly showed a T cell-inflamed phenotype, featuring an even distribution of CD8+ T cells in 
tumor center as well as margin. 
CD8+ T cell activation was assessed via FCM according to expression levels of T cell matura-
tion markers as well as inhibitory receptors. We observed significantly lower fractions of ef-
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Figure 6: GIST shows decreased fractions of suppressive myeloid cells.
Fractions of immune cell subtypes in different STS subtypes as determined by CIBERSORT algo-
rithm according to publicly available RNA data, and displayed as box and whisker plots. Number 
of analyzed tumors per STS subtype is described in materials and methods. *represents p-value 
<0.05 according to Mann-whitney U test.
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Figure 7: GIST shows decreased expression of PDL2, CD86, ICOSL and 4-1BBL genes.
A) RNA expression of IR ligands PDL1 (CD274), PDL2 (PDCD1LG2), and Galectin-9 (LGALS9) in dif-
ferent STS subtypes according to publicly available data, and displayed as box and whisker plots. 
B) RNA expression of co-stimulatory ligands CD80, CD86, ICOS ligand (ICOSLG), OX40 ligand (TN-
FRSF4), and 4-1BB ligand (TNFRSF9) in different STS subtypes according to publicly available data, 
and displayed as box and whisker plots. Number of analyzed tumors per STS subtype is described 
in materials and methods. *represents p-value <0.05 according to Mann-whitney U test.
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fector memory CD8+ T cells (TEM: CD45RA-, CCR7-) in GIST but not in myxofibrosarcoma nor in 
pleomorphic sarcoma, despite the fact that all three STS subtypes harbor equal numbers and 
similar spatial distributions of CD8+ T cells. In addition, GIST differed from myxofibrosarco-
ma and pleomorphic sarcoma by having the highest fraction of effector memory expressing 
CD45RA CD8+ T cells (TEMRA: CCR7-/CD45RA+). The CD8+ TEMRA cells are generally considered 
to be terminal effector cells, however, differentiation to this terminal effector phenotype is 
not necessarily the result of vigorous T cell receptor (TCR)-mediated stimulation, but can 
also be the result of excessive cytokine stimulation.[34, 35] Another recognized measure of 
T cell activation through TCR stimulation [36] is increased expression of inhibitory receptors 
(IRs). Again, GIST and also liposarcoma displayed lower fractions of PD1, LAG3 and espe-
cially TIM3-expressing CD8+ T cells when compared to myxofibrosarcoma and pleomorphic 
sarcoma. In fact, GIST demonstrated low numbers of PD1+LAG3+TIM3+CD8+ T cells, which 
are considered functionally compromised T cells [37], when compared to the latter two STS 
subtypes. These phenotypical analyses of CD8+ TILs argue that in GIST, despite high numbers 
of these T cells, there is limited TCR-driven T cell activation. For CD4+ T cells differences in 
maturation stages of CD4+ TIL were not as outspoken as for CD8+ TIL. Fractions of IR-ex-
pressing CD4+ T cells were lower compared to CD8+ T cells, especially for LAG3 and TIM3 the 
fractions of T cells were much lower and did not show any differences between STS subtypes 
(supplementary data). 
To explore any differences in TCR-mediated stimulation across STS subtypes, we examined 
TCR diversity using in silico tools and publicly available NGS data. Analysis into the number 
of TCR-Vβ sequences demonstrated a high level of variation and revealed, when analyzing 
the 10 most abundant TCR-Vβ sequences, that GIST and liposarcoma had a significantly low-
er frequency of dominant T cell clones. This observation is particularly true for the single 
most dominant T cell clone, and is suggestive for a more polyclonal T cell repertoire in GIST 
and liposarcoma, and a more oligoclonal T cell repertoire in myxofibrosarcoma and pleomor-
phic sarcoma, the latter finding being in agreement with a report by Pollack and colleagues. 
With respect to parameters of immunogenicity, mutational burden as well as expression of 
genes involved in antigen processing and presentation were analyzed. Mutational load of 
tumors, often considered a surrogate marker for potentially mutated peptides that can be 
presented by MHC molecules (neo-antigens) on malignant cells, has been associated with 
higher response rates to checkpoint therapy and adoptive T cell therapy with TILs [38-40]. 
Interestingly, in leiomyosarcoma reduced expression of genes encoding neo-peptides was 
identified as a potential mediator of resistance to immune checkpoint therapy.[41] Although 
it has already been reported that STS subtypes differ with respect to genomic alterations, 
[22, 42, 43] only few studies have assessed mutational load in STS subtypes in relation to 
number and phenotype of CD8+ TILs. Along these lines, the TCGA database has recently been 
thoroughly interrogated for mutational load in STS subtypes, but did not include GIST.[22] In 
our analyses, we observed a generally low mutational load for all STS subtypes when com-
pared to Melanoma and other tumor types[44], yet this load was different between the STS 
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subtypes showing significantly higher mutational load in myxofibrosarcoma and pleomorphic 
sarcoma compared to liposarcoma. Altered expression of genes involved in antigen process-
ing and presentation have, besides mutational load, also been associated with resistance 
to checkpoint therapy [45]. We observed no differential gene expression of components of 
MHC class I and II presentation among different STS subtypes. Others did find differences in 
gene expression between antigen presentation molecules, however most of such differences 
were found between synovial sarcoma and other subtypes.[32]
Subsequently, parameters that may affect CD8+ T cell function, such as the presence of im-
mune-suppressive cells and expression of co-signaling ligands were analyzed. The presence 
of Tregs, M0, and M2 macrophages in different STS subsets, did not show significantly higher 
fractions in GIST when compared to the other highly CD8+ T cell-rich myxofibrosarcoma and 
pleomorphic sarcoma. For the co-inhibitory ligands, GIST showed a lowered expression of 
PDL2, but not PDL1 when compared to other STS subtypes. Previous studies have shown 
longer median progression free- and overall survival in patients with head and neck squa-
mous cell cancer treated with pembrolizumab, in case tumors were PDL2-positive but not 
PDL2-negative.[46] PDL2 expression is regulated by both interferon (IFN)β and γ, [47] and 
lower expression of PDL2 in GIST is suggestive for a lower interferon-I signature potentially 
reflecting the lower level of T cell activation found in this study. For the co-stimulatory li-
gands, clearly lowered expression for ligands of CD28 (CD86), ICOS (ICOSL) and 4-1BB (41BBL, 
TNFRSF9) was found. These ligands are generally expressed by innate immune cells, such 
as dendritic cells and macrophages, but also by tumor cells, and fulfill critical roles in T cell 
activation although the exact role in cancer immune therapy is not yet clarified [48]. CD86 
expression has been reported to be significantly higher in pleomorphic compared to liposar-
coma; however, GIST and myxofibrosarcoma were not included in this analysis.[32] To the 
best of our knowledge this is the first study that investigated the expression of a large series 
of co-signaling ligands in GIST and demonstrated a profoundly lowered level of expression of 
PDL2, CD86, ICOSL and 41BBL in this STS subtype. The underlying mechanism of why these 
ligands show a lower expression in GIST compared to other STS subtypes requires further 
studies. We would like to argue, however, that lowered expression of co-stimulatory ligands 
in GIST, but not lowered immunogenicity, may be at the basis for less CD8+ T cell activation as 
we discussed above. We also observed significantly lower fractions of CD137 positive CD8+ T 
cells in GIST compared to other STS subtypes (measured by FCM), but since we did not have 
this data for all samples data is not shown.
Our study has several limitations, such as: relatively small numbers of tumors; gene-expres-
sion analysis only included dedifferentiated liposarcoma while our FCM analysis included 
dedifferentiated/well-differentiated and myxoid liposarcoma; and some GIST tumors used 
in FCM analysis were pre-treated with Imatinib (n=5 out of 9), and some pleomorphic sarco-
mas (and myxofibrosarcomas were pretreated with radiotherapy with no significant differ-
ences between pre-treated and untreated tumors in any of the parameters analyzed (data 
not shown). Notwithstanding these shortcomings, this study is by our knowing the first study 
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with an in-depth analysis of STS subtype immunogenicity using a wide scale of different tech-
niques. 
In conclusion, our study revealed that quantity and quality of CD8+ T cells as well as param-
eters of the tumor immune micro-environments that affect numbers and function of CD8+ 
T cells are clearly different among STS subtypes (Figure 8). Building on these data, we spec-
ulate that myxofibrosarcoma and pleomorphic sarcoma are suitable candidates for check-
point therapy. Since checkpoint therapy is primarily effective in inflamed tumors [49, 50], 
not all myxofibrosarcomas and pleomorphic sarcomas are expected to equally benefit from 
checkpoint therapy, providing a rationale to further stratify patient tumors according to im-
mune parameters. For tumors that are less immunogenic (i.e., having a lowered mutational 
burden), other therapeutic options may be required (e.g. radiotherapy, chemotherapy) to 
sensitize tumors for checkpoint therapy or adoptive T cell therapy. With respect to GIST, we 
speculate that treatment with co-stimulatory agonistic antibodies may show efficacy.
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Figure 8: Overview of immune parameters of different STS subtypes.
Immune analyses of different STS subtypes are schematically summarized according to two sets 
of parameters, those that reflect intra-tumoral CD8 T cells A) as well as those that reflect the im-
mune micro-environment B). CD8 T cell-related parameters include: T cell quantity (i.e., number 
of T cells per gram as presented in Figure 1A); T cell differentiation (fraction of effector memory 
cells, Figure 2B); Co-inhibitory receptors (fraction of T cells co-expressing PD1, LAG3 and TIM3, 
Figure 3B) and T cell clonality (fraction of 10 most dominant clones, Figure 4B). Parameters related 
to immune micro-environment include: mutational load (mutations per Mb, Figure 5A); Inhibitory 
immune cells (fractions of regulatory T cells, and M0 and M2 macrophages, Figure 6); Co-inhibi-
tory ligands (expression of PDL2 and Galectin9, Figure 7A); and Co stimulatory ligands (expression 
of CD86, ICOSL and 4-1BBL, Figure 7B). The listed parameters were utilized to compute Z-scores*. 
Circle sizes represent mean Z scores that are normalized (range: -0.82 to 0.83) for all parameters 
per STS subtype. *Z-scores were calculated as follows: (X - μ) / σ where X is the value of the param-
eter, μ is the population mean, σ is the standard deviation. 
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Supplementary Table 1: number of samples in different publicly available data sets.
Rnaseq (gse71121) MicRoaRRay (gse71121) dnaseq (tcga)
GIST 10 291 92
Leiomyosarcoma 36 89 98
Liposarcoma 18 45 56
Myxofibrosarcoma 15 43 22
Pleomorphic sarcoma 42 89 50
1GSE17743, 2SRP042250
SUPPLEMENTARY DATA
Supplementary Figure S1: Differential fractions of matured CD4+ T cells in STS subtypes.
A) FCM analysis of maturation stages of CD4+ T cells in different STS subtypes based on expression 
of CD45RA and CCR7. See Figure 2 for definitions. B) TEMRA cells as percentage of CD4+ T cells rep-
resented by box-and whisker plots. See figure 2 for patient numbers; *represents p-value <0.05 
according to Mann-whitney U test.
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Supplementary Figure S2: Inhibitory receptor (co-)expression on CD4+ TIL.
A) FCM analysis of fractions of PD1, LAG3, and TIM3-expressing CD4+ T cells in different STS sub-
types. B) FCM analysis of fractions of CD4+ T cells co-expressing PD1, LAG3 and/or TIM3 in dif-
ferent STS subtypes. FCM analysis was only performed on samples with at least 200 CD4+ T cells 
in the staining tube. See figure 3 for patient numbers; *represents p-value <0.05 according to 
Mann-whitney U test.
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GENERAL DISCUSSION
The research presented in this thesis consists of studies on: (1) monitoring of immunological 
parameters during cellular therapy and (2) assessment of immune signatures in different 
tumor types. Accordingly, this final chapter is split up into two parts. Part 1 summaries our 
findings to define markers that give a better understanding of mechanisms that may underlie 
successful and safe adoptive T cell treatment. Part 2 of this thesis further focuses on moni-
toring of T cells in settings other than adoptive T cell treatment. With respect to part 2, we 
first monitored changes in peripheral T cell characteristics during Dendritic cell (DC) therapy 
of mesothelioma. Secondly, we assessed intratumoral T cell characteristics, and explored spe-
cific differences between soft tissue sarcoma (STS) subtypes.
PART 1: IMMUNE MONITORING IN CHIMERIC ANTIGEN RE-
CEPTOR (CAR) T CELL THERAPY.
Adoptive transfer of T-cells has demonstrated significant clinical responses in several tumor 
types. Especially T cells genetically engineered to express CD19 specific CARs have shown 
impressive clinical responses in B cell malignancies. This recently resulted in the FDA approval 
of CD19 CAR T cell products for treatment of acute lymphocytic lymphoma (ALL), and certain 
types of non-Hodgkin lymphoma (NHL).[1] However, in solid tumor types, this approach is 
less well developed and translational as well as clinical studies are needed to get more insight 
into parameters that determine efficacy and toxicity from CAR T cell therapies. Chapter 2 to 5 
of this thesis describe findings from a phase-I clinical trial using a CAR:Fc(ε)RIγ directed to car-
boxy-anhydrase-IX (CAIX), an antigen that is over-expressed on Renal Cell Carcinoma (RCC). In 
this phase I dose escalation trial, patients with metastatic renal cell carcinoma were treated 
in five cycles with this first-generation CAR. A total of 12 patients were treated in three co-
horts. Unfortunately, no objective clinical responses were observed, though in vivo activity 
of CAIX CAR T-cells was reflected by observed on-target liver toxicities.[2, 3] The last cohort 
of patients were pre-treated with CAIX (G250) antibodies to prevent on-target toxicity, and 
demonstrated significantly lower toxicities compared to the first two cohorts.[4] In this trial 
we performed extensive monitoring of pre-infusion T cell products and in vivo parameters to 
identify predictors of effective T cell therapy. 
Quantification of CAR T cells in blood of patients
In chapter 2 we have assessed the number of infused CAR T cells by two different assays: 1) 
flow cytometry (FCM), and 2) quantitative PCR in peripheral blood. Peripheral persistence of 
adoptively transferred T cells is the net result of proliferation, cell death and extravasation to 
peripheral tissues of transferred cells in vivo and has been correlated with response.[5-8] In 
the Rotterdam CAR T cell trial, CAR T-cells in patient blood were quantified by FCM for CAR 
protein and qPCR for CAR DNA and RNA. However, in contrast to a previous report [9], we 
found no significant correlations between numbers of CAIX CAR T-cells and CAIX CAR DNA 
copies. This is possibly due to limited number of patients, and a wide variation in CAR DNA 
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copy numbers found in T-cell preparations of individual patients [2]. In addition, CAR DNA 
levels might not directly reflect the level of CAR protein expression and may in fact overesti-
mate the number of T cells that are reactive to CAIX in vivo. In fact, CAR surface expression 
decreased in time in T cell infusion products as well in T cells derived from blood following 
T-cell treatment. This decrease in CAR surface expression was accompanied by a decrease in 
CAR mRNA expression, the latter potentially reflecting a decreasing gene transcription during 
the culture of non-reactivated T-cells. In previous studies, using a similar γ- retroviral vector 
backbone, a decreased surface expression has also been observed for a TCR transgene which 
has been attributed to a waning LTR-driven gene transcription due to metabolic quiescence 
of gene-transduced T-cells.[10] This loss of transgene expression might be vector dependent 
as so far no such event has been described in other studies using different vector backbones. 
Based on the findings in chapter 2, we recommend enumeration of CAR T cells using FCM 
even though this technique requires immediate processing of patient, good antibodies, and 
facilities with advanced expertise with respect to flow cytometers and cellular processing.
Markers that correlate to CAR T cell numbers and activity in blood of 
patients
Next in chapter 2, we assessed the plasma cytokine levels during patient treatment with CAIX 
CAR T cells and correlated these to the peripheral CAR T cells number and measures of toxici-
ty. Since cytokine levels are easy to assess, these would represent useful surrogate marker for 
T cell persistence. Interestingly, out of 27 cytokines tested, only IL-6 and IFN-y correlated with 
CAR T cells numbers in vivo. In the CD19 CAR T-cell trials, plasma cytokine levels of GM-CSF, 
IL-2, IL-10, TNF-α, IFN-γ and in particular IL-6 were closely monitored because these cyto-
kines were strongly elevated in patients with clinical symptoms of cytokine release syndrome.
[5, 7-9, 11-17] In CD19 CAR T-cell studies, cytokine release syndromes may occur due to high 
accessibility of CD19-positive B cells (tumor cells as well as healthy B cells) together with the 
use of second generation CD19 CARs, including CD28 or 4-1BB (CD137) co-stimulatory do-
mains. [18] In our ‘first-generation’ CAR T-cell trial directed towards CAIX-positive Renal Cell 
chaPteRs 2 and 3: MaJoR findings
- Peripheral numbers of CAR T-cells are best captured by flow cytometry and not by quan-
titative polymerase chain reaction.
- CAR surface as well as gene expression are down-regulated following T-cell infusion
- The presence of CAR T-cells in blood correlated with plasma levels of IFN-γ and IL-6
- During the 14 days in vitro expansion of CAR T cells prior to administration:
o T cell phenotype shifted from predominantly CD4+ to a CD8+ T cells
o T cell maturation shifted from naïve to predominantly central effector T cells
- High fraction of naïve CD8 T cells at baseline (prior to genetic modification) or central 
effector CD8 T cells at 2 weeks of CAR T cell culture correlated with fold expansion and 
absolute numbers of circulating CAR T cells in patients at 1 month after start of therapy.
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Cancer, only one patient showed a high increase of IL-6 plasma levels. Interestingly, this par-
ticular patient received the highest CAIX CAR T-cell dose but did not present with the typical 
clinical symptoms of cytokine release syndrome. Along these lines, we have ‘only’ detected 
about a 15-fold increase of IFN-γ levels , whereas in the second generation CD19 CAR T-cell 
trials an over 1000 fold increase of IFN-γ levels were observed.[9] 
We have used liver enzyme elevations as surrogate markers for CAR T cell activity since CAIX 
expressing bile ducts of patients were targeted by these T cells which led to liver toxicity. Al-
though mean blood levels of Alkaline phosphatase (AP), Gamma-glutamyltransferase (GGT), 
Aspartate transaminase (ASAT) and Alanine transaminase (ALAT) displayed similar kinetics 
as the numbers of CAR T-cells in blood, neither liver enzymes nor CTCAE toxicity grading did 
significantly correlate with CAR T-cell numbers. Bearing in mind the small number of patients, 
we still argue that the above-mentioned IL-6 and IFN-y serve well as indicators for peripheral 
persistence and in vivo activity of gene modified T cells. 
T cell infusion characteristics affecting CAR T cell numbers and activ-
ity in vivo.
Aside from in-patient parameters, we were also interested whether specific characteristics of 
the T cell infusion product could affect peripheral T cell numbers. In chapter 3 we assessed 
the T cell maturation stage prior to and during GMP processing and how these maturation 
stages correlate with CAR T cell numbers/expansion in patients. Preclinical studies in mice 
and monkeys suggest improved in vivo persistence and anti-tumor responses when T cells 
in early stages of differentiation (such as naïve or central memory cells) are used for genetic 
modification and treatment[19, 20]. In fact, the differentiation state of CD8+ T cells appeared 
to be inversely related to their capacity to proliferate and persist.[21, 22] Previously, we have 
described a shift from naïve T cells to more maturated stages during IL-2-containg cultures 
of transduced T cells.[23] In our CAIX CAR study, we showed that patients with more CD8+ 
naïve T cells at baseline (from leukapheresis) or more CD8+ T central effector cells at cul-
ture day 14 demonstrated a higher fold increase in numbers of CAR T cells in vivo, resulting 
in higher blood counts of CAR T cells in these patients for at least 4 weeks. These findings 
may bear clinical relevance as younger T cells have been shown to positively correlate with 
clinical effectiveness in CD19 CART cell trials.[24-27] In fact, the CAIX CAR T cell trial is the 
first CAR study targeting a solid tumor that reveals a correlation between pre-infusion and 
pre-expansion T cell characteristics and in vivo CAR T cell numbers. In only one other non-
CD19 CAR trial, targeting neuroblastoma with GD2 CAR T cells, a correlation was described 
between in vivo CAR T cell persistence and the proportion of CD4+ or central memory T cells 
in the infusion product.[25] Our observations are in line with the notion that effector T cells 
derived from naive rather than memory T cell subsets possess superior features for adop-
tive immunotherapy [28], though in the latter study no correlations were made with in vivo 
parameters. Based on these findings we advocate for enhancing T cell persistence in vivo by 
increased fractions of CD8+ T naïve cells before transduction (e.g., by selection of the naïve 
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CD8+ T cell fraction) and/or the reduction of T cell maturation during the in vitro culture of 
gene-transduced T cells by using T cell co-stimulatory agents and cytokines IL15 and IL21 
during T cell processing. [23]
Overall lessons from the Rotterdam CAR T cell trial
In chapter 4 we give a thorough overview of the CAIX CAR T cell trial and the results that were 
collected in the past years, which enabled us to formulate the following recommendations 
for upcoming receptor (CAR/TCR) gene-modified T cell studies:
On target/off organ toxicity
The CAIX CAR T cell trial was the first trial using CAR-engineered T cells in Europe. This study 
demonstrated demonstrating in vivo activity of CAR T cells, unfortunately this was reflected 
by on target toxicity of CAR T cells attacking CAIX expressing bile duct epithelial cells, poten-
tially masking anti-tumor efficacy of these CAR T cells. Also, in other trials with CAR T cells, 
severe toxicities have been described. [16] In recent years several tools have been estab-
lished to better ensure T cell therapy safety. For example, target antigens should be carefully 
selected using in silico and laboratory techniques to ensure unique expression by tumor cells 
and not on normal somatic tissues.[29, 30]. In addition, screenings are available to detect 
binding of the CAR molecule to surface molecules that are expressed by healthy cells in the 
body. [31] Alternatively, receptor-engineered T cells can be co-transduced with a so-called 
death-switch, e.g., human caspase-9 that triggers apoptosis of T cells upon the treatment 
with small molecules.[32] Especially in early phase-I trials with CAR T cell the latter approach 
would, at early signs of toxicities, potentially limit development of (severe) adverse events.
Immunogenicity of CAR 
In most clinical studies, immunogenicity of the CAR has not been measured nor recognized 
as a possible limitation of therapeutic efficacy, most likely due to the applied non- myeloabla-
tive preconditioning of patients in most studies, together with single T-cell infusions. Yet, our 
study clearly demonstrated the immunogenicity of xenogeneic protein sequences presented 
by T-cells.[33] Therefore, for the construction of CARs and TCRs, we advocate the use of fully 
human complementarity-determining regions (CDRs), and patient pre-treatment with lym-
phoablative preconditioning followed by infusion of only a single dose of CAR T cells.
Lack of T-cell persistence and therapy efficacy
In the CAIX CAR T cell trial, the CAIX expressing renal cell tumors did not show any shrinkage 
on radiological assessment. This is likely due to lack of CAR T cell persistence, and possibly 
the lack of sufficient accumulation and activation of CAR T cells within tumor tissue due to 
an immunosuppressive microenvironment. In our study, patients were not pre-treated with 
lymphoablative preconditioning, and were treated with a 1st generation CAR. In subsequent 
studies, the introduction of a CD28 or CD137 intracellular signalling domain into the CAR 
(2nd generation CARs) led to increased CAR T cell persistence and the first clinically relevant 
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responses. Also, patients participating in these studies were lympho-ablated, which is hy-
pothesized to deplete inhibitory immune cell subsets like Myeloid-derived suppressor cell 
and T regulatory cells.
The best clinical results with CAR T-cells so far, have been achieved in haematological diseases 
treated with CD19 CARs. In these patients, the malignant, CD19 expressing B cells are present 
in blood and bone marrow and are easily accessible for CAR T cells. In contrast, to eradicate 
solid tumors is much more challenging. In order to sensitize the tumor micro-environment 
and thus support infiltration and action of the CAR T cells, several new strategies are now 
developed like CAR T cells that, upon activation, secrete factors like IL-12 [34-36], IL-18 [37] 
and HVEM. [38, 39] Future clinical trials are pending in order to see the effects of these new 
CARs. See Kunert et al, for an overview of gene-engineering strategies to enhance therapeu-
tic efficacy of CAR T cells.[40]
Finally, in chapter 5 we narrate extensively about immune monitoring performed in other 
clinical adoptive T cell trials. We provide an overview of clinical responses, and the immune 
monitoring performed in trials with TILs, and CAR/TCR gene modified T cells. This manuscript 
was published in 2015 and included studies until 2015. Interestingly, to date (2018) the top-
ic, and issues pointed out in this chapter are still timely since good and robust predictors of 
efficacy and safety of treatment with T cells, and especially in solid tumors, are still lacking. 
[41] At this point, a total of 18 studies have published results about CAR T cell treatment in 
solid tumors. In these trials, no uniform efforts have been made to monitor immunological 
changes in patients and correlate these with clinical parameters. However, we emphasize 
that a better understanding of tumor immunity but also the immunological state of the pa-
tient, and analysis of the T cell infusion product are pivotal to identify predictors of clinical 
responses. In future clinical studies, we advocate that such parameters should be included 
in study protocols.
PART 2: IMMUNE MONITORING BEYOND T CELL THERAPY
The second part in this thesis describes the characterization of T cells in two different set-
tings. First, we assessed immune cell changes in peripheral blood during dendritic cell (DC) 
therapy and second, we assessed the differences in immune profiles in different sarcoma 
tumor subtypes.
Dendritic Cell vaccination study in mesothelioma
Chapter 6 documents the immune effects of treatment of mesothelioma patients with autol-
ogous DCs loaded with an allogeneic tumor lysate. The clinical outcomes of this first-in-hu-
man phase-I clinical trial have been published previously and demonstrated promising clin-
ical responses. In nine enrolled patients two partial responses were observed, of which one 
remarkable response of 70% tumor reduction in a treatment-naïve patient within six weeks 
from start of treatment and which lasted for two years.[42] In this phase I dose escalation 
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study, peripheral blood was collected before and after each of three treatments with DCs 
that were pulsed with a lysate prepared from a mixture of five mesothelioma cell lines. Using 
multiplex flow cytometry, we observed an increase in the peripheral numbers of B cells, CD4 
and CD8 T cells, but not of NK cells at week 6 (i.e., 2 weeks after the last of 3 vaccinations). 
Next, we assessed whether vaccination would enrich for T cells recognizing tumor antigen. To 
this end, mesothelin, which was expressed by all the mesothelioma cell-lines that were used 
to load the dendritic cells, was used as a lead antigen. We were unable to demonstrate major 
changes in T cell reactivity towards mesothelin. Also, analysis of TCRβ diversity did not show 
shifts towards clonality, and do not suggest a T cell response directed against a single anti-
gen as a result of DC therapy. Others demonstrated that vaccination of melanoma patients 
with gp-100 peptide loaded DCs induced a broad T cell response to a wide variety of (neo)
antigens. Not only the number of neoantigen-specific T cells increased, but also the number 
of clonotypes per antigen increased, indicating a further diversification of the repertoire.[43] 
As shown in chapter 6 and by others, monitoring of specific T cells in peripheral blood upon 
vaccination, is challenging due to the unknown antigen specificity and low frequency of indi-
vidual T cell clones, and may be circumvented either by vaccination with very immunogenic 
antigens like NY-ESO-1 or MART-1 [44, 45] or in vitro enrichment of specific T cells, which may 
make it less attractive for future use in clinical practice.
Besides T cell clonality, we also assessed changes in frequencies of T cells positive for a va-
riety of markers. Treatment-related changes were most notable for CD4+ T cells, showing 
an increased frequency of cells positive for ICOS, PD-1 and HLA-DR after treatment. This is 
indicative for T cell activation, as T cells upregulate HLA-DR [46], ICOS [47]1BcUF1Q and PD-1 
[48] after activation through TCR engagement. In the study described in chapter 6 patient 
numbers are too low to correlate the immune related data with clinical outcome. Yet, our 
findings on the abovementioned activation markers may proof useful for future studies with 
larger patient groups to evaluate their relationship with treatment efficacy.
TILs and immune micro-environment in sarcoma subtypes
In chapter 7, we have generated a multi-parameter inventory of the immune microenviron-
ment as well as CD8+ TILs of different STS subtypes. We aimed to thoroughly chart the immu-
nogenicity of most common STS types, which in turn may provide valuable information about 
the STS subtype eligibility for immunotherapy. STS are a group of heterogeneous tumors of 
mesenchymal origin with over 50 different subtypes, for which the exploration of immu-
notherapeutic strategies has been limited. First studies show that some STS subtypes may 
respond to anti-PD1 Ab therapy [49, 50] as well as to adoptive T cell therapy.[51] A recent 
phase 2 study treating 85 metastasized STS patients with anti-PD-1 Ab nivolumab (n=43) or 
nivolumab plus anti-CTLA4 Ab Ipilimumab (n=42) concluded that nivolumab monotherapy 
does not warrant further study in an unselected STS population given the limited efficacy. 
Yet, the nivolumab plus ipilimumab combination treatment showed promising efficacy in 
certain STS subtypes like undifferentiated pleomorphic sarcoma and leiomyosarcoma.[52] 
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Since in other tumor types it is evident that numbers and activation state of immune cells 
in tumors, in particular CD8+ TILs, have predictive value with respect to the responsiveness 
to immune therapies [53, 54], we have extended these studies to different STS subtypes. 
Using Liposarcoma (LPS), Gastro-intestinal stromal tumors (GIST), Leiomyosarcoma (LMS), 
Myxofibrosarcoma (MFS) and pleomorphic sarcoma (PMS), we have measured quantities 
and qualities of TIL, and T cell evasive mechanisms via in situ stainings and single cell flow-
cytometry, as well as DNA and RNA sequencing data analysis. Our data demonstrated clear 
differences between the different STS subtypes concerning intra-tumoral T cell numbers, T 
cell activation and maturation, and clonality. GIST, MFS and PMS appear to have the highest 
T cell numbers, while GIST have much lower fractions of activated and maturated T cells, and 
in GIST the TCR repertoire is more diverse compared to MFS and PMS (Figure 8, chapter 7). 
These data suggest that in GIST, only limited TCR-driven T cell activation/expansion occurs. To 
explain the differences found between the STS subtypes, we further analyzed the different 
STS subtypes for: antigen presentation/processing, mutational load, inhibitory cell subsets 
and inhibitory and co-stimulatory ligands. No differential gene expression was observed for 
molecules of both the MHC-I and MHC-II antigen presentation pathways. Mutational load 
was somewhat higher in MFS and PMS compared to LMS and LPS, however low compared 
to other tumor types like melanoma.[55] Inhibitory cell subsets like M2 macrophages were 
low in GIST and high in MFS and PMS. The expression of PD1L2 was low in GIST compared to 
all other STS subtypes and the TIM3 ligand Galectin-9 was lowest in LMS and highest in MFS 
and PMS. Most notably, expression of costimulatory ligands CD86, ICOSL, and 4-1BB ligand 
were all lowest in GIST, compared to other STS subtypes, and generally highest in MFS and 
PMS. In conclusion, quantity and quality of CD8+ T cells as well as parameters of the immune 
micro-environments are clearly different among STS subtypes. Building on these data, we 
speculate that MFS and PMS are suitable for checkpoint therapy. Since checkpoint therapy is 
primarily effective in inflamed tumors [56, 57], not all Myxo- and Pleomorphic sarcomas are 
expected to equally benefit from checkpoint therapy, providing a rationale to further strat-
ify patient tumors according to immune parameters, such as density of PD1-positive CD8 T 
cells. For tumors that are less immunogenic (i.e., having a lowered mutational burden), other 
therapeutic options may be required (e.g. radiotherapy, chemotherapy) to sensitize tumors 
for checkpoint therapy or adoptive T cell therapy. With respect to GIST, we speculate that 
treatment with co-stimulatory agonistic antibodies may show efficacy.
Collectively, part 2 of this thesis showed approaches of immune monitoring in two different 
settings namely: I) during DC therapy in peripheral blood to monitor response to DC vaccina-
tion, and II) in a pre-clinical setting, by monitoring the tumor microenvironment, in particular 
the intratumoral T cells, to find new rationales for (immuno)therapy. 
In an era where there is more emphasis on personalized medicine, we advocate that new clin-
ical study protocols should always include additional monitoring of the tumor microenviron-
ment, and/or the peripheral immunity. Preferably before, during, and if possible after treat-
ment. Especially sampling before and after treatment can give valuable information about 
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therapy induced changes which in turn could lead to rationales to combine therapies. With 
a variety of techniques like multiplex flow cytometry, multiplex in situ immunohistochem-
istry, and next generation DNA/RNA sequencing becoming more affordable and accessible 
nowadays, we would like to advocate in-depth analysis and (immuno)monitoring of both the 
tumor and peripheral blood should be a standard in every immunotherapeutic clinical trial.
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SUMMARY
Immune therapy has proven to be an important new treatment strategy in cancer. The “tradi-
tional” treatment modalities in oncology are in addition to resection or debulking of tumors, 
radiotherapy and chemotherapy. Immunotherapy of cancer is a strategy that harnesses the 
body’s immune system to combat tumors. Despite the promise of immunotherapeutic ap-
proaches, a significant fraction of patients does not yet respond to these therapies. To date 
no markers are yet available to robustly predict therapy outcome or provide enough under-
standing into the underlying mechanisms that define unsuccessful treatment or toxicity. It is 
of pivotal importance to obtain such markers, since this will lead to improved stratification 
of patients for immune therapy. In addition, patient stratification can prevent unnecessary 
treatment and increase cost-effectiveness of these treatments.
Chapter 1 starts with a general introduction into immunology, cancer and subsequently de-
scribes different approaches how the immune system could be exploited to combat cancer. 
This chapter also describes the focus and structure of this thesis.
This thesis is split into two parts. In the first part (chapters 2 to 5), we have focused on im-
mune monitoring tools that were used in a CAR T cell phase-I trial to find parameters that 
correlate with in vivo behavior of administered T cells. In the second part (chapter 6 and 7), 
we have monitored changes in T cells numbers, T cell clonality and T cell phenotype in the 
blood compartment in a phase I trial with Dendritic Cell therapy. Also, in the second part, we 
have assessed the characteristics of intra-tumoral T cells as well as the immune micro-en-
vironment in several soft tissue sarcoma (STS) subtypes in order to identify new immune 
monitoring.
PART 1: IMMUNE MONITORING IN CHIMERIC ANTIGEN RE-
CEPTOR (CAR) T CELL THERAPY
Chapter 2 describes immune monitoring performed in a phase-I CAR trial treating patients 
with metastasized clear cell renal cell carcinoma (RCC). Twelve patients were treated with 
CAR T cells targeting Carboxy-anhydrase IX (CAIX). In this trial no clinical responses were ob-
served, and patients experienced transient toxicities most likely due to low CAIX expression 
in bile ducts. In chapter 2 the number of infused CAR T cells was assessed by two different 
quantitative assays using blood samples: 1) flow cytometry (FCM), and 2) qPCR. No significant 
correlations between numbers of CAIX CAR T-cells and CAIX CAR DNA copies were found. We 
concluded that CAR DNA levels do not directly reflect the level of CAR protein expression and 
may in fact overestimate the number of T cells that are reactive to CAIX in vivo. Subsequently, 
we have set out to find surrogate markers for T cell persistence. Notably, we found that plas-
ma levels of IL-6 and IFN-y correlated with CAR T cells numbers in vivo. Finally, in chapter 2 
we have assessed whether liver enzyme elevations can act as surrogate markers for in vivo 
CAR T cell activity. Unfortunately, neither liver enzymes nor CTCAE toxicity grading did signifi-
cantly correlate with CAR T-cell numbers. 
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In chapter 3 we have assessed T cell maturation stages prior to and during transduction and 
expansion, and how these maturation stages correlate with CAR T cell numbers/expansion in 
patients. Chapter 3 showed that patients with higher fractions of naïve CD8+ T cells at base-
line (from leukapheresis) or central effector CD8+ T cells at culture day 14 demonstrated a 
higher fold increase in CAR T cells numbers in vivo, resulting in higher blood counts of CAR T 
cells in these patients for at least 4 weeks. Based on these findings we advocate to implement 
strategies to increase fractions of naïve CD8+ T cells before transduction (e.g., by selection of 
naïve CD8+ T cell fraction from patient blood) and/or reduce T cell maturation during in vitro 
culture of T cells (e.g. by using T cell co-stimulatory agents and cytokines IL-15 and IL-21).
Chapter 4 gives a thorough overview of the Rotterdam CAIX CAR T cell trial and the results 
that were collected in the past years, which enabled us to formulate recommendations for 
upcoming receptor (CAR/TCR) gene-modified T cell studies, particularly with respect to: on 
target/off organ toxicity, immunogenicity of CAR, and T-cell persistence and therapy efficacy. 
Chapter 5 describes immune monitoring performed in other clinical adoptive T cell trials. An 
overview is provided of clinical responses, and the immune monitoring performed in trials 
with TILs, and CAR/TCR gene modified T cells. This chapter emphasizes that a better under-
standing of tumor immunity but also the immunological state of the patient, and analysis of 
the T cell infusion product are all pivotal to identify predictors of clinical responses. In future 
clinical studies, we advocate that such parameters should be included in study protocols.
PART 2: IMMUNE MONITORING BEYOND T CELL THERAPY
Chapter 6 documents the immune effects in mesothelioma patients treated with autologous 
DCs loaded with an allogeneic tumor lysate. In nine enrolled patients two partial respons-
es were observed, of which one remarkable response of 70% tumor reduction in a treat-
ment-naïve patient within six weeks from start of treatment and which lasted for two years. 
Patients in this trial demonstrated an increase in the peripheral numbers of B cells, CD4 and 
CD8 T cells, but not of NK cells after vaccination. Subsequent analysis of T cells specific for 
mesothelin, an antigen that is highly present in tumor lysate, as well as bulk T cells did not 
show shifts towards TCR clonality due to vaccination. This suggests that the T cell response 
is not directed against a single antigen as a result of DC therapy. Other treatment-related 
changes were most notable for CD4+ T cells, showing an increased frequency of cells positive 
for ICOS, PD-1 and/or HLA-DR after treatment, changes that are indicative for T cell activa-
tion. In the study described in chapter 6 patient numbers are too low to correlate the im-
mune related data with clinical outcome. Yet, our findings may proof useful for future studies 
with larger patient groups to evaluate their relationship with treatment efficacy.
Chapter 7 describes a multi-parameter inventory of the immune microenvironment as well 
as CD8+ TILs of different STS subtypes, thereby aiming to provide valuable information about 
subtype eligibility for immunotherapy. Data demonstrated clear differences between the dif-
ferent STS subtypes concerning intra-tumoral T cell numbers, T cell activation and matura-
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tion, as well as T cell clonality. Gastro intestinal stromal tumors (GIST), myxofibrosarcoma 
and pleomorphic sarcoma have the highest T cell numbers, while GIST has much lower frac-
tions of activated and maturated T cells, and in GIST the TCR repertoire is more diverse com-
pared to myxofibrosarcoma and pleomorphic sarcoma. Further analyses of the STS tumors 
for: antigen presentation/processing, mutational load, inhibitory cell subsets and inhibitory 
and co-stimulatory ligands revealed no differential expression of genes involved in antigen 
presentation/processing. Mutational load was somewhat higher in myxofibrosarcoma and 
pleomorphic sarcoma compared to leiomyosarcoma and liposarcoma, however mutational 
load was overall low compared to other tumor types like melanoma. Frequencies of inhibito-
ry cell subsets were low in GIST and high in myxofibrosarcoma and pleomorphic sarcoma. The 
expression level of inhibitory ligands was also low in GIST compared to all other STS subtypes, 
and highest in myxofibrosarcoma and pleomorphic sarcoma. Most notably, expression level 
of costimulatory ligands was lowest in GIST, and generally highest in myxofibrosarcoma and 
pleomorphic sarcoma. Building on the collection of these data, we speculate that myxofibro-
sarcoma and pleomorphic sarcoma are suitable for checkpoint therapy. With respect to GIST, 
we speculate that treatment with co-stimulatory agonistic antibodies may show efficacy.
Finally, in Chapter 8 the main findings of this thesis are described and discussed. In an era 
where there is more emphasis on personalized cancer treatment, it is pivotal that new clin-
ical study protocols include additional monitoring of the tumor micro-environment, and/or 
peripheral immunity. Preferably before, during, and if possible after treatment tumor and/or 
blood samples should be collected, which will provide valuable information about therapy-in-
duced changes which in turn rationalize choices for new (combination) therapies. With a vari-
ety of techniques like multiplex flow cytometry, multiplex in situ immunohistochemistry, and 
next generation DNA/RNA sequencing becoming more and more affordable and accessible, 
we recommend in-depth immune monitoring of both tumor and peripheral blood becoming 
part of immunotherapeutic clinical trials.
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LEKENUITLEG EN NEDERLANDSE SAMENVATTING
In Nederland overlijden drie op de tien mensen aan de gevolgen van kanker. Kanker is daar-
mee de belangrijkste doodsoorzaak. Tot op heden is uitgezaaide (gemetastaseerde) kanker in 
de meeste gevallen niet te genezen en is de behandeling van gemetastaseerde ziekte gericht 
op het voorkomen van ziekteprogressie. De “traditionele” behandelingsstrategieën in de on-
cologie zijn chirurgie, radiotherapie en chemotherapie, maar in de laatste jaren is ook immu-
untherapie sterk in opmars. Immuuntherapie is anders dan de traditionele behandelingen, 
omdat deze zich richt op het verbeteren of herstellen van de patiënt zijn/haar eigen afweer 
tegen de kanker, terwijl traditionele behandelingen zich richten op het direct doden maken 
van kankercellen. Een aantal immuuntherapieën hebben al indrukwekkende klinische resul-
taten laten zien, met een verbeterde overleving ten opzichte van chemo- of radiotherapie, en 
soms volledige genezing. Dit hoofdstuk geeft een korte introductie over het immuunsysteem, 
de interactie hiervan met oncologische ziektebeelden en hoe het immuunsysteem wordt 
gebruikt voor immuuntherapieën. Na deze introductie volgen de belangrijkste resultaten uit 
dit proefschrift.
HET IMMUUNSYSTEEM
Het immuunsysteem beschermt ons tegen ziekteverwekkers (pathogenen), zoals bacteriën, 
virussen en parasieten, maar speelt ook een rol bij het opsporen en uitroeien van ontspoorde 
(kwaadaardige) cellen. Het immuunsysteem kan grofweg worden verdeeld in twee subsyste-
men: 1) het aangeboren en 2) het verworven immuunsysteem. Deze twee subsystemen zijn 
complementair en zorgen tezamen voor een effectieve immuunrespons.
Aangeboren immuunsysteem
De belangrijkste onderdelen van het aangeboren immuunsysteem zijn de fysieke en che-
mische barrières (huid, slijmvliezen, speeksel) en het complementsysteem. Dit laatste sys-
teem bestaat uit een reeks eiwitten die ervoor zorgen dat immuuncellen pathogenen makke-
lijker kunnen herkennen en vernietigen. Daarnaast bestaat het aangeboren immuunsysteem 
ook uit een reeks immuuncellen zoals: basofielen, dendritische cellen, eosinofielen, mest-
cellen, monocyten, macrofagen, neutrofielen en “natural-killer” cellen. Al deze cellen heb-
ben hun eigen specifieke rol in de herkenning en eliminatie van pathogenen. Ook zijn deze 
immuuncellen, en dan met name de macrofagen en dendritische cellen belangrijk voor het 
herkennen, doden, verwerken en vervolgens presenteren van pathogeen-afkomstige eiwit-
fragmenten, ook wel “antigenen” genoemd. Macrofagen en dendritische cellen worden daar-
om ook wel antigeen-presenterende cellen genoemd. De gepresenteerde antigenen kunnen 
vervolgens worden herkend door cellen uit het adaptieve immuunsysteem, dat hiertegen 
een specifieke en sterke afweer ontwikkelt tegen dat pathogeen. Ten slotte produceren de 
geactiveerde cellen van het aangeboren immuunsysteem stoffen, chemo- en cytokines gen-
oemd, die andere immuuncellen aantrekken, waardoor er op de plaats waar het pathogeen 
zit een ontsteking ontstaat. 
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Verworven immuunsysteem
Het verworven immuunsysteem bestaat uit zeer gespecialiseerde cellen die antigenen kun-
nen herkennen. Het adaptieve immuunsysteem omvat (antistof producerende) B-cellen, 
CD4+ helper T cellen en CD8+ celdodende (cytotoxische) T cellen. B-cellen herkennen anti-
genen direct via de B-celreceptor (BCR). T cellen hebben een T cel receptor (TCR) dat kleine 
antigeen fragmenten (peptiden) herkent die worden gepresenteerd door moleculen van het 
major histocompatibility complex (MHC) op het oppervlak van bijvoorbeeld macrofagen of 
dendritische cellen. De BCRs en TCRs zijn uniek en komen voort uit genetische recombinatie 
van de DNA-gecodeerde segmenten bij de aanmaak van de B- en T-cellen. Deze recombinatie 
vormt B- en T-lymfocyten die veel verschillende antigenen herkennen, waaronder antigenen 
die worden gepresenteerd door gezonde weefsels. Om dit te voorkómen ondergaan lymfo-
cyten een selectie tijdens de uitgroei van stamcel naar lymfocyt, waarbij lymfocyten die in 
staat zijn gezonde weefsels te herkennen worden geëlimineerd. Wanneer de overgebleven 
B of T cellen een antigeen herkennen, worden deze geactiveerd en vermeerderen deze cel-
len zich snel)expansie). Vervolgens zullen deze cellen het pathogeen dat het antigeen tot 
expressie brengt aanvallen en elimineren. Na eliminatie van dat antigeen worden er immu-
nologische geheugencellen gevormd. Hierdoor zullen bij een tweede infectie met hetzelfde 
pathogeen, de antigeen-specifieke B en T cellen sneller uitgroeien en het pathogeen sneller 
elimineren.
Naast de hierboven beschreven ‘reactieve’ immuuncellen zijn er ook immuuncellen die 
dergelijke reacties kunnen afremmen. Dit is belangrijk om een hyperactiviteit van het immu-
unsysteem te voorkomen en daarmee de ontwikkeling van auto-immuniteit. Er zijn verschil-
lende van deze remmende immuuncellen, zoals “Myeloid derived suppressorcellen” (MDSC), 
“M2-macrofagen” en “T-regulatory cellen” (Tregs). Zij brengen moleculen tot expressie en 
produceren stoffen, cytokines, die een remmende werking hebben op de ‘reactieve’ immu-
uncellen.
Tumoren als verstoorde mini-organen
Tumoren bestaan niet alleen uit kankercellen maar ook uit cellen van bloedvaten, onders-
teunende weefsels en verschillende immuuncellen. Al deze niet kankercellen samen in een 
tumor vormen de tumor micro-omgeving en zijn bepalend voor de eigenschappen van tu-
moren en daarmee ook hun gevoeligheid voor (immuun)therapie. Tegenwoordig weten we 
dat CD8+ cytotoxische T cellen erg belangrijk zijn in het herkennen en doden van tumorcel-
len. Het aantal en de locatie van deze immuuncellen in tumoren bepaalt de prognose van 
patiënten. Een hoge frequentie van tumor infiltrerende lymfocyten (TIL), en met name de 
CD8+ cytotoxische TILs, correleert bijvoorbeeld met een verhoogde overleving van patiënten 
met melanoom (huid)-, hoofd en nek-, borst-, urotheel-, eierstok-, colorectale en longkanker. 
Veel immuuntherapieën zijn er op gericht om deze T cellen te activeren, of om op een andere 
manier een antitumor respons te forceren.
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Immuuntherapieën in kanker
Hierbij onderscheiden we therapieën met stoffen, die de immuunreactie van het lichaam 
tegen kanker(cellen) versterken, en daarnaast zijn er therapieën waarbij extra immuuncellen 
aan de patiënt worden toegediend (adoptieve cellulaire therapie). 
Niet cellulaire immuuntherapieën
Bij niet cellulaire immuuntherapieën worden stoffen (bijv. cytokines, zoals Interleukine-2 (IL-
2) of interferon-α aan de patiënt toegediend die de immuuncellen ‘oppeppen’). Een ander 
voorbeeld is ‘tumorvaccinatie’, het toedienen van tumor-afkomstige antigenen en peptiden 
om een specifieke immuunreactie tegen de tumor op te wekken. Deze antigenen worden 
opgenomen door antigeen presenterende cellen die vervolgens T cellen activeren. Tot zover 
hebben deze strategieën echter slechts beperkte resultaten opgeleverd in de behandeling 
van kanker. 
Een andere strategie waarmee in meerdere tumortypen indrukwekkende klinische resultaten 
worden behaald is de zogeheten ‘immuun checkpoint’ therapie. Immuun checkpoints zijn 
eiwitten op het oppervlak van immuuncellen die ervoor zorgen dat het immuunsysteem niet 
over-reageert. Een voorbeeld hiervan is de “programmed cell death-1 receptor” (PD1). Deze 
komt tot expressie op onder andere CD8+ T cellen, zodra deze T cellen worden geactiveerd. 
Als PD1 bindt met een ligand voor PD1 (PDL1 of PDL2) aanwezig op het oppervlak van een 
andere cel, zal PD1 een signaal afgeven waardoor de immuuncel geremd wordt. Sommige 
tumortypen maken hier slim gebruik van en hebben PDL1 op hun celoppervlak. Hierdoor 
worden geactiveerde T cellen geremd wanneer zij in contact komen met deze kankercellen. 
Immuun checkpoint therapie (in dit geval PD1) blokkeert deze interactie tussen PD1 en diens 
ligand. Hierdoor worden de immuuncellen niet meer geremd wanneer zij de tumorcel weer 
kunnen elimineren. 
Cellulaire immuuntherapieën
Bij cellulaire immuuntherapie worden (in het laboratorium bewerkte) immuuncellen aan de 
patiënt toegediend. De twee belangrijkste cellulaire therapieën zijn het toedienen van den-
dritische cellen of T cellen. 
Dendritische cel therapie
Bij dendritische cel therapie wordt een vaccin toegediend, bestaande uit dendritische cellen 
beladen met antigeen. Deze dendritische cellen (DCs) worden in het laboratorium gemaakt 
uit monocyten die worden verkregen uit het bloed van patiënten en verder worden opge-
kweekt in aanwezigheid van cytokinen en beladen met tumorantigenen (eiwitten of pep-
tiden). Deze ‘beladen’ DCs worden vervolgens teruggegeven aan de patiënt om T cellen in 
de patiënt te activeren. De vaccin-specifiek geactiveerde T cellen kunnen de tumorcellen 
vervolgens herkennen en aanvallen.
In plaats van het in vivo (in de patiënt) activeren van T cellen door middel van checkpoint in-
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hibitors of toegediende DCs, kunnen tumor-specifieke T cellen ook ex vivo worden vermeer-
derd of zelfs worden gegenereerd, zodat zij een specifiek tumor antigeen herkennen. Dit heet 
T celtherapie. In het kort zijn er twee belangrijke vormen van T cel therapieën: 
T cel therapie met Tumor Infiltrerende Lymfocyten (TIL)
Bij TIL therapie worden er uit een tumor(biopt) T cellen (op)gekweekt en teruggegeven aan 
de patiënt (Figuur 1A). Deze TILs bevatten in meer of mindere mate tumor specifieke T cellen, 
die initieel ’geremd’ zijn, maar eenmaal geïsoleerd van hun micro-omgeving weer functioneel 
zijn. De TILs worden vervolgens ex vivo vermeerderd tot grote aantallen en teruggegeven aan 
de patiënt. Met deze therapie zijn zeer indrukwekkende klinische resultaten behaald, vooral 
in patiënten met gemetastaseerd melanoom met klinische objectieve radiologische respon-
sen rond de 50%, en in 20% van de gevallen zelfs volledige genezing van patiënten. Buiten de 
behandeling van patiënten met melanoom zijn de klinische resultaten van TIL therapie echter 
nog beperkt. 
T cel therapie met Chimeric Antigen Receptor (CAR) of TCR T cellen
Omdat het niet altijd mogelijk is om TILs uit tumoren te verkrijgen, is er een alternatieve 
manier ontwikkelt om T cellen te gebruiken voor therapie. Hierbij worden T cellen uit het 
bloed van patiënten geïsoleerd en vervolgens in het laboratorium bewerkt (genetisch gema-
nipuleerd), waardoor zij een specifieke receptor tot expressie brengen en daarmee een anti-
geen op tumorcellen kunnen herkennen. Er worden twee typen receptoren onderscheiden: 
1) receptoren gebaseerd op antistoffen, de zogeheten Chimeric Antigen Receptors (CAR), of 
2) receptoren gebaseerd op T cel receptoren (TCR). Beide type receptoren kunnen specifiek 
binden aan een antigeen dat tot expressie gebracht wordt op kankercellen, de CAR aan mem-
braan antigenen en de TCR aan een eiwit fragment (peptide) in het MHC complex, dat kun-
nen ook peptiden zijn van intra cellulaire eiwitten. Wanneer een CAR of TCR aan een antigeen 
bindt, zal de T cel geactiveerd worden en de (kanker)cel vernietigen.
CARs zijn afgeleid van het antigeen-bindend deel van een antistof en bevat een transmem-
braan, en een intracellulair domein, waardoor het verankerd is in de celmembraan en na 
binding aan antigeen een signaal de cel in kan sturen. Het principe van CAR/ TCR-T cel be-
handeling wordt weergegeven in figuur 1B. Studies met de ‘eerste generatie’ CARs lieten 
slechts beperkte klinische resultaten zien, maar studies met tweede generatie CARs hebben 
veelbelovende resultaten opgeleverd. Deze tweede generatie CARs hebben een extra inge-
bouwd signaalversterkings-domein dat is afgeleid van costimulatoire moleculen. Vooral in 
hematologische ziekten van B cellen, die het antigeen CD19 tot expressie brengen, hebben 
CARs gericht tegen het CD19 indrukwekkende klinische responsen laten zien. Bijvoorbeeld in 
Acute Lymfatische B-cel Leukemie (B-ALL) werd er complete genezing gezien in 70 tot 100% 
van de patiënten.
Een nadeel van CAR T cellen ten opzichte van TCR T cellen is echter dat alleen extracellulaire, 
en geen intracellulaire antigenen kunnen worden gekozen. Helaas zijn de klinische resultaten 
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van de CAR- en TCR- T celtherapie in solide tumoren nog niet zo indrukwekkend als voor de 
CD19 CAR in hematologische maligniteiten. Voor een effectieve CAR en TCR T celtherapie is 
de keuze van het antigeen waarop de receptor is gericht essentieel. Wanneer het antigeen 
namelijk niet alleen door de tumor maar ook door gezond weefsel tot expressie wordt geb-
racht kan dit leiden tot ernstige toxiciteit (auto-immuniteit).
FOCUS VAN DIT PROEFSCHRIFT: IMMUUN MONITORING
Ondanks de hierboven beschreven veelbelovende ontwikkelingen reageert een aanzienlijk 
deel van de patiënten niet op immuuntherapie. Tot nu toe zijn er nog geen goede klinische 
of immunologische merkers (parameters) die aangeven of een patiënt mogelijk baat heeft 
of niet bij immuuntherapie. Ook zijn er geen goede merkers bekend die de onderliggende 
mechanismen van een succesvolle behandelingen, of juist het ontbreken daarvan, of het op-
treden van bijwerkingen voorspellen. Het is zeer belangrijk om dit soort merkers voorhanden 
te krijgen, omdat dit kan leiden tot betere selectie van patiënten en ook nieuwere inzicht-
en die de therapie kunnen verbeteren. Verbeterede patiënt selectie is belangrijk omdat dit 
onnodige behandelingen voorkomt, kwaliteit van leven verbetert, en de kosten effectiviteit 
verhoogt. Om dit soort merkers te vinden is het uitgebreid volgen (monitoren) van immunol-
ogische en klinische parameters binnen patiënt studies essentieel.
Dit proefschrift is opgesplitst in twee delen. In het eerste deel hebben we ons gericht op 
verschillende immuun monitoring strategieën in een fase-I CAR T cel studie die een indicatie 
kunnen geven over de aantallen CAR T cellen die in het bloed van patiënten terug te vinden 
zijn, en daarmee voorspellend kunnen zijn voor de therapie uitkomst. In het tweede deel 
hebben we, ten eerste, in een fase-I DC vaccinatie studie gezocht naar merkers van een im-
muunrespons in patiënten tegen het vaccin. Ten tweede zijn de karakteristieken van T cellen 
in tumoren bestudeerd, waarbij we ons gericht hebben op weke delen tumoren (sarcomen), 
met als doel verschillende sarcoom subtypen uit elkaar te trekken wat betreft voorspelde 
gevoeligheid voor immuuntherapie.
Deel 1: T cel monitoring in CAR T cel therapie
Hoofdstuk 2 tot en met hoofdstuk 4 van dit proefschrift beschrijven de bevindingen van een 
fase-I klinische studie, waarin twaalf patiënten zijn behandeld met CAR T cel therapie. In deze 
studie werd gebruikt gemaakt van een CAR gericht tegen het carboxy-anhydrase-IX (CAIX) an-
tigeen. Dit antigeen komt hoog tot expressie op het niercelcarcinoom. Helaas werden er geen 
klinische responsen gezien. Wel werd gezien dat CAR T cellen een sterke activiteit vertoon-
den aangezien patiënten levertoxiciteit ontwikkelden. Nader onderzoek toonde vervolgens 
aan dat het CAIX antigeen in lichte mate ook voorkomt op de cellen in de grote galwegen. 
Om deze toxiciteit tegen te gaan werden de laatste serie patiënten voorbehandeld met een 
CAIX bedekkend antistof. Dit resulteerde in aanmerkelijk minder toxiciteit vergeleken met de 
andere patiënten. Gedurende deze studie is er zeer uitgebreid onderzoek gedaan en zijn vele 
verschillende parameters gemeten. Zo zijn onder andere de eigenschappen van T cellen in 
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het infusie product onderzocht, maar ook zijn er verschillende in vivo parameters gemeten 
om te kijken welk van deze parameters mogelijk een effectieve T cel therapie zouden kunnen 
voorspellen. 
Bepalen van het aantal CAIX CAR T cellen in bloed van patiënten
In hoofdstuk 2 is bloedonderzoek beschreven gericht op 1) het aantal CAR T cellen gemeten 
met flow cytometrie (FCM) en spiegels van 2) CAR DNA en CAR RNA gemeten met molecu-
laire technieken. Het aantal CAR T cellen dat we meten is het netto resultaat van het aantal 
CAR T cellen dat is toegediend, het aantal dat na transfusie verloren gaat en het aantal dat 
door groei erbij komt. Meerdere studies hebben al laten zien dat er een verband bestaat 
tussen het aantal CAR/TCR T cellen dat na toediening aanwezig is in het bloed van de patiënt 
en de respons op therapie. Daarom is het belangrijk om dit aantal nauwkeurig te kunnen 
meten. Interessant is dat wij geen duidelijk verband vonden tussen de metingen van het aan-
tal CAR T cellen met FCM en het aantal CAR DNA kopieën. Daarnaast zagen we een afname 
van de mate van CAR expressie op T cellen, mogelijk geassocieerd met vermindering van de 
algemene T cel activiteit.
Het meten van aantallen CAR T cellen in patiënten kan dus het beste gedaan worden door 
middel van FCM. Het enige nadeel van FCM is dat afgenomen bloedmonsters meteen opgew-
erkt moeten worden en dat instituten een flow cytometer moeten hebben of in staat moeten 
zijn om samples meteen in te vriezen.
Surrogaatmerkers voor CAR T cel aantallen
Tijdens de CAR T cel behandeling is bij de patiënten op meerdere tijdspunten bloed afge-
nomen, waarin cytokines zijn gemeten. In hoofdstuk 2 is er gekeken of de concentratie van 
cytokines correleerden met het aantal CAR T cel in het bloed en met de geobserveerde bi-
jwerkingen. Van verschillende cytokines die zijn gemeten, correleerden alleen interleukine-6 
(IL-6) en Interferon-gamma (IFN-y) met het aantal CAR T cellen (gemeten met FCM). Er zijn 
geen vergelijkbare studies bekend die de cytokine concentraties direct hebben gecorreleerd 
met het aantal T cellen. Wel zijn in enkele CAR T cel studies cytokine concentraties bepaald 
tijdens de therapie. In deze eerdere studies zijn vooral IFN-γ en IL-6 nauwgezet bestudeerd, 
omdat deze cytokines sterk verhoogd waren in patiënten met een zogeheten cytokine storm, 
waarbij zeer hoge cytokine concentraties waarneembaar waren na toediening van CAR T cel-
len. Cytokine stormen komen relatief vaak voor in patiënten met een grote hematologische 
tumormassa die worden behandeld met CD19 CAR T cellen. In de Rotterdamse CAIX CAR T cel 
studie werden er lang niet zulke hoge cytokine waarden gezien. Een belangrijk punt in deze 
studie is het kleine aantal patiënten, waardoor het moeilijk is in te schatten of de data ook 
naar een grotere groep mensen valt te extrapoleren. Desondanks zien wij duidelijk dat IL-6 
en IFN-y potentieel belangrijke parameters zijn die een reflectie geven van het aantal CAR T 
cellen, en mogelijk CAR T-celreactiviteit in patiënten. 
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Ex vivo CAR T cel eigenschappen voor CAR T cel aantal en activiteit 
in patiënt
Naast de parameters die gemeten kunnen worden in patiënten gedurende T cel therapie, 
wordt er in hoofdstuk 3 gekeken naar de eigenschappen van de CAR T cellen in het infusie-
product. T cellen doorlopen verschillende maturatiestadia gedurende hun levensloop, die 
deels wordt beïnvloed door hun omgeving en de signalen die zij krijgen. In hoofdstuk 3 heb-
ben we gekeken of de T cel maturatiestatus, voor en gedurende het proces van transduceren 
en vermeerderen van T cellen, invloed had op de aantallen cellen in de patiënt. We vonden 
dat patiënten met relatief meer jonge CD8+ CAR T cellen in het uitgangsmateriaal (T cellen 
vóór het transduceren en vermeerderen), meer CAR T cellen in het bloed hadden dan pa-
tiënten met minder jonge T cellen. Ook als het CAR T cel product na kweek verrijkt was voor 
zogeheten ‘effector T cellen’ resulteerde dat in hogere CAR T cel aantallen in het bloed. De 
CAIX CAR T cel studie laat, als eerste CAR T cel studie in vaste tumoren, zien dat er een ver-
band bestaat tussen T cel karakteristieken in het infusie product en aanwezigheid van CAR T 
cellen in de patiënt. 
In hoofdstuk 4 geven we een compleet overzicht van het beloop en de gepubliceerde resul-
taten van de CAIX CAR T cel studie en hebben de volgende aanbevelingen geformuleerd voor 
toekomstige CAR (TCR) T cel studies wat betreft de volgende aspecten:
1. On target/off organ toxiciteit 
Om in de toekomst bijwerkingen van CAR T cellen te voorkomen, is het essentieel om anti-
genen te selecteren die alleen tot expressie komen op tumor en niet op de gezonde cellen. 
In de afgelopen jaren zijn er meerdere technieken ontwikkeld om T cel therapie veiliger te 
maken. Er zijn nu verschillende computer en laboratoriumtesten beschikbaar die kunnen 
aantonen of antigenen tot expressie komen op gezonde cellen in het lichaam, en of de CAR 
behalve het bekende antigeen ook andere antigenen herkent. Daarnaast kan er in CAR T cel-
len een ‘noodrem’ worden ingebouwd, een zogeheten ‘kill-switch’. Indien nodig kunnen deze 
CAR T cellen snel worden verwijderd uit het lichaam.
2. Herkenning van de CAIX CAR door het eigen immuunsysteem
In de CAIX CAR T cel studie werd er een reactie gevonden van het immuunsysteem van de 
patiënten tegen de CAR, dat voor een deel uit vreemd (muizen) eiwit bestaat. In de meeste 
klinische CAR T cel studies wordt geen melding gemaakt van een immuunrespons tegen de 
gebruikte CAR. Dit komt hoogstwaarschijnlijk doordat in de meeste T cel studies vooraf het 
immuunsysteem van de patiënten sterk wordt afgezwakt door een vorm van chemotherapie. 
Daarnaast zijn in de nieuwe generatie CARs de vreemde eiwit sequenties geminimaliseerd 
of volledig afwezig. Verder wordt er nu in meeste CAR studies maar één gift CAR T cellen 
gegeven, terwijl in de CAIX CAR T cel studie patiënten maximaal 10 giften van CAR T cellen 
kregen toegediend. 
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3. Gebrek aan T cel persistentie en effectiviteit van de therapie.
In de CAIX CAR T cel studie werd gebruik gemaakt van een eerste generatie CAR. Ondanks het 
feit dat er wel degelijk CAR T cel activiteit werd gezien in de vorm van levertoxiciteit, werden 
er geen radiologische anti-tumor responsen gezien. Er zijn een aantal mogelijke oorzaken en 
oplossingen hiervoor:
- CAIX CAR T cellen persisteerden relatief kort in patiënten (hoofdstuk 2). De nieuwe 
tweede generatie CAR T cellen zijn echter aanmerkelijk langer detecteerbaar in patiënt-
en.
- Immunosuppressieve eigenschappen van de tumor die T cel activiteit verminderen. Er 
zijn op dit moment meerdere nieuwe strategieën ontwikkeld om de tumor omgeving 
meer toegankelijk te maken voor T cellen. Toekomstige klinische trials moeten aantonen 
of dit ook daadwerkelijk leidt tot betere klinische responsen.
In hoofdstuk 5 wordt een overzicht gepresenteerd van de immuunmonitoring die is gedaan 
in andere studies met klinische TIL en CAR/TCR T cel therapie. Dit hoofdstuk is gepubliceerd 
in 2015 en refereert alleen studies tot dat moment. Interessant is dat momenteel (2018) het 
onderwerp van immuunmonitoring en de belangrijkste punten in dit hoofdstuk nog steeds 
erg actueel zijn aangezien goede predictoren voor adoptieve T cel therapie nog steeds ont-
breken. Met name voor solide tumoren is er nog weinig data (18 gepubliceerde studies), 
maar in deze studies is er maar beperkt gekeken naar de immunologische veranderingen in 
patiënten gedurende de therapie of de eigenschappen van het T cel product; iets dat wij juist 
willen aanraden om de kans op het vinden van gewenste predictoren te vergroten. 
DEEL 2: T CEL MONITORING IN NIET- T CEL THERAPIE
Wat betreft T cel monitoring in niet-T cel therapieën, is als eerste gekeken in patiënten be-
handeld met DC vaccinatie therapie, en ten tweede is gekeken in onbehandelde sarcoom 
subtypen. 
T cel monitoring in dendritische cel vaccinatie
Hoofdstuk 6 beschrijft een studie waarin getracht is een immuunreactie te meten in het 
bloed van patiënten met mesothelioom die zijn behandeld met DC vaccinatie. De patiënten 
in deze studie werden behandeld met autologe DCs die zijn opgekweekt uit monocyten en 
vervolgens zijn beladen met een lysaat gemaakt uit mesothelioom tumor cellijnen. De thera-
pie werd goed verdragen en in één van de negen behandelde patiënten werd duidelijke een 
klinische respons gezien, met 70% tumorreductie 6 weken na start behandeling, en deze 
reductie hield 2 jaar aan. 
In het bloed werd immuun activatie gemeten na toediening van het DC vaccin in de vorm 
van een toename van het aantal B cellen, en CD4 en CD8 T cellen. Vervolgens is onderzocht 
of er in het bloed van deze patiënten T cellen konden worden aangetoond gericht tegen 
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mesotheline, een veelvoorkomend antigeen in het tumorlysaat, en of deze T cellen in aantal 
toenamen door de DC therapie. Er werd echter geen verandering gezien in het aantal me-
sotheline-specifieke T cellen vóór en ná behandeling. Een effectieve T cel reactie kan leiden 
tot uitgroei van bepaalde T cel klonen, waardoor er een verschuiving kan optreden van een 
polyklonaal naar een oligoklonaal repertoire van TCRs. Analyse van de totale TCR diversiteit 
in het bloed toonde echter evenmin veranderingen vóór en ná behandeling. De bevindingen 
in hoofdstuk 6 zijn suggestief voor een brede cellulaire immuunreactie. Wat betreft CD4+ T 
cellen in het bloed zagen we ná DC therapie een vermeerdering van de fractie T cellen pos-
itief voor activatie merkers. Het aantal patiënten in deze studie is te klein om deze data ook 
aan klinische uitkomsten te correleren. Desondanks zijn de gevonden activatiemerkers inter-
essant om in toekomstige studies in grotere patiënt cohorten te analyseren, en te correleren 
met klinische parameters.
T cel en tumor monitoring in sarcomen
In hoofdstuk 7 van dit proefschrift zijn de CD8 TILs en de eigenschappen van de micro- om-
geving van verschillende sarcoom subtypes in kaart gebracht. Het doel van deze studie was 
om meer inzicht te krijgen in de aanwezigheid en staat van immuuncellen in de tumor en hoe 
de tumor micro-omgeving hier invloed op heeft. Sarcomen zijn een zeer diverse groep van 
tumoren, en de eerste studies met immuun checkpoint therapie en adoptieve T cel therapie 
hebben laten zien dat sommige sarcoom subtypes mogelijk gevoelig en sommige subtypes 
niet gevoelig zijn voor deze therapieën. Ons onderzoek geeft mogelijk inzicht in welke immu-
untherapieën effectief kunnen zijn voor de verschillende sarcoom subtypes.
Hoofdstuk 7 beschrijft dat er duidelijke verschillen zijn in T cel aantallen, en hun activatie- en 
maturatie status, tussen vijf onderzochte sarcoom subtypen. Gastro-intestinale stromale tu-
mor (GIST), myxofibrosarcoom, en pleomorf sarcoom hebben de hoogste aantallen T cellen in 
de tumor. Interessant is dat van deze drie subtypes, GIST een veel lagere fractie geactiveerde 
en mature cellen heeft, en een meer polyklonaal T cel repertoire. Deze waarnemingen zijn 
erg suggestief voor minder antigeen-gedreven reacties van T cellen in GIST. De sarcoom sub-
typen zijn verder onderzocht op aanwezigheid van (i) antigeen presenterende moleculen, (ii) 
het aantal DNA mutaties, (iii) remmende immuuncellen en (iv) remmende of stimulerende 
liganden. Er werden tussen de sarcoom subtypes geen verschillen gevonden in de expressie 
van antigeen presenterende moleculen. Wel werden in myxofibrosarcoom en pleomorf sar-
coom een hoger aantal DNA mutaties gevonden ten opzichte van het leiomyosarcoom en 
liposarcoom (een aanwijzing voor verhoogde immunogeniciteit). GIST had relatief de laagste 
aantallen met immuunsuppresieve cellen. De aanwezigheid van de remmende moleculen 
was lager in GIST dan in alle andere sarcomen. Ook was de aanwezigheid van stimulerende 
moleculen het laagst in GIST, en was deze juist hoger in het myxofibrosarcoom en het pleo-
morf sarcoom. Op basis van deze bevindingen zouden het myxofibrosarcoom en pleomorf 
sarcoom het meest in aanmerking komen voor immuun checkpoint therapie. Sarcoom sub-
types die minder immunogeen zijn zouden mogelijk eerst moeten worden voorbehandeld 
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(bijvoorbeeld met radio- of chemotherapie) om tumoren gevoeliger te maken voor check-
point therapie. Daarentegen zou GIST mogelijk baat hebben bij een benadering waarin de 
immuun-stimulerende moleculen worden geactiveerd.
CONCLUSIE
Er worden de laatste jaren veel klinische studies uitgevoerd met (nieuwe) immuuntherapieën 
in verschillende tumorsoorten. Dit wordt vaak gedaan terwijl er tevoren onvoldoende infor-
matie is verzameld over de immunologische kenmerken van de tumor die een patiënt heeft. 
Meerdere studies hebben ondertussen aangetoond dat de tumor micro-omgeving mede 
bepalend is voor het al dan niet aanslaan van immuuntherapie. Daarom is het essentieel om 
in nieuwe (klinische) studie protocollen op de juiste wijze de tumorkarakteristieken, maar 
ook de eigenschappen van immuuncellen in het bloed in kaart te brengen. Bij voorkeur vóór, 
tijdens en indien mogelijk ná behandeling. Deze informatie kan vervolgens weer leiden tot 
identificatie van predictoren voor therapie succes.
Met het pallet aan beschikbare technieken, zoals multiplex flowcytometrie, multiplex in situ 
immunohistochemie en Next Generation DNA/RNA-sequencing (die steeds betaalbaarder en 
toegankelijker worden) zou immunologische analyse van tumor en bloed standaard moeten 
worden opgenomen in klinisch kankeronderzoek.
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Dan ben ik nu toegekomen aan het schrijven van het laatste stuk van dit proefschrift waarin ik 
graag van de mogelijkheid gebruik wil maken om een aantal mensen te bedanken. Een boekje 
komt namelijk alleen tot stand door intensieve samenwerking en ondersteuning van velen.
Allereerst wil ik graag mijn promotor prof.dr. Stefan Sleijfer bedanken. Beste Stefan, je bent 
gedurende de afgelopen jaren een belangrijke steunpilaar geweest voor mij, en dus voor de 
totstandkoming van dit proefschrift. De besprekingen die we hadden waren nuttig waarbij 
je altijd weer in staat was om de data of een manuscript in no-time te doorgronden en van 
waardevolle feedback te voorzien. Daarnaast ben je ook altijd degene geweest die als geen 
ander de tijdslijnen in de gaten hield. Naast de inhoudelijke begeleiding was je ook in staat om 
af en toe te peilen hoe het met mij ging buiten het werk. Dit heb ik als erg fijn ervaren. Verder 
was er gelukkig ook altijd plaats voor het bediscussiëren van belangrijke zaken als voetbal et 
cetera, al ben ik bang dat we het daarover nooit helemaal eens gaan worden. Ik hoop dat we 
in ieder geval in de toekomst nog aan een aantal mooie projecten kunnen werken.
Als tweede wil ik graag mijn copromotoren dr.ir. Cor Lamers en dr. Reno Debets bedanken. 
Op dit boekje staat maar één van jullie als “officiële” copromotor omdat niet twee man van 
dezelfde groep copromotor kan worden. Ik heb bij mijn weten echter altijd twee copromo-
toren gehad.
Beste Cor, de eerste hoofdstukken van dit boekje waren niet mogelijk zonder al het werk 
dat jij en de mensen betrokken bij de CAIX CAR trial hebben verricht. Jij was dan ook voor 
de totstandkoming van deze hoofdstukken absoluut onmisbaar. Elke keer als we tijdens onze 
besprekingen met Reno tot het punt kwamen met de conclusie dat we bepaalde data miste, 
wist je wel weer een mapje of DVD’tje tevoorschijn te toveren met de benodigde data. We 
zijn zelfs in de krochten van de Daniël, in de stoffige archieven gedoken en uiteraard mét 
resultaat. Ook tussen de stapels papier op je bureau wist je feilloos papers te vinden die onze 
hypotheses konden ondersteunen en nog vaker ook weer onderuit konden halen. Dit heeft 
vooral in de laatste hoofdstukken erg geholpen. Misschien nog wel net zo belangrijk, ben je 
altijd een mijn “lab vader” geweest en heb je er in het begin voor gezorgd dat ik snel in het 
lab kon aarden. Zo nu een dan een geruststellende blik als de wanhoop blijkbaar weer van 
mijn gezicht droop, evenals de gesprekken die ik nodig had om soms iets te ventileren zal ik 
niet vergeten. Heel erg veel dank hiervoor.
Beste Reno, als iemand mij heeft laten zien wat wetenschap is, en wat dat inhoudt dan ben 
jij dat geweest. Onze discussies met betrekking tot het opzetten van experimenten, de uit-
komsten hiervan, en het schrijven van papers waren altijd uitgebreid en intensief maar result-
eerde altijd in een mooi eindproduct. Je dwong mij dan ook altijd om het uiterste uit mezelf te 
halen zoals ik heb gezien dat je dat ook bij jezelf doet. Dat was niet altijd even makkelijk, maar 
heeft er zeker voor gezorgd dat dit boekje is, zoals het nu is. Nadat we de discussies in jouw 
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kamer hadden afgerond was er gelukkig ook nog ruimte om totaal niet werk gerelateerde 
punten aan de koffietafel de bediscussiëren. Hierbij schuwde je het nooit om de advocaat 
van de Duivel te spelen. Dit kon ik erg waarderen. Evenals bij Stefan denk ik dat we het over 
sommige punten nooit eens gaan worden, maar dat maakt dat ik graag nog langskom voor 
projecten en natuurlijk voor koffie bij de TI groep in de toekomst.
Prof.dr. van der Burg, prof.dr. Aerts en prof.dr. Verhoef, hartelijk dank voor het plaatsnemen 
in mijn kleine commissie en de tijd die jullie hebben genomen voor het kritisch doorlezen 
van dit proefschrift. Joachim, ik vond de samenwerking in het dendritische cell vaccinatie 
hoofdstuk zeer prettig, waarbij jouw klinische blik altijd mooie nieuwe invalshoeken gaf in de 
werkdiscussies. Kees, de samenwerking in het sarcoom hoofdstuk met jou en dr. Grünhagen 
heb ook ik als erg fijn ervaren. Jouw enthousiasme en bevlogenheid in de besprekingen van 
de data waren voor mij ook altijd heel enthousiasmerend. Dirk, bedankt hierbij voor de vele 
samples die we uiteindelijk hebben kunnen verzamelen.
Prof.dr. Hendriks, beste Rudi, bedankt voor het plaatsnemen in mijn grote commissie. We 
hebben elkaar voornamelijk gezien bij de TCC-meetings, en natuurlijk in de besprekingen 
samen met Joachim voor het dendritische cell vaccinatie hoofdstuk. Bedankt hiervoor. Prof.
dr. Martens en dr. Buschow, bedankt voor het plaatsnemen in mijn grote commissie, de tijd 
die jullie hebben geïnvesteerd in het lezen van dit proefschrift wordt zeer gewaardeerd. Ik kijk 
uit naar de discussie. 
Maud, ik kon er niet omheen om jou als mijn paranimf te vragen. Jij bent voor mijn promotie 
namelijk erg belangrijk geweest. Je begon als mijn student waarbij je een grote bijdrage hebt 
geleverd aan het sarcoom manuscript. Vele tumor samples heb je daarvoor tot laat moeten 
opwerken, en ik denk uiteindelijk met een mooi resultaat. Niet alleen inhoudelijk was je erg 
belangrijk, ook jouw vrolijke persoonlijkheid bracht altijd veel moois. Ik was dan ook heel 
blij dat jij uiteindelijk bij ons in de groep kon komen werken. Dit vooral omdat ik vanaf toen 
iemand had die minstens net zoveel koffie weg kon zetten als ik, en we van koffie halen een 
uitje konden maken. Ik ben benieuwd wat de toekomst verder brengt maar ik hoop dat we 
elkaar nog vaak tegenkomen. 
Astrid, ook om jou kon ik absoluut niet heen toen ik een paranimf moest uitkiezen. Jij hebt 
net als Maud vele tumoren opgewerkt, maar daarnaast heb je ook heel veel gedaan voor 
projecten die niet in dit boekje staan zoals het IMPA- en het BTLA-project. Je bent niet alleen 
inhoudelijk, maar ook in de groep altijd erg belangrijk geweest. Je nuchtere kijk op dingen, en 
je vermogen om ook in moeilijkere tijden altijd vrolijk en optimistisch te zijn kijk ik tegen op. 
Bedankt voor de fijne samenwerking, al ben je voordat het IMPA en het BTLA stuk af is nog 
niet van me af.
André. Toen ik aankwam in het TI lab zaten we met z’n tweeën weggestopt in een kamertje 
met relatief weinig daglicht, slechte luchtverversing, een airco die in de zomer stuk was en in 
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de winter rustig 29 graden aantikte. Je zei toen: “Welcome to the magical world of science”. 
Ons kantoor werd al snel omgedoopt tot “The Cave”. Het klikte meteen. Je ben de afgelopen 
jaren altijd degene geweest bij wie ik inhoudelijke vragen kon stellen, maar ook degene die 
als geen ander wist waar je in een PhD traject tegenaan loopt. Ik denk dat we samen heel wat 
geld aan psychotherapie hebben bespaard door regelmatig een biertje met elkaar te drinken 
na het werk. Interessant was dat we vaak tegen dezelfde dingen aanliepen maar dat we dit 
vaak op een heel verschillende manier oploste. Ik wens je veel succes in je verdere loopbaan. 
Bedankt dan jij mijn collega was en bedankt voor de vriendschap die is ontstaan. Dat we 
elkaar nog veel mogen zien.
Dora. Jij kwam André en mij vergezellen in het knusse kantoortje. Uiteraard met nu twee Duits 
sprekende cave-leden moest ik op mijn hoede zijn en om jullie invasie te stoppen werden de 
Duitse conversaties altijd door mij onderbroken met: “NEIN, NEIN, NEIN”. Ondanks de Duitse 
overheersing, en het feit dat met jouw komst er nog minder zuurstof beschikbaar was kon 
ik je alleen maar gaan waarderen. Je bent niet alleen slim, je werkt ook nog eens keihard en 
komt daarmee tot hele mooie resultaten. Bewonderenswaardig was ook altijd hoe je in je 
“Dora bubbel” zat en je totaal kon afsluiten voor de dingen die om je heen gebeurde. Ik heb 
dit geprobeerd want het had me een hoop stress kunnen schelen, echter jammerlijk gefaald. 
Bedankt voor de vele uren die we samen hebben doorgebracht, de feedback op mijn werk, 
je eerlijkheid en je humor.
Priscilla. Als er één echte supporter is van 010, dan ben jij het wel. Je was dan ook een zeer 
welkome aanvulling op het bestaande trio in “The Cave”. Eindelijk had ik iemand om dage-
lijks mee te ouwehoeren over voetbal. Je voorkeur voor de subtop van Nederland maakte 
je een gewillig slachtoffer op de maandag morgen. Veel dank hiervoor. Naast je fanatisme 
voor voetbal, ben je ook een zeer fanatieke werker. Sterker nog, ik denk dat er van de PhD’s 
niemand zoveel uurtjes wegzet als jij. Aangezien je een project hebt waarbij je vanaf nul bent 
begonnen heb je ook veel tegenslagen maar je slaat je hier elke keer weer optimistisch door-
heen. Groot respect hiervoor maar ik weet met jouw doorzettingsvermogen dat dit tot mooie 
papers zal leiden. Bedankt voor de vele voetbaldiscussies, je eerlijkheid en je directheid.
Dan zijn er nog meerdere andere PhD’s die deel uit maakte van de Tumor Immunologie groep 
die ik wil bedanken. Mesha, de oorsprong van cynisme en sarcasme. Ondanks dat we relat-
ief weinig hebben samengewerkt kwam ik je wel vaak in het lab tegen. Dankzij jou ben ik 
Pakistaanse muziek nog steeds niet gaan waarderen. Wel bedankt voor je humor, de leuke 
gesprekken en succes en geluk gewenst in de toekomst. Bas, mijn mede cliniclown. Samen 
hebben we nog aan een aantal projecten gewerkt en dat was een hele prettige samenwerk-
ing. Daarnaast heb ik altijd erg met en om je kunnen lachen. Succes met het verdere beloop 
in de kliniek en ik hoop je in de toekomst nog vaak tegen te komen. Pim, nu ik weer terug 
ben in de kliniek kan ik alleen maar nog meer respect voor je opbrengen. We komen elkaar 
ongetwijfeld nog tegen in de kliniek, en anders wil ik graag nog eens wat Gin komen proeven.
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Dan zijn er binnen het Tumor Immunologie lab nog de mensen die het fundament van de 
groep vormen en ervoor zorgen dat het lab niet veranderd in een totale anarchie. 
Ten eerste Cor B. Cor, jij bent binnen het lab een van de belangrijkste pijlers die ervoor zorgt 
dat het geen totale puinzooi wordt. Altijd sta je voor iedereen klaar en schiet je iedereen di-
rect te hulp ook als dit betekent dat je zelf in de knoop komt met je andere taken. We hebben 
niet veel direct samengewerkt aan projecten, maar indirect hebben we heel veel werk verzet 
samen. Waar ik Pris had voor de voetbal, had ik jou voor álle andere onderwerpen waarover 
ik kon ouwehoeren en kon discussiëren. Tot mijn grote vreugd kon je je ook opwinden in deze 
discussies, waardoor dat soms een doel an sich werd voor mij. Het was een mooie symbiose. 
Dank voor de prettige samenwerking, de leuke pauzes, je duidelijke standpunten en het feit 
dat ik altijd op je kon terugvallen met dingen die speelden.
Rebecca, jij had de taak om samen met Sabine mij in te werken gedurende de eerste paar 
maanden. Daar was in het begin uiteraard wat geduld voor nodig. Nu ik je wat beter heb 
leren kennen, kan ik alleen maar respect opbrengen voor de manier waarop dat is gegaan. 
Je ben zelf een van de meest efficiënte mensen in het lab en dan een cliniclown een kunstje 
leren moet pittig voor je zijn geweest. Je hebt oog voor detail, grote kennis van verschillende 
assays en bent ongekend uitgesproken. Dat laatste kon ik altijd erg waarderen, en ik heb onze 
samenwerking op verschillende projecten dan ook altijd erg fijn gevonden. Concreet, duideli-
jk en efficiënt. Bedankt voor alle hulp en ondersteuning.
Mandy, nu heb ik al een “lab vader” aangewezen, maar natuurlijk moet er ook een “lab moed-
er” zijn. Gefeliciteerd! Jij krijgt deze titel toegewezen en ik weet zeker dat je hem waardeert. 
Jij bent degene bij wie ik net als bij Cor B. altijd langs kon komen voor hulp bij problemen. Je 
bent daarbij altijd geduldig en bent ook vrijwel altijd in staat een positieve draai te geven aan 
dingen die niet lopen. Daarnaast ben je binnen de groep een belangrijke bindende factor die 
alles en iedereen een beetje in de gaten houdt en bijstuurt waar nodig. Kortom, onmisbaar. 
Bedankt hiervoor en voor de hulp en ondersteuning gedurende de afgelopen jaren.
Sabine, zoals hierboven al kort vermeld mocht jij mij inwerken. Dankzij jouw geduld kreeg ik 
het labwerk op gegeven moment in de vingers. Daarnaast heb jij een grote bijdrage geleverd 
aan de eerste hoofdstukken van dit proefschrift. Je vertrek uit de groep was dan ook erg jam-
mer, want ik had graag nog met jou aan meerdere projecten willen werken.
Rosita, als iemand niet mag ontbreken in dit dankwoord dan ben jij het. Je bent een zeer be-
langrijke factor in de Tumor Immunologie groep, want met jouw komst kwam er ineens struc-
tuur in agenda’s en werd het inplannen van afspraken ineens een stuk makkelijker. Aangezien 
ik van structuur houd, kwam je dan ook als een geschenk uit de hemel. Daarnaast sta je nog 
voor een ander hemellichaam, aangezien je altijd het zonnetje bent in je kantoortje zonder 
daglicht (alias aquarium). Hiermee weet je altijd de hele grijze doffe gang op te vrolijken. 
Dank voor je vrolijkheid, de leuke gesprekken en je hulp gedurende de laatste jaren.
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Dan zijn er nog een aantal mensen die niet deel uitmaakten van de tumor immunologie 
groep, maar die mij wel veel hebben geholpen of waar ik erg fijn mee heb samengewerkt. 
Dr. Kraan (Jaco) en Mai bedankt voor alle hulp gedurende het eerste jaar met de Fortessa. 
Zonder jullie hulp zat ik daar nu waarschijnlijk nog mijn uren te slijten. Margaretha en Pau-
line jullie wil ik graag bedanken voor de fijne samenwerking op het dendritische cell paper. 
Pauline, ik ben erg benieuwd naar jouw boekje! 
Iedereen betrokken bij de TIP meetings (dat waren er op het einde te veel om los in dit 
dankwoord te zetten), bedankt voor de interessante discussies, standpunten en de leerzame 
journal clubs. 
Dr. van Kasteren, beste Marjo, bedankt voor het in mij gestelde vertrouwen gedurende de 
laatste maanden in mijn periode als ANIOS. Onze tussentijdse gesprekken heb ik altijd als ver-
helderend ervaren en ik ben blij dat ik de komende jaren door kan zetten als arts in opleiding 
met jou als opleider. 
Collega’s en assistenten in het ETZ te Tilburg. Jullie allemaal heel erg bedankt voor het warme 
nest waarin ik terecht ben gekomen. Ik kan niet anders zeggen dat we een fantastisch team 
hebben, waarbij we allemaal keihard werken om de beste zorg te kunnen leveren.
Dan als laatst zijn er nog de mensen die ook een hele grote bijdrage hebben geleverd aan dit 
proefschrift zonder zich daarvoor inhoudelijk met zaken te bemoeien. Namelijk de mensen 
die mij hebben gesteund gedurende de afgelopen jaren. Laat ik beginnen met te zeggen dat 
ik jullie allemaal niet de aandacht heb gegeven die ik had willen geven.
Bart, Suus, Felix, Lori, Milou, Thijs, Niek en Lieve bedankt voor de mooie skivakanties. Deze 
hebben mij altijd heel veel goed gedaan en de broodnodige ontspanning gegeven. Dat we in 
de toekomst dit nog vaak mogen herhalen.
Erik, Simeon en Ivo, oude liefde roest niet. Jullie vriendschap voelt voor mij als een belangri-
jke steun waar ik altijd op terug kan vallen. Ons samenzijn is altijd vertrouwd en ondanks dat 
we inmiddels vele jaren verder zijn, waan ik me vaak gewoon weer op ons “pauze bankje” bij 
de N-gang. Ivo, ik kijk uit naar jouw boekje.
Luuk, Egmond, Tim, Caspar, Danny en Joris, bedankt voor jullie vriendschap. Waar we als 
los zand bij elkaar kwamen is een hechte vriendengroep ontstaan gedurende onze studen-
tenjaren. Jullie hebben mij in Maastricht als geen ander meegemaakt en opgevoed. Onze 
jaarclubavonden waren altijd even mooi en het is een tijd waar ik nog vaak weemoedig aan 
terug denk. Arbeiders. Dat zijn we nu, een heftige constatering. Desalniettemin zijn de avon-
den samen gelukkig nog als vanouds. Dat er nog heel veel mogen volgen.
Ad, Truus, Vera, Stefan, Ruben, Marit, Wil en Liesbeth. Als mijn schoonfamilie zijnde had ik 
jullie natuurlijk niet voor het uitkiezen, maar soms moet je in het leven gewoon geluk heb-
ben. Bedankt voor jullie interesse, de vele leuke avonden, vakanties en het prettige samenzi-
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jn. Ruben en Marit, ik hoop dat jullie snel weer naar Nederland komen met Sofia!
Jan, Joke, Siko en Diede bedankt voor de altijd onvoorwaardelijke liefde en steun in alles 
wat ik doe. Pap en mam, jullie zijn natuurlijk de basis waarop dit boekje is gemaakt. Jullie 
bevlogenheid en ondernemerschap in het leven hebben mij zeker geholpen om dit boekje te 
kunnen maken. Ook jullie luisterend oor en advies was altijd van grote waarde voor mij. Siko 
en Diede ik ben blij dat ik mij jullie grote broer mag noemen. Ik ben echt super trots op jullie 
en de dingen die jullie allemaal doen.
Leonie, de laatste alinea van dit boekje is voor jou. Als geen ander gaf je mij gedurende de 
laatste jaren de afleiding die ik soms zelf maar moeilijk kon vinden. Met een lange geeuw of 
met de mededeling: “BOORIIING” werd mijn werk altijd gerelativeerd en in perspectief gezet. 
Het is echter dankzij jouw nimmer aflatende onbaatzuchtigheid, liefde en steun dat ik altijd 
in staat ben geweest om mij vol op mijn promotie te kunnen storten. Dit terwijl jij ook al die 
tijd vol met jouw eigen opleidingstraject bezig was. Als ik ergens van overtuigd ben geraakt, is 
dat we samen alles aankunnen. Ik hou van je, en kijk uit naar al het moois wat nog voor ons 
in het verschiet ligt.
